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PREFACE 
The research work presented in this PhD thesis has been conducted entirely in the Section for 
Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 
Copenhagen in collaboration with Statens Serum Institut, Copenhagen from November 2009 to October 
2012. The work was supported by a grant from the Danish Council for Independent Research, 
Technology and Production Sciences (FTP).  
 
The thesis is structured as a review of paratuberculosis infection in cattle and following articles that are 
published or accepted or under revision in peer reviewed international journals: 
 
Article 1:   
Thakur, A., Aagaard, C., Stockmarr, A., Andersen, P., Jungersen, G. 2012. Cell-mediated and humoral 
immune responses after immunization of calves with recombinant multi-antigenic MAP subunit vaccine 
at different ages. Manuscript. Revised version accepted for publication in Clin. Vaccine Immunol. 
 
Article 2:   
Thakur, A., Riber, U., Davis, W.C., Jungersen, G. 2012. Increasing the ex vivo antigen-specific IFN-γ 
production in subpopulations of T cells by anti-CD28, anti-CD49d and recombinant IL-12 costimulation in 
cattle vaccinated with recombinant proteins from Mycobacterium avium subspecies paratuberculosis. 
Manuscript. Under revision in Vet. Immunol. Immunopathol.  
 
Article 3:   
Thakur, A., Pedersen, L.E., Jungersen, G. 2012. Immune markers and correlates of protection for vaccine-
induced immune responses. Vaccine 30, 4907-4920. 
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Article 4:   
Thakur, A., Aagaard, C., Riber, U., Andersen, P., Jungersen, G. 2012. A novel multi-stage subunit vaccine 
against paratuberculosis induces significant immunity and reduces bacterial burden in tissues. 
Manuscript in preparation.  
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SUMMARY 
Paratuberculosis is a chronic progressive granulomatous enteritis of ruminants caused by 
Mycobacterium avium subsp. paratuberculosis (MAP). Paratuberculosis in cattle is clinically 
characterized by weight loss, emaciation and diarrhea and subclinically by reduced milk production 
leading to considerable economic losses to farming community. Paratuberculosis is a staged infection in 
which young calves acquire the infection in the first months of life, may progress into a prolonged 
asymptomatic stage of about 2-5 years and may eventually become clinically infected animals. 
Vaccination with whole-cell live or inactivated vaccines prevents or delays the development of clinical 
stage of the disease but does not eliminate MAP and is usually accompanied by interference with bovine 
tuberculosis diagnostics as well as local tissue damage. Subunit vaccines with well-defined antigens in 
combination with a suitable adjuvant offer the possibility to avoid these limitations and induce a strong 
T helper 1 (TH1) type immune response that has been associated with protection against MAP.   
 
The aim of the study was to identify proteins from different stages of infection and formulate them into 
a multi-stage subunit vaccine with activation of protective immune response in experimentally 
challenged calves, with a focus on cell-mediated immune responses chiefly interferon gamma (IFN-γ) 
and polyfunctional T cells. The antigen composition of the vaccines was selected based on previous 
immunogenicity studies in cattle and experimental knowledge from in vitro and in vivo expression 
studies with M. tuberculosis proteins in mice (101). The vaccines were used to investigate the influence 
of age on vaccine-induced T cell responses and measuring vaccine-induced protective efficacy after 
experimental challenge. Effect of costimulation on vaccine-induced T cell responses and immune 
correlates of vaccine-induced protection were further characterized.   
 
Early expressed and latency-associated MAP proteins were formulated in cationic adjuvant formulation 
(CAF) 01 and tested in calves through two different experiments, MAP multi-stage vaccine (MSV)-1 and 
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2. FET11 vaccine, a combination of a fusion protein of four early expressed MAP proteins and a latency-
associated MAP protein formulated in CAF01 adjuvant was tested by an experimental MAP challenge in 
calves. FET11 vaccination at 16 weeks of age induced significant immune response and conferred 
protective immunity characterized by a mean 1.1 log10 reduction in bacterial numbers in the gut tissues 
compared to control animals and was superior to a commercial whole-cell heat inactivated vaccine, 
Silirum® or FET11 vaccination at 2 weeks (Article 4). In both MSV experiments, most significant immune 
responses were observed against Esx-secretion system proteins and latency proteins (Article 1 and 4). 
However, the immunogenicity of two recombinant MAP proteins common in both studies was different, 
emphasizing the possibility of dynamics of MAP infection guiding the differential immune response. 
There was an association between age of vaccination and induced immune responses. Older animals (4 
months) developed a more robust immune response (Article 1 and 4). Furthermore, no significant 
increase in the immune response was observed 8 weeks after second booster vaccination in MAP MSV-1 
study (Article 1). However, decreased immune responses after one year period in MAP MSV-2 
experiment, warrants the use of a booster vaccination. The experimental challenge of calves with mid-
log-phase frozen stock MAP cultures correlated well with whole-blood IFN-γ responses to PPDj in 
advanced weeks of the study, which signifies PPDj response as a marker of MAP experimental infection 
(Article 4). This challenge study also supports the possibility of establishing a uniform and repeatable 
bovine MAP infection model involving large number of animals procured at different times. The results 
also show the potential application of quantitative real-time PCR (qPCR) for the evaluation of microbial 
load in tissues and vaccine efficacy (Article 4).   
 
Costimulation of vaccine-induced ex vivo T cells significantly increased IFN-γ levels following use of anti-
CD28 and anti-CD49d antibodies (Article 2). Recombinant interleukin IL-12 (rIL-12) also resulted in very 
high levels of IFN-γ production but was accompanied by high background levels. Thus enhanced antigen-
specific immune response with anti-CD28/CD49d costimulation could be suitable for characterizing 
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vaccination or infection-mediated responses, while rIL-12 with a more TH1 biased potentiation of 
antigen-specific IFN-γ production warrants its use for diagnostic purposes.  
 
The results of this study also highlight the role of innate immune cells such as gamma delta (γδ) T cells 
and natural killer (NK) cells in paratuberculosis infection (Article 2). Antigen-specific IFN-γ production by 
γδ T cells and NK cells was observed in vaccinated calves. Although the levels were low compared to 
CD4+ T cells, IFN-γ production by these innate effector cells might compensate the immature immune 
system of young calves to counteract MAP infection.           
 
A number of immunological markers were discussed as potential vaccine-induced immune correlates 
with emphasis on infections requiring T cell-mediated immunity (Article3). Traditionally, neutralizing 
antibody titers are associated with vaccine-mediated immune protection. However, advancement of 
biological techniques has allowed identifying and appreciating immune markers as candidates for novel 
correlates of protection. 
 
 Taken together, this study has provided information on developing a multi-stage vaccine against 
paratuberculosis and has increased the knowledge regarding age of vaccination, experimental MAP 
infection, costimulation signals for measuring T cell responses, and immune correlates of protection.     
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RESUMÉ (DANISH SUMMARY) 
Paratuberkuloseer en kronisk fremadskridende granulomatøs enteritis hos drøvtyggere forårsaget af 
Mycobacterium avium subsp. paratuberculosis (MAP). Klinisk paratuberkulose hos kvæg er 
karakteriseret ved vægttab, afmagring og diarré og subklinisk paratuberkulose ved reduceret 
mælkeproduktion, hvilket medfører betydelige økonomiske tab for landbruget. Paratuberkulose er en 
gradvis infektion, hvor unge kalve smittes med infektionen i de første levemåneder, som kan efterfølges 
af en langvarig asymptomatisk fase på omkring 2-5 år, og i sidste ende kan blive klinisk inficerede dyr. 
Vaccination med hele og levende celler eller inaktiverede vacciner forhindrer eller forsinker udvikling af 
den kliniske fase af sygdommen, men fjerner ikke MAP og medfører som regel en påvirkning af 
diagnostik for bovin tuberkulose samt lokale vævsskader. Subunit-vacciner med veldefinerede antigener 
i kombination med en egnet adjuvans giver mulighed for at undgå disse begrænsninger og inducerer et 
kraftig T-hjælper 1 (Th1) type immunrespons, som er blevet associeret med beskyttelse mod MAP. 
 
Formålet med studiet var at identificere proteiner fra forskellige infektionsstadier og inkorporere dem i 
en flertrins subunit-vaccine til aktivering af beskyttende immunreaktion i eksperimentelt inficerede 
kalve, med fokus på cellemedierede immunresponser hovedsagelig interferon gamma (IFN- γ) og 
polyfunktionelle T-celler. Antigensammensætningen af vaccinerne blev valgt baseret på tidligere 
immunogenecitets-undersøgelser i kvæg og eksperimentel viden fra in vitro og in vivo 
ekspressionsstudier med M. tuberculosis proteiner i mus (101)., Vaccinerne blev anvendt til at 
undersøge betydningen af alder på vaccine-inducerede T-cellereaktioner og til at måle den vaccine-
inducerede beskyttende virkning efter eksperimentel infektion. Effekten af co-stimulering på vaccine-
inducerede T-cellereaktioner og immun-korrelationer for vaccine-inducerede beskyttelse blev yderligere 
karakteriseret. 
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Tidlig udtrykt og latens-associerede MAP-proteiner blev formuleret i kationisk adjuvansformulering 
(CAF) 01 og testet i kalve gennem to forskellige eksperimenter, MAP flertrins vaccine (MSV) -1 og 2. 
FET11 vaccine, en kombination af et fusionsprotein af fire tidlig udtrykte MAP-proteiner og et latens-
associeret MAP-protein formuleret i CAF01 adjuvant, blev testet ved en eksperimentel MAP re-infektion 
af kalve. FET11 vaccination ved 16 ugers alderen inducerede et signifikant immunrespons og gav 
beskyttende immunitet karakteriseret ved en middelværdi på 1,1 log10 reduktion i antallet af bakterier i 
tarmvæv sammenlignet med kontroldyr, og var bedre end en kommerciel helcelle, varme-inaktiveret 
vaccine, Silirum® eller FET11 vaccination ved 2 uger (artikel 4). I begge MSV-eksperimenter blev de mest 
signifikante immunresponser observeret mod ESX-sekretionssystem-proteiner og latens-proteiner 
(artikel 1 og 4). Dog var immunogeniciteten af to rekombinante MAP-proteiner, som blev brugt i begge 
undersøgelser, forskellige, hvilket understreger muligheden for at dynamikken af en MAP-infektion kan 
inducere forskellige immunresponser. Der var en sammenhæng mellem vaccinationsalderen og 
inducerede immunresponser. Ældre dyr (4 måneder) udviklede et mere robust immunrespons (artikel 1 
og 4). Desuden var der ikke signifikant stigning i immunresponset observeret 8 uger efter anden 
booster-vaccination i MAP MSV-1-studiet (artikel 1). Reducerede immunresponser efter et år i MAP 
MSV-2 eksperimentet, taler dog for anvendelsen af en booster-vaccination. Den eksperimentelle re-
infektion af kalve med mid-log-fase, frosne stock MAP-kulturer korrelerede godt med fuldblods IFN-γ-
reaktioner mod PPDj i de senere uger af studiet, hvilket understreger PPDj-reaktion som en markør for 
eksperimentel MAP-infektion (artikel 4). Dette infektions-studie understøtter også muligheden for at 
etablere en ensartet og reproducerbar bovin MAP-infektionsmodel med et stort antal dyr anskaffet på 
forskellige tidspunkter. Resultaterne viser også den potentielle anvendelse af kvantitativ real-time PCR 
(qPCR) til evaluering af mikrobielle belastning i væv og vaccineeffektivitet (artikel 4). 
 
Co-stimulation af vaccine-inducerede ex vivo T-celler forøgede IFN-γ niveauerne signifikant efter brug af 
anti-CD28 og anti-CD49d antistoffer (artikel 2). Rekombinant IL-12 (rIL-12) resulterede også i meget høje 
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niveauer af IFN-γ produktion, men resulterede også i høje baggrundsniveauer. Derfor kan et forstærket, 
antigen-specifikt immunrespons med anti-CD28/CD49d co-stimulation være egnet til karakterisering af 
vaccinations- eller infektionsmedierede responser, mens rIL-12 med et mere Th1-rettet immunrespons 
begrænser anvendelsen til diagnostiske formål. 
 
Resultaterne af denne undersøgelse fremhæver også rollen af medfødte immunceller såsom gamma 
delta (γδ) T-celler og naturlige dræberceller (NK) ved paratuberkulose-infektion. Antigen-specifik IFN-γ 
produktion af γδ T-celler og NK-celler blev observeret i vaccinerede kalve. Selv om niveauet var lavt, 
sammenlignet med CD4+ T-celler, kan IFN-γ produktion af disse medfødte effektorceller kompensere for 
det umodne immunsystem hos unge kalve og modarbejde MAP-infektion. 
 
En række immunologiske markører blev diskuteret som potentielle vaccine-inducerede immunkorrelater 
med vægt på infektioner, der kræver T-celle-medieret immunitet. Traditionelt er neutraliserende 
antistof-titrere blevet forbundet med vaccine-induceret immunbeskyttelse. Imidlertid har udviklingen af 
nye biologiske teknikker tilladt identifikation og anerkendelse af immune markører som nye korrelater 
for beskyttelse. 
 
 Samlet set har dette studie givet information omkring udvikling af en flertrins-vaccine mod 
paratuberkulose og har tilført viden om alder ved vaccination, eksperimentel MAP-infektion, co-
stimulations-signaler til måling af T-celle responser, og immun-korrelater for beskyttelse. 
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INTRODUCTION 
Paratuberculosis in Cattle 
Paratuberculosis or Johne’s disease is a chronic, progressive, and ultimately fatal enteric disease of 
mainly ruminants caused by Mycobacterium avium subsp. paratuberculosis (MAP). Paratuberculosis has 
a broad host range and can be found in many different species of wildlife and domestic ruminants. 
Paratuberculosis has an increasing economic impact worldwide and some zoonotic relevance due to 
increased association of MAP with Crohn’s disease in humans (119). Paratuberculosis was first described 
in 1895 by Johne and Frothingham as a chronic enteritis in cattle (62). 11 years later in 1906, Bang 
differentiated the disease from tuberculosis (6). While the isolation of etiological bacterium was not 
achieved until several years later when Twort and Ingram cultured the bacterium and designated it as 
Mycobacterium enteritidis chronicae pseudotuberculosis bovis, Johne (168).  
      
Mycobacterium avium subsp. paratuberculosis (MAP) 
MAP belongs to Mycobacterium avium complex (MAC) under the genus Mycobacterium, a group of acid-
fast bacteria. MAC contains 28 serovars of two species: Mycobacterium avium and Mycobacterium 
intracellulare. Mycobacterium avium belongs to genus Mycobacterium, family Mycobacteriaceae, 
suborder Corynebacterineae, and order Actinomycetales. MAC has been divided into three subspecies: 
Mycobacterium avium subsp. avium, MAP, and Mycobacterium avium subsp. silvaticum. Among the 
three subspecies, only MAP is pathogenic in healthy hosts, while Mycobacterium avium subsp. avium 
and Mycobacterium avium subsp. silvaticum are unable to cause disease in healthy hosts but may do in 
immunocompromised hosts. 
 
MAP is an intracellular pathogen. MAP is a small 0.5 x 1.5 µm, straight or curved rod-shaped, gram stain 
positive, acid-fast, obligate aerobic, non-motile bacterium that grows in clumps of 10-100 bacterial cells. 
MAP is usually considered a non-spore forming bacterium, however, a spore-like morphotype in 
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chronically starved MAP cultures have been found recently (85). MAP is characterized by very slow 
growth rate, with a generation time of approximately 30 hrs (84) and requiring 8-12 weeks for visible 
colony formation. MAP forms small 1-2 mm, usually white, domed, rough, non-pigmented colonies on 
artificial media, such as Herrold egg yolk or Lowenstein-Jensen (LJ) medium. MAP also has a dependence 
on siderophore mycobactin J, an iron-chelating cell wall component, for growth in primary cultures 
(165). The complete genome of the reference MAP strain K-10 (an isolate from Wisconsin dairy herd, 
1990 and since then maintained in the lab; lab passage status is unknown) has been sequenced and is 
characterized by a single circular chromosome of 4,829,781 base pairs, relatively high guanine-cytosine 
(GC)-content (69%), and an abundance of insertion sequences (IS) and putative virulence factors, PE/PPE 
proteins (89). MAP genome sequence has annotated upto 4587 total genes. A total of 58 repetitive DNA 
sequences, insertion sequences (IS) have been recognized within the MAP genome, including 17 copies 
of IS900, 7 copies of IS1311 and 3 copies of ISMav2 (89). IS900 is the first insertion sequence to be 
characterized in mycobacteria and is unique to MAP, though other mycobacteria have been reported to 
have IS900 like sequences (38).  
 
Like other mycobacteria, MAP possesses a thick cell wall containing 60% lipid and consisting of many 
layers. This multilayered cell wall confers on it the properties of acid-fastness, hydrophobicity (128), 
increased resistance to chemicals e.g. chlorine (182), and physical processes such as high-temperature 
short-time (HTST) pasteurization (48). The thick cell wall comprising of peptidoglycans, polysaccharides 
and lipids gives an advantage for the prolonged survival of MAP inside the host but leads to slow growth 
rate because of restricted nutrient uptake through the cell wall (36). A prominent lipopolysaccharide 
molecule of the cell envelope, lipoarabinomannan (LAM) plays a role in the pathogenesis of 
paratuberculosis (160). Broadly, MAP strains can be divided into two major groups or strain types, sheep 
(S) or Type I and cattle (C) or Type II. Application of molecular typing techniques revealed new strain 
types, intermediate (21) or Type III (32) and Bison type (189). However, recent data from whole-genome 
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sequencing supports only Types I and II with intermediate and bison strains part of Type I and Type II 
strains, respectively (2). Other characteristic features of MAP are the ability to persist for extended 
periods of dormancy in the environment (190) and water sources (188), biofilm formation (23), and 
aerosolization (188). In addition, cell wall deficient (CWD) forms of MAP have been reported in patients 
with sarcoidosis and Crohn’s disease (57).                
  
Epidemiology and the disease  
Paratuberculosis is a disease of ruminants with cattle, sheep and goats regarded as the principle 
affected animals. However, paratuberculosis has also been diagnosed in a wide range of other free-
ranging and domesticated ruminants such as bison, moose, riverine buffalo, bighorn sheep, deer, 
antelope, yak and camelids including camels, llamas and alpacas (96). MAP has been isolated from non-
ruminant wildlife including rabbit, hare, fox, stoat, wild boar, badger, opossum, kangaroo, crow, wood 
mice and ferret (97). MAP has also been reported from horses, pigs, chicken, fish, and non-human 
primates (59).    
 
The primary route of transmission of infection is through ingestion of milk, colostrum, feed or water 
contaminated with MAP microorganisms (51). Moreover, cows with clinical symptoms can transmit the 
infection vertically through the utero-placental route (192). Faecal shedding has been found to 
contribute significantly not only to cow-to-calf but also calf-to-calf transmission (4). A less common 
transmission route is through the semen of infected bulls (5). Spread of infection across herds is through 
introduction of infected animals to the healthy stock, with lateral transmission between adjoining 
pastures also possible (191). Young animals (< 12 months of age) are regarded most susceptible to 
paratuberculosis (86) but adult cattle can become infected too. Experimental infection studies in cattle 
have shown that between 4 months and 1 years of age, it is difficult to infect the calves and by 1 year, 
susceptibility of calves is similar to adult cattle. One speculation for the increased susceptibility of young 
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calves is the ‘open gut’ during the first 24 hours of birth, whereby MAP also cross the intestinal barrier 
along with colostral antibodies through pinocytosis. Age resistance in cattle has also been associated 
with the abatement of peyer’s patches (PP) in the small intestine, considered as the portal of entry for 
MAP after birth and development of adaptive immune system in adult cattle. In addition, genetic 
variation in susceptibility for paratuberculosis has been described in cattle (77) and has been linked to 
single nucleotide polymorphisms in multiple genes like toll- like receptor (TLR)-2 (76) and nucleotide 
oligomerization domain (NOD)-2 (134) that are associated with MAP resistance or susceptibility. 
Furthermore, the magnitude of the MAP dose ingested will also affect the course of the infection. 
Animals that ingest a higher MAP dose tend to progress quickly to clinical stage of disease compared to 
ones ingesting lower dose.   
 
Since the first recognition of paratuberculosis in dairy cattle, MAP has dispersed across species and 
geographical boundaries. This spread has coincided with industrialization, degree of economic 
consideration in animal agriculture and export of dairy heifers with supposedly prior MAP infection from 
Europe and North America to other continents of the world. Current prevalence estimates suggest that 
>50% of cattle herds in Europe (112) and >68% in North America are infected (91). Though, Norway (54) 
and Sweden (157) claim to be free of bovine paratuberculosis, positive cases from dairy cattle have been 
reported from both the countries. These herd level prevalence studies were carried out using an 
enzyme-linked immunosorbent assay (ELISA), and true prevalence could be even higher because the 
sensitivities of ELISAs were overestimated. 
 
Pathogenesis 
Paratuberculosis disease process starts with oral ingestion and passage of MAP through the epithelial 
barrier of the intestine, translocation through the mucosal epithelium by dome microfold (M) cells, 
phagocytosis in the intestinal mucosa and gut-associated lymphoid organs (GALT), and persistence in 
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subepithelial macrophages. This is followed by spread of infection to adjacent lymph nodes and 
dissemination. Macrophages are the vehicles for the dissemination of MAP through infected sites. It has 
been shown that MAP infected macrophages reach the mesenteric lymph nodes after crossing intestinal 
barrier within 1 h of surgical inoculation of intestine (198). Macrophages provide a favorable 
environment for MAP replication and persistence. In later stages, infected epithelial cells are sloughed 
into the intestine and passed with the faecal discharge. The number of MAP bacilli excreted in the 
faeces of clinically infected animals could exceed 108 cells per g faeces (18).   
  
Paratuberculosis in cattle is characterized by a staged infection that can be divided into four stages 
according to disease severity, immune response and ability of diagnosis (Figure 1): stage 1, silent 
preclinical infection; stage 2, subclinical infection; stage 3, clinical infection; and stage 4, advanced 
clinical infection. Animals genetically resistant to paratuberculosis contain the infection and remain in 
the stage 1 without ever changing stages or only under conditions of an immunocompromise. In silent 
preclinical infection, susceptible animals remain asymptomatic carriers for the initial 2-4 years after 
infection with very little MAP shedding in the faeces, although cell-mediated immune (CMI) response 
and delayed type hypersensitivity (DTH) reaction may be detected. Intermittent MAP shedding in faeces 
detectable by faecal culture, no clinical signs, strong CMI responses and poor antibody responses 
characterizes stage 2. Stage 3 and 4 animals develop protein-loosing enteropathy characterized by 
intermittent or persistent diarrhea. The hallmark clinical sign in cattle is watery or ‘pipe-stream’ diarrhea 
often with ‘foam or bubbles’ due to the high protein content in faeces. The intestinal wall thickens, 
caused by hypoproteinemia and edema due to decreased intravascular osmotic pressure (20). This 
results in malabsorption of nutrients, gradual weight loss despite normal or increased food intake, 
submandibular oedema, reduced milk production by 20% or more, and decreased fertility (70). Bacterial 
shedding is persistent with strong production of antibodies against MAP and a waning CMI response. 
The infection can disseminate to several extra-intestinal sites, including lymph nodes. Animals in 
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advanced clinical disease become weak, emaciated, and suffer from profuse diarrhea. Intermandibular 
oedema or bottle jaw is characteristic of this stage and animals eventually die of dehydration and 
cachexia (166). However, most animals are culled before reaching this terminal stage. It has been 
suggested that for every clinically confirmed paratuberculosis infected cow there are another 15-25 
infected cows in a herd (184). This phenomenon has been described as the ‘iceberg effect.’         
 
         Stage 1                 Stage 2                          Stage 3+4 
 
 
 
 
 
 
Infection    Time  
Figure 1: Stages of MAP infection in cattle with dogma accompanying diagnostic options (Figure Aneesh 
Thakur).   
 
Disease pathology   
Macroscopic changes associated with paratuberculosis in cattle include intestinal wall thickening, 
lymphadenitis leading to lymphangiectasis, and lymph node enlargement (Figure 2). Affection of the 
mucosal epithelium of the distal ileum is the major component of the pathogenesis and is characterized 
by an oedematous wall with raised corrugations (Figure 2). The serosal and mesenteric lymphatic vessels 
are dilated and thickened. The mesenteric lymph nodes are pale, swollen and oedematous. 
Extraintestinal lesions in liver, hepatic lymph nodes and kidney have been reported (53). Interestingly, 
the degree of intestinal lesions often doesn’t correlate with the clinical outcome (13).  
   
             CMI response 
              Antibodies 
             Faecal shedding               
             IFN-γ detection  
  Antibody detection 
             IFN-γ and Antibody  
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Figure 2: Ileal wall thickening and corrugations and lymph node enlargement (Photo Johne’s disease: 
Animal Health Australia www.animalhealthaustralia.com.au).  
 
Histopathological lesions are characterized by focal, multifocal or diffuse granulomatous inflammation 
of the intestine and mesenteric lymph nodes. In both human and bovine tuberculosis, chronic 
granulomatous lesions are typical and are characterized by a central caeseation, surrounded by 
macrophages, epitheloid cells and multinucleate giant cells which in turn are covered by lymphocytes, 
macrophages and a fibrous capsule. However, there is never a tuberculous granuloma formation in 
bovine paratuberculosis although multiple granulomas are seen in goats (92) and caseous lesions are 
observed in deer (95). Lesions in bovine paratuberculosis have been classified into mild, moderate or 
severe (13). Mild lesions are characterized by the presence of giant cells and few macrophages in the 
intestinal villi and paracortical zone of mesenteric lymph nodes with no acid-fast bacilli (AFB). In 
moderate form, there are many macrophages and giant cells extending up to intestinal mucosa and 
submucosa and mesenteric lymph nodes and few AFB. Severe form has profuse infiltration of 
macrophages and giant cells in all layers of intestine and lumen of lymphatic vessel, blunted villi and 
Enlarged lymph node 
Ileal wall corrugations 
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distended intestinal crypts. Cellular infiltration extends to paracortical as well as subcapsular region of 
mesenteric lymph node and AFB are demonstrable in large numbers. Depending upon the extent of 
severity, lesions can also be classified as focal, multifocal or diffuse. Focal lesions extend up to intestinal 
villi or ileocaecal and jejunal lymph nodes. Multifocal lesions spread till the lamina propria of ileum, ileal 
and jejunal lymph nodes. Diffuse lesions further can be paucibacillary, multibacillary or intermediate 
type (46). Diffuse paucibacillary type is characterized by profuse lymphocytic infiltration and few AFB, 
while multibacillary lesions have a large numbers of macrophages with abundant AFB and few 
lymphocytes. Paucibacillary form is generally accompanied by higher CMI response while multibacillary 
form is often characterized by strong antibody response. Intermediate form shows features of both 
paucibacillary as well multibacillary types with AFB corresponding to macrophage presence and may 
thus represent the transitional nature of the intermediate form.        
 
Diagnosis 
Diagnosis of bovine paratuberculosis can be divided into assays that detect either the infectious agent or 
a MAP-specific immune response in the host. The diagnostic assays that detect MAP in the clinical 
samples such as faeces or tissues could be culture or polymerase chain reaction (PCR) based methods. 
These methods have high specificity (98-100%) but low sensitivity (about 70%) in animals with clinical 
disease. The sensitivity is even poor (about 25%) for subclinically infected animals (114, 185). Although 
pathology induced by MAP is characteristic, diagnosis based on pathological changes, demonstration of 
AFB or immunohistochemisry and in situ hybridization conducted on tissue sections is not specific (186). 
Since MAP is an obligate pathogen, cultivation and identification of MAP is a definitive diagnostic test. 
However, actual challenge is the identification of subclinically infected animals, which intermittently 
shed low number of bacteria in the faeces and are usually negative on standard antibody tests (114). 
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Culturing 
Cultivation of MAP is a highly specific method and requires some critical steps such as decontamination 
of clinical samples, enrichment, prolonged incubation periods, and identification using genotyping 
means. Both solid as well as liquid media can be used to culture MAP such as LJ medium, Harrold’s egg 
yolk medium, Middlebrook (MB) 7H10 or 11 agar, and MB7H9 broth. Incubation periods vary from 12-20 
weeks on solid medium and 8-12 weeks on the liquid medium. Enrichment of the media using 
mycobactin J is essential for primary culturing of MAP. Egg yolk, sodium pyruvate, dyes such as brilliant 
green, methylene blue and antimicrobials such as malachite green, vancomycin, penicillin G, 
amphotericin B have been used to stimulate the growth of MAP. Radiometric detection of C14-labelled 
carbon dioxide produced in mycobacterial cultures was adapted for MAP using BACTEC12B liquid 
medium and detection through BACTEC 460 system (29). A new fluorescent detection system called 
BACTEC MGIT 960 based on identification of a fluorescent signal generated in the liquid medium as the 
oxygen is consumed is gaining acceptance for detection of MAP (158). Culturing of MAP is a costly and 
time-consuming procedure. Culture of samples pooled from more than one animal or the environment, 
is usually practiced for determining the herd prevalence. In addition to faecal samples, tissues such as 
intestine and associated lymph nodes, milk, blood and environmental samples, including soil, water and 
pasture have been used for the isolation of MAP.  
 
PCR 
Confirmation of the MAP cultures through IS900 PCR is a highly sensitive (100%) method. However, 
direct PCR on the clinical samples have been found to be of low sensitivity due to PCR inhibitors that can 
lead to false-negative results. Thus standard PCR based assays don’t give a practical alternative to other 
diagnostic methods. To counter this problem, new methods have been developed such as 
immunomagnetic separation (47) and hybridization capture (98). Despite a lot of work in the field, the 
most common target of conventional PCR is still the IS900 gene. A comparison of 13 PCR assays found 
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IS900 PCR assay to be most sensitive with an assay detection limit of 0.1 pg DNA (172). Few other 
markers have proved useful for the identification of MAP including F57, ISMAP02, ISMav2, heat shock 
protein (Hsp) X, gene 251 and 255. Nested PCR is another sensitive method to detect MAP but suffer 
from risk of cross-contamination. Multiplex assays incorporating more than one marker at a time such 
as IS900, F57 and 16S PCR assays have been developed to confirm MAP (164). qPCR is yet another 
sensitive technique that allows ‘absolute’ quantification of MAP in clinical samples. Further, it can be 
combined with reverse transcriptase PCR for MAP mRNA detection and expression analysis (9).                       
 
Immunoassays 
MAP diagnosis can also be performed with immunoassays that depend on the interaction of host with 
the microorganism, leading to a measurable immune response. These assays can detect either the CMI 
(tuberculin skin sensitivity or IFN-γ production) or humoral responses (IgG1 response). Immune 
responses in paratuberculosis were believed to be characterized into earlier pro-inflammatory reaction 
dominated by IFN-γ and IgG2 and later anti-inflammatory reaction dominated by IgG1 antibodies (110). 
However, recent knowledge has challenged the existence of TH1 over TH2 dormancy in MAP (10). In fact, 
both responses may occur simultaneously and thus pose a challenge for the accurate diagnosis. In 
addition, the disease progression, faecal shedding and antibody responses don’t follow a set order (93). 
Few infected cows produce antibodies several years prior to continuous shedding of MAP, while in 
others, antibodies may not be detectable in early stages of infection. 
 
CMI based assays 
There are two CMI based diagnostic assays for the detection of MAP infection: intradermal tuberculin 
skin test and IFN-γ release assays (IGRAs). Tuberculin skin test measures the delayed type 
hypersensitivity after intradermal inoculation of johnin or avian purified protein derivative (PPD). 
However, skin testing suffers from the drawback of cross-reaction with environmental bacteria and MAP 
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or M. bovis vaccines, in addition to more handling of animals. Skin testing has been replaced to a large 
extent with the IFN-γ assay, first described for the diagnosis of bovine tuberculosis in 1990 measuring 
secreted IFN-γ in response to an antigen (196). 
 
In IGRAs, whole-blood samples are cultured with MAP antigens or PPD antigen and IFN-γ release in 24 
hrs cultures is measured through ELISA. These assays have the advantages of shorter timeframe, 
repeatability, and objective interpretation of results and less animal handling. But suffer from low 
specificity, complex logistics and higher price. Current IGRAs use PPD as the stimulating antigen. PPD is a 
poorly defined mixture of mycobacterial antigens from different strains and has lower specificity due to 
cross-reactive antigens. Further, PPD used for IGRAs is not standardized because the genomic variability 
is very high among the organisms used for preparing PPD (143). Thus well-defined specific antigens 
should be used for improving the performance of IGRAs. One of the other limitations for the use of 
IGRAs in their current form is the variable sensitivity (0.13 to 0.85) and specificity level (0.88 to 0.94) in 
cattle (114). Further, non-specific IFN-γ production in calves less than 15 months of age has been 
observed (117). Another requirement for the IGRAs is the immediate processing of whole-blood samples 
within 8 hrs of transport to the lab to maintain the specificity. However, this issue has been addressed 
by the use of costimulatory cytokines such as IL-7, IL-12, and IL-18. In spite of all the limitations, IGRAs 
are still promising in early detection of paratuberculosis (56, 63). A negative association between IGRAs 
results obtained before first calving and milk antibody ELISA results at different ages after calving has 
been observed, indicating the key role of CMI responses in the control of paratuberculosis (102).  
 
Serology based assays 
MAP-specific antibodies in the serum samples can be detected by assays such as complement fixation 
test (CFT), agar gel immunodiffusion test (AGID) or ELISA. Of all three, ELISA is the most sensitive test 
with age related increase in the sensitivity (113). Lower specificity of the ELISA tests due to cross-
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reacting antibodies have been improved by the absorbing sera with Mycobacterium phlei. Specificities 
ranging from 98.8% (28) and 99.7% (129) have been obtained using this method. Consequently, the 
sensitivity of the assays is compromised in animals without clinical signs as compared to the higher 
sensitivity in clinically affected animals (114). Thus one of the limitations of the ELISA tests is poor 
sensitivity in early stage infected animals posing a challenge for the timely diagnosis of the infection.  
 
Several commercial ELISA kits for bovine paratuberculosis are currently available, and many studies have 
compared their accuracy. Similar to CMI based assays, ELISA tests also face the challenge of having 
suitable antigen representing the entire range of immunodominant antigens for MAP. Most widely used 
antigen is PPA-3, which is the M. avium strain 18 protoplasmic antigen. While other used antigens 
include whole-cell sonicated extract, PPD, and protoplasmic antigens, and cell wall antigen 
lipoarabinomannan (LAM) but they show variable potency and cross-reaction. Another important 
consideration for serological diagnosis of MAP infection is the antibody isotype. As there is 
predominance of IgG1 and IgG2 isotypes in different stages of MAP infection (78), therefore, it is 
important to measure the right antibody isotype responses.        
 
Milk antibody ELISA is also used for diagnosis of MAP infection and offers the advantages of individual 
and bulk milk sampling, ease of sampling, low cost of testing, and herd surveillance. A positive ELISA is 
useful for predicting that an animal would subsequently become infectious. Cattle with repeated 
positive milk ELISA are found to be more likely to be MAP shedders in near future compared to other 
with fluctuating immune responses (109). However, many factors have to be taken into consideration 
for the interpretation of milk ELISA results including stage of lactation, milk yield and days in milk. Stage 
of lactation has a major effect on the odds of testing positive in milk antibody ELISA, particularly during 
the first days of lactation, where the odds are 3-27 times higher than mid-lactation (111). In the 
advanced stages of paratuberculosis, a state of anergy may occur that leads to almost no milk antibody 
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responses (16). It was observed that in herd surveillance programs, days in milk 1-5 should be excluded, 
while milk yield data for the effect of dilution should be taken into account in order to predict test 
results corresponding to disease progression (111).  
 
Thus for the accurate diagnosis of paratuberculosis, the performance of both the CMI and serological 
based assays ought to be improved by incorporating MAP-specific antigens. New methods such as spot 
protein array have been developed for initial antigen screening (8). A number of characterized MAP 
antigen candidates with diagnostic potential have been summarized and categorized into secreted, cell 
wall and membrane, lipoprotein, heat shock and hypothetical proteins (100). Using a cocktail of novel 
immunogenic antigens of MAP is a good approach to increase the sensitivity and specificity of the ELISA 
test for diagnosis of paratuberculosis (104). Despite all the improvements the fundamental question 
remains the same i.e. what is the purpose of the applied diagnostic test? Our research group has earlier 
addressed this question and highlighted the significant impact of the diagnostic target condition as well 
as the purpose of testing on the utility of available tests (64). 
        
Paratuberculosis: Immunobiology 
Uptake and Innate immune response to MAP 
After oral ingestion of MAP, the bacilli enter the mucosal surface of intestinal tissue through peyer’s 
patches (PP). PPs are lymphoid aggregates within GALT and allow selective transport of antigens. 
Microfold (M) cells are the portal of entry for MAP inside PP. M cells, unlike enterocytes, are 
characterized by lack of brush border epithelium, digestive enzymes and surface mucus and thus 
provide an unobstructive path for ingested bacilli (40). MAP has fibronectin attachment protein in the 
cell wall that is activated during its passage though acidic contents of abomasum, which allows 
opsonization through fibronectin protein in the body fluids. Fibronectin then serves as a bridge to bind 
MAP with fibronectin receptor α5β1, on the luminal surface of M cells (141). In addition, pattern 
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recognition receptors (PRR) such as TLR4 and platelet activation factor receptor have been involved in 
the bacterial uptake through M cells (169). Recent evidence also suggests MAP uptake by enterocytes 
(139). After crossing the intestinal epithelial layer, MAP is expelled at the basolateral side and taken up 
by the subepithelial macrophages or dendritic cells (DCs). Various PRR have been implicated in the entry 
of mycobacteria into macrophage or DCs such as TLRs, NACHT-like receptors including NOD1 and NOD2 
receptors, mannose receptor, complement receptors (CR1, CR3, and CR4), immunoglobulin receptor 
(FcR), scavenger receptors (e.g. CD163), inhibitory receptors (such as C-type 2 lectins like DC-
SIGN/CD209), and others (124). TLRs, TLR2 and TLR4 are important in the detection and initiation of 
adaptive immune response by activation of intracellular signaling pathways through MyD88, mitogen-
activated protein kinase (MAPK), and nuclear factor-κB (NF-κB), leading to induction of cytokines (61). 
TLR2, TLR4 and NOD2 receptors have been reported to be involved in MAP recognition by macrophages 
(41), highlighting the key role of TLRs in mediation of innate immune responses. TLR-mediated 
intracellular signaling leads to production of cytokines and chemokines such as IL-1, IL-6, IL-8, IL-12 and 
tumor necrosis factor alpha (TNF-α) that initiate proinflammatory immune responses (187).     
 
Once inside the macrophages, MAP persists by surviving the microbicidal properties of macrophages by 
inhibiting the maturation of phagosomes and preventing apoptosis. Lower expression of transferrin, an 
early phagosome marker and higher expression of lysosome-associated membrane protein-1 (LAMP-1), 
a late phagosome marker have been shown on phagosomes with live MAP (55). Interference with the 
normal course of phagosome maturation into a phagolysosome has been linked to an inhibition of 
phagosome acidification, which in turn leads to poor microbicidal functions such as nitric oxide, reactive 
oxygen species and lysosome hydrolases (82). Markers from Rab GTPase family, Rab5 and Rab7 that are 
critical for intracellular signaling for phagosome-lysosome fusion have been found to be altered by 
mycobacterial infection (19). A recent study has shown reduced phagosome-lysosome fusion in MAP 
infected human monocyte cell lines evidenced by reduced recruitment of Rab-7 interacting lysosomal 
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protein (RILP) in Rab-7 staining phagosomes containing live MAP (71). In addition, MAPK pathway was 
found to promote MAP survival by preventing acidification of phagosomes (147). Pathogenic MAP also 
evades apoptosis of macrophages and there is evidence for the longer survival of MAP using this 
strategy (195).       
 
NK cells are innate effector cells that have been shown to restrict the growth of mycobacteria through 
the production of IFN-γ and cytolytic activity (33). NK cells are usually found in a resting state and need 
activation signals for effector functions provided by DC (15). In addition, NK cells with memory functions 
have been described (161). Thus NK cells serve an important link between innate and adaptive immune 
system (Figure 3). In MAP infection, NK cells produce IFN-γ (117), but a larger role still remains to be 
elucidated. 
 
Figure 3: Illustration of induction and regulation of CMI and humoral immune responses (Figure Aneesh 
Thakur). 
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Cell-mediated immune response to MAP 
IFN-γ is regarded as a canonical cytokine in mycobacterial infections including paratuberculosis (149). 
The chief producers of IFN-γ include innate immune cells such as NK, invariant NK T (iNKT) cell and γδ T 
cells and adaptive immune cells, CD4+ and CD8+ T cells. IFN-γ has the ability to synergize or antagonize 
the effects of cytokines, growth factors, and signaling pathways and is important for the activation of 
macrophages, which in turn exerts increased phagocytosis and bactericidal effect. MAP may remain 
intact or replicate in persistently infected macrophages, or are degraded for antigen presentation to T 
cells. Activated macrophages in turn produce increased amounts of IL-1α, TNF- α, IL-6, IL-8, IL-12, IL-18, 
and IL-23. Enhanced production of IL-1α leads to upregulation of an antiapoptotic protein, TNF receptor-
associated factor 1 (TRAF1) that in turn limits signaling of CD40, TNF-α, and CD95 (FAS) and 
programmed cell death (25). The resultant effect is the recruitment and prolonged survival of 
macrophages at the MAP infection site leading to diffuse granulomatous inflammation. IL-8, a 
chemotactic factor recruits other immune cells such as neutrophils and lymphocytes to the affected 
area (106). IL-12, IL-18 and IL-23, produced by activated macrophages stimulate IFN-γ production by 
CD4+ T cells and γδ T cells (120). Once activated, macrophages or dendritic cells emigrates the site of 
MAP encounter to PP or the mesenteric lymph nodes, the sites of T cell activation and critical signaling 
events. Several adhesion molecules such as CD62L, CD44, VLA-4 and chemokine receptors such as CCR7 
and its ligands, CCL19 and CCL21 are associated with activated macrophage or dendritic cell migration to 
the lymph nodes (136). The cascade of cytokines then leads to activation of T cells in combination with 
antigen presentation. T cell activation is an instructively programmed process and is divided into 3 key 
signals (50)(Figure 4). During Signal 1, macrophages or DCs present antigen associated with major 
histocompatibility complex (MHC) class I to CD8+ or class II molecules to CD4+ T cell, respectively. Signal 
2, the costimulatory cell surface signal involves interaction of CD80 (B7-1) and CD86 (B7-2) on the 
antigen presenting cells (APCs) with the CD28 on T cells. While, Signal 3 is provided by cytokine cascade 
described above. Activated T cells will in turn travel through peripheral blood and home to mucosal 
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MAP affected sites in order to exert their effector functions (Figure 3). Activated T cells produce IL-2, 
which helps in the clonal expansion of CD4+ helper T cell and CD8+ cytotoxic T cells.  T cells produce a 
myriad of cytokines and based upon their effector functions can be differentiated into distinct T cell 
lineages.   
 
Figure 4: Signals for T cell activation. From Gutcher and Becher, 2007 (50). 
 
T cell subsets  
CD4+ helper T cells (TH) are predominant proliferating cell populations and major producers of IFN-γ in 
MAP infection (149). TH cells can differentiate into several types of effector cells: TH1, TH2, TH17, and 
TH3/regulatory T cells, each characterized by production of distinct sets of cytokines. TH1 cells produce 
IFN-γ, TNF-α and IL-2, activate macrophages and generate CD8+ cytolytic T lymphocytes (CTL), all 
required for control of MAP. The signature TH1 cytokine, IFN-γ, enhances IgG2a class-switching (25). TH2 
cells produce IL-4, IL-5, and IL-13 that enhance antibody production and antibody-dependent cellular 
responses against MAP. The signature TH2 cytokine, IL-4, instructs B cells to produce antibodies. In 
paratuberculosis, early and late stages of disease have been associated with a predominance of TH1 and 
TH2 cells, respectively. However, recent findings suggests towards a less distinct predominance of both T 
cell subsets in mycobacterial infections including paratuberculosis (10, 148). TH17 cells produce IL-17, IL-
21 and other cytokines/chemokines, recruit neutrophils and have been shown to play a possible role in 
the pathology of MAP infection in animals (130, 145) as well as humans (119) (Figure 3). TH3/regulatory 
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T (Treg) cells serve to maintain self and peripheral tolerance. Treg cells mediate suppression of effector 
cell by producing IL-10, transforming growth factor beta (TGF-β) and IL-35 (Figure 3). Yet, new T cell 
subtypes have been identified recently including follicular helper T cells (TFH), TH9 cells, TH22 cells, 
mucosa-associated invariant T cells (MAIT), and alternative MHC 1b restricted T cells with possibilities of 
identifying even more subsets in the future (116). The TH1 and TH2 immune profile may represent the 
most stable of all cell lineages and being programmable to memory phenotype (162), however, other 
cell types are more plastic both in vitro and in vivo with TFH appearing to be the most fluid subset. New 
findings argue that although some cytokines are selectively produced, many are broadly expressed and 
that helper cells can change their phenotype and therefore, their plasticity and heterogeneity should 
not be ignored (116) (Figure 5).   
 
Figure 5: Helper T cell differentiation (a) The classical T cell lineage model (b) Flexibility and plasticity of 
helper T cells. From O’Shea and Paul, 2010 (116).  
 
Cytotoxic CD8+ T cells (CTL), are another major fraction of αβ T cells that also play a role in defense 
against MAP by removing infected cells through contact-dependent lysis and release of cytokines (24). 
Activation of CD8+ T cells through presentation of mycobacterial antigen from phagosome on the MHC 
class I molecule occurs through the process of cross-presentation. CTL activates apoptotic cell death in 
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the mycobacteria infected cell releasing preformed secretory granules including perforin, granzymes, 
and granulysin or FAS/FAS ligand pathway (197). CD8+ T cells also contribute to IFN-γ production in MAP 
infected animals  (152). Although CD4+ T cells have been found to play a role in the early stages of 
paratuberculosis, CD8+ T cells may play a more significant role in late infection (81). 
 
γδ T cells, a distinct linage of T cells expressing γδ T cell receptor (TCR) have increasingly been identified 
to play a role in host defense against mycobacterial infections as well as serving a bridge between innate 
and adaptive immunity (Figure 3). γδ T cell number can exceed 50% of the circulating T lymphocytes in 
blood and lymph in the young animals (193). γδ T cells are characterized by absence of MHC restriction, 
enormous γδ TCR diversity and their ability to recognize soluble proteins and non-protein molecules 
such as mycobacterial lipids by CD1 molecule. In addition, bovine γδ T cells respond directly to pathogen 
associated molecular patterns (PAMPs) and may even act as APCs (22). γδ T cells produce cytokines and 
have cytotoxic properties and play a yet undefined role in early MAP infection. Quantities of IFN-γ 
secreted by γδ T cells in response to MAP antigens appear to be lower than produced by CD4+ T cells, 
but the response is antigen-specific (144). γδ T cells were not able to restrict the growth of MAP after 
challenge but were involved in the formation of epitheloid granuloma instead (163). However, in 
another study, loss of CD4+ T cell in the final stages of paratuberculosis have been associated with an 
increase in γδ T cells (75).        
 
Regulatory T (Treg) cells play a critical role in the maintenance of tolerance by regulating immune 
responses to self and foreign antigens and also in mycobacterial infections. Treg cells are a very 
heterogeneous T cell population with distinct subsets including thymus derived, naturally occurring 
CD4+CD25+FoxP3+ Treg and many subsets of peripherally developed, induced or adaptive Tregs 
(CD4+CD25-) such as IL-10 secreting TR1 cells and TGF-β secreting TH3 cells. Treg cells suppress the 
activation, proliferation and effector functions of CD4+, CD8+, NK, B cells and APCs through cytokine-
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mediated suppression by IL-10, TGF-β, IL-35, CD25 or by direct cell-to-cell contact-mediated suppression 
through CTL antigen (CTLA) 4, lymphocyte activation gene 3 (LAG-3), granzyme A and B, and FAS-FAS 
ligand (135). In mycobacterial infections with long subclinical phase including paratuberculosis, reduced 
effector T cell activity has been associated with the development of Treg cells. In paratuberculosis 
clinically infected cattle, MAP antigen stimulated peripheral blood mononuclear cells (PBMCs) secrete 
IL-10 (27), while the infected tissues secrete elevated levels of TGF-β (72). In animals infected with 
paratuberculosis, it was proposed that Treg cells could play a role in the advanced stages of infection by 
antagonizing TH1 response (31). IL-10 produced from PBMCs of cattle with subclinical paratuberculosis 
was found to reduce IFN-γ secretion (31).  IL-10 production from PBMCs of MAP infected animals have 
been shown to be predominantly derived from monocytes (92, 94, 159). Recently, CD4+CD25+Treg cells 
producing IL-10 have been identified in bovine paratuberculosis (26). However, γδ T cells have also been 
associated with regulatory activity in MAP infection in cattle (17).    
 
Humoral immune response to MAP 
Antibody responses generally correlate to mycobacterial-elicited pathology in accordance with the belief 
that Mycobacteria spp. induce antibody primarily late in the course of infection. Little data is available 
that strongly associates B cell responses with paratuberculosis, although an antibody response is usually 
associated with the onset of clinical paratuberculosis. Antibodies can play a role in the extracellular 
phase of MAP when translocating from lumen to intestinal macrophages or from dying infected 
macrophages to young uninfected monocytes and macrophages. Antibodies may even facilitate uptake 
of MAP on their target through macrophage Fc receptors (FcR) and it could even be speculated that 
increased levels of antibodies are mediators rather than indicators of disease progression. Two subsets 
of B cells have been recognized based on the expression of surface marker CD5, CD5+ B cells or B1 cells 
and CD5- B cells or conventional B cells. Once activated, B cells can differentiate into either antibody 
secreting plasma cells or memory cells. Antibodies mediate their protective effects through a wide panel 
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of classical effector functions such as neutralization, opsonization, complement fixation, oxidative burst, 
and antibody- dependent cell-mediated cytotoxicity (ADCC) (Figure 3). In addition to antibody 
production, B cells can act as APCs and play a role in the activation of CD4+ TH2 cells. Studies in 
mycobacterial infections have linked B cell function with disease state such as delayed dissemination of 
M. tuberculosis from lungs to spleen and liver in B cell knockout mice (11). In clinically MAP infected 
cattle, a high increase in B cell numbers was reported compared to subclinical cattle (177). Likewise, a 
decrease in the CD5dim B cell population along with a concomitant increase in CD5bright B cells 
(equivalent to B1a cells) was observed in subclinically infected cattle, reflecting a shift in host immunity 
during the disease process (151). In MAP experimental challenge studies in calves, a strong B cell 
response was observed with a difference between routes of challenge (150). MAP-specific antibody 
responses were found to be higher in calves challenged intraperitoneally than the calves challenged 
orally. Although MAP antibody responses are usually observed in clinical stages, they can be measured 
from 2 years of age with the current diagnostic assays. However, a transient antibody response was 
detected 70 days post-infection against defined recombinant MAP antigens (7). MAP infection is usually 
accompanied by a shift in the percentage of B cells in the peripheral blood, with high numbers in clinical 
infected cattle compared to subclinically infected or control cattle (153).  
 
In cattle, a distinction between TH1 and TH2 associated antibody isotypes have been described with IgG2 
and IgM isotypes classified as type 1, while IgG1 and IgA classified as type 2 isotypes (39). In 
paratuberculosis, shifting of the two isotypes has usually been attributed to a loss of type 1 reactivity. 
However, loss of type 2 reactivity have been described to few MAP antigens such as Hsp70 and LAM 
(78). All these findings suggest a role for B cells in regulating pathogenesis of MAP infection and an 
optimism to develop recombinant antigens from different stages of disease to fully understand the role 
of B cells in paratuberculosis.      
 
40 
 
Immune memory 
Memory T cell pool is heterogeneous and comprised of cells with different migratory and effector 
capacities (136). Thus some memory cells express chemokines and immune markers required for 
migration to lymph nodes and are called central memory T cells (TCM). Other memory T cells do not 
express lymph node homing markers but migrate to tissues and infection sites to execute effector 
functions and are referred to as effector memory T cells (TEM). Both these memory T cell types have 
increasingly been associated with strong immune responses in secondary infections and have potential 
as immune correlates of vaccine-induced protection (Figure 6).  
 
 
Figure 6: Models for effector and memory T cell differentiation. From Seder et al., 2008 (142). 
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Unlike human and mice memory T cells, the TCM and TEM cells are not yet fully characterized in 
ruminants. One of the reasons is the lack of species-specific antibodies and markers for labeling central 
and effector memory T cells. In experimental MAP infection studies in calves, an increased expression of 
activation markers such as CD25, CD26 and memory marker CD45RO+ have been observed among CD4+ 
and CD8+ T cells following restimulation of PBMCs with MAP antigens (3, 81, 175). L- Selectin or CD62L, 
mediates specific adhesion to peripheral lymph node vascular addressins targeting resting lymphocytes 
to areas of high antigen concentration with lymph nodes. Low expression of CD62L (CD2+CD62L-) has 
been used to define memory T cells in paratuberculosis (181). CD44 is a T cell marker that is up 
regulated on lymphocytes upon activation and has been associated with memory T cells with effector 
functions. In M. bovis infection in cattle, expression of CD25 and CD44 was found to be increased in 
proliferating T cells in the periphery compared to decreased expression of CD62L (176). This over 
expression was accompanied by a high IFN-γ release confirming their effector memory status. In 
ruminants, TCM have not been fully characterized as yet due to lack of specific antibodies against 
chemokine receptors such as CCR7. However, TCM and TEM have been described in cattle following 
Mycoplasma mycoides subsp. mycoides infection based on CD62L and CD45RO memory markers along 
with gene expression of CCR7 (167). 
 
MAP persistent infection 
One of the hallmarks of mycobacterial infections is their ability to maintain infection in the host even in 
the presence of inflammation, innate immune defense and a robust adaptive immune response, and 
thereby giving rise to persistent infections, which can be life-long at times. MAP is an intracellular 
bacterium and uses several survival tactics to adopt a persistent life style including modulation of initial 
uptake, immunoescape and immunomodulation. Different routes of entry can alter the intracellular fate 
of MAP e.g. complement receptor (CR1) and mannose receptor mediated uptake of MAP doesn’t 
stimulate the production of superoxide anion (60) and NADPH oxidase (156), respectively. Also, CR3-
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mediated uptake doesn’t affect the intracellular fate of MAP. MAP cell wall lipoglycan, mannosylated 
LAM (ManLAM) induces marked expression of both IL-10 and TNF-α through TLR-2 signaling. High IL-10 
expression in turn suppresses both the inflammatory and immune response to MAP.  
 
MAP can escape the potential microbicidal mechanisms of phagocytes by inhibiting phagosome-
lysosome fusion and phagosomal acidification (195). This has been recognized as a major 
immunoescape mechanism in persistent MAP infection. MAP infected bovine macrophages have the 
ability to produce superoxide dismutase (SOD) and evade killing by reactive oxygen intermediates (ROIs) 
including superoxide anion, hydrogen peroxide, and hydroxyl radical produced during the process of 
phagocytosis (179). Likewise, MAP infected macrophages produce insufficient amounts of reactive 
nitrogen intermediates (RNIs) such as nitric oxide (199).  
 
Apoptosis of mycobacteria infected macrophages is another mechanism for the intracellular killing of 
bacilli. Mycobacteria including MAP resist apoptosis for their prolonged survival (195). Recently, it was 
reported that MAP-infected macrophages show a drastically low ability to activate caspases and 
subsequently suppresses host cell apoptosis (65). Adenosine tri-phosphate (ATP) released from resting 
cells as well as cells undergoing apoptosis or necrosis can kill MAP through the activation of purinergic 
receptors. Elimination of extracellular ATP has been found to increase the survival of MAP-infected 
bovine monocytes (194).  
 
MAP favors its survival by exploiting ongoing granulomatous inflammatory reaction by recruiting new 
macrophages that are used for bacterial dissemination. MAP then interferes with macrophage activation 
and production of cytokines including IL-8, IL-12 and TNF-α (179) or promotes rapid IL-10 production. In 
addition, MAP also attenuates MHC class I and II expression in bovine monocyte-derived macrophages 
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(180). Thus MAP employs a broad anti-immune strategy to survive and escape host immune elimination 
that leads to a chronic persistent infection.          
 
Immune markers and correlates of protection 
In infections with long periods of latency such as mycobacterial infections, measuring the immune 
response from clinical endpoints is difficult and thus the development of vaccines will rely on 
demonstration of immunological correlates of protection. A correlate of protection is a specific immune 
response to a vaccine that is closely related to protection against infection or disease or other defined 
endpoint (125). However, for persistent infections with long latency such as mycobacterial infections, it 
is difficult to define the absolute correlates of protection. CMI responses, chiefly IFN-γ production has 
served as the basis for the selection of candidate vaccine antigens in mycobacterial infections. However, 
a few recent studies have challenged the role of IFN-γ in protection against tuberculosis infection (42, 
66). At the same time, in paratuberculosis, instead of a TH1 CMI response, a strong antibody response 
has been observed following Hsp70/DDA vaccination (74). The role of antibodies in mycobacterial 
infections has already been appreciated by others (45). T cell quality i.e. T cells capable of producing IFN-
γ, TNF-α and IL-2 cytokines, referred to as ‘polyfunctional T cells’ have been demonstrated as a hallmark 
of vaccine-induced protective immunity as well as infection in several chronic intracellular infections 
(30, 142). However, other studies have failed to correlate risk of disease or protection with 
polyfunctional T cells (42). Polyfunctional T cells have been demonstrated recently in cattle naturally 
infected with M. bovis (183). A number of other immunological parameters have been studied as 
markers of protection in mycobacterial infections but have yielded inconsistent results (174).    
 
Control: whole-cell vaccines 
After the paratuberculosis disease recognition in 1895 and isolation of the causative bacteria in 1911, 
Vallee and Rinjard soon introduced vaccination for the control of paratuberculosis in the year 1934 
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(171). This vaccine consisted of a live non-virulent MAP strain with an adjuvant made of olive oil, liquid 
paraffin and pumice powder. The results of this vaccine prompted the use of vaccine against 
paratuberculosis in other countries. In the 20th century, a number of vaccines were developed and were 
available commercially such as killed, live attenuated or improved whole-cell based vaccines. Most of 
the currently used vaccines use same basic formulation of whole bacilli in an oil adjuvant. Vaccination in 
cattle does not play a central role in paratuberculosis control in any country. All of these vaccines 
prevent the clinical signs and reduce faecal shedding but were unable to prevent the onset of infection 
(170). An important disadvantage of these vaccines is the interference with serological diagnosis of 
paratuberculosis and tuberculosis infections as these vaccines does not hold potential for a DIVA 
(differentiating infected from vaccinated) (80, 155). Thus vaccination against MAP might not allow 
disease eradication, yet interfere with national tuberculosis eradication programs and poses a challenge 
for the export of cattle. There are also safety concerns with inactivated vaccines as localized tissue 
damage has been reported in humans by accidental self-inoculation (123).        
 
MAP vaccines: recent development 
New paratuberculosis vaccines have been developed over the years with emphasis on subunit vaccines, 
mostly MAP recombinant proteins with adjuvants (67, 74), DNA vaccines (132, 140), expression library 
immunization (58), and mutant MAP strains (14, 121). Many immunodominant protein antigens 
inducing strong TH1-type immune response have been developed and tested in MAP experimental 
infections in calves but found to have low efficacies: members of antigen 85 complex, Ag85A, Ag85B, 
and Ag85C (107); Hsp65 (GroEL) and Hsp70 (DnaK) (79); lipoprotein P22, a Lppx/LprAFG family of 
mycobacterial lipoprotein (37); PPE family proteins, MAP1518 and MAP3184 (108); SOD (MAP2121c) 
(144); and MPP14, a 14-kDa secreted protein (118). A cocktail of recombinant proteins (Ag85A, Ag85B, 
Ag85C and SOD) in combination with MPL or MPL+IL-12 adjuvant were tested in experimental MAP 
infected calves but failed to induce complete protection (67). Subunit vaccines have the advantage that 
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well-characterized antigens can be used to induce immune responses. Moreover, it has been shown that 
candidate Hsp70/DDA subunit vaccine did not interfere with the specificity of comparative skin test, is 
suitable for developing antibody based assays and it serves as a DIVA vaccine (137, 138) but it does not 
give complete protection. The development of new vaccines against paratuberculosis needs to consider 
several aspects including safety, efficacy, absence of interference with tuberculosis and paratuberculosis 
diagnosis, possibility for a DIVA strategy, and ability to control onset and progression of infection in 
animals. Many experimental MAP challenge studies in cattle have highlighted the importance of 
parameters such as experimental challenge conditions, dose, inoculation route, challenge strain, age, 
samples, analysis and experimental endpoints to be critical for the establishment of a bovine infection 
model.  
 
Experimental MAP infections 
Different MAP strains of cattle were found to produce different immunological profiles in 
experimentally infected calves (154). In terms of age, older animals were found to be more resistant to 
infection (103). Infectious dose ranging from 1 x 106 colony forming units (CFU) to 4-8 x 1010 CFU have 
been used in different experimental challenge studies (52). In addition to the common oral challenge, 
other routes such as intratonsillar, subcutaneous, intravenous, intrauterine, intranasal, and 
transtracheal routes have been used in cattle. Variable infection levels have been reported using either 
oral, subcutaneous or intravenous routes of inoculations (87). Similarly, variation in genetic 
susceptibility between breeds and blood lines has been observed in cattle (77). International guidelines 
for the experimental challenge models for paratuberculosis have been proposed by the Johne’s Disease 
Integrated Project (JDIP) Animal Model Standardization Committee (AMSC) in year 2007 (52). In addition 
to ruminants, mouse models have been used for the testing of vaccine candidates. Although mice are 
not the target species for paratuberculosis, they serve as a valuable tool for the preclinical testing of 
potential vaccine candidates owing to availability of a broader immunological toolbox, various genetic 
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backgrounds of inbred mice and the low maintenance cost (52). One of the other important needs for 
the development of new vaccines against paratuberculosis is the evaluation of vaccine efficacy and 
potency. Due to slow progression of disease, lengthy experimental trials, and associated high costs, it is 
imperative to define vaccine immune correlates and protection markers to develop potency tests.      
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AIMS OF THE STUDY 
The main aim of the thesis was to identify antigens from different phases of MAP infection and 
formulate them into a vaccine with targeted activation of protective CMI responses. Development of a 
multi-stage vaccine against paratuberculosis has the potential to significantly increase the health and 
welfare of infected cattle and reduce the environmental contamination with this supposedly zoonotic 
bacterium. 
          
Hypotheses 
1. The protein expression profile of MAP is different in acute versus chronic stages of the infection 
2. A vaccine stimulating CMI against both acute and latent stage antigens will be able to decrease 
bacterial load in newly infected animals and prevent the re-activation of infection leading to 
clinical disease in older animals. 
3. Immune response to MAP vaccine will be influenced by the age of vaccination. 
4. Polyfunctional T cells will be an immunological correlate of vaccine-induced protection. 
 
Research Strategy 
The clinical course of paratuberculosis is usually described as a progressive infection, but although 
animals become infected in early life, the typical clinical case of paratuberculosis is an adult cow that has 
not shown any clinical (or immunological) sign of infection for several years. Rather than a simple 
straightforward progression of disease, we believe it may, therefore, be more correct to describe the 
slow pathogenesis of paratuberculosis as an initial acute, actively dividing phase followed by a latent, 
resting phase where the infection is hiding from adverse immune reactions inside macrophages and only 
replicates slowly, if at all. During the latent phase, the bacterium expresses a different profile of 
proteins, and at a low level, compared to the active phase. Thus in order for a modern vaccine to be 
efficiently protective against new infections and also fight existing latent infections, the vaccine must 
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address these different sets of proteins expressed in different phases of the infection. We call this 
vaccine strategy a ‘multi-stage’ vaccine. Such a vaccine should be able to decrease the bacterial load in 
newly and latently infected animals and prevent re-activation of dormant bacteria. Furthermore, the use 
of well-defined antigens in the vaccine makes possible the use of standard ELISA assays with 
complimentary antigens (e.g. a paratuberculosis LAM ELISA) to develop a DIVA vaccine. Using this 
strategy, two prototype vaccines Ag85b-ESAT6-Rv2660c and Ag85b-TB10.4-Rv2659c have been proven 
to be superior to Ag85b-ESAT-6 and Ag85b-TB10.4 (e.g. the vaccines without the therapeutic antigen), 
both as a preventive multi-stage vaccine and as a therapeutic vaccine against latent tuberculosis in 
animal models such as mice and non-human primates. We have followed a similar strategy and 
identified MAP antigens from the different phases, formulated corresponding fusion proteins in an 
adjuvant with specific targeting of cell-mediated immune responses, and tested this vaccine in an 
experimental MAP bovine model. 
 
Specific Objectives 
• To formulate a multi-stage vaccine against paratuberculosis with strong activation of cell-
mediated immune responses based on antigens from MAP representative of both acute and 
latent stages of the infection 
• To characterise the vaccine-induced immune responses and the short-term protective efficacy 
of the vaccine against an experimental MAP infection in young calves 
• To provide the basis for a subsequent evaluation of long-term therapeutic effect of the vaccine 
in chronic infected cattle 
These specific objectives were investigated through following studies: 
1. Influence of age of vaccination on MAP vaccine-induced T cell responses  
2. Costimulation and vaccine-induced ex vivo IFN-γ production by T cell subsets 
3. Immune markers and correlates of protection for vaccine-induced immune responses 
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4. A multi-stage MAP vaccine-induced immune responses and protective efficacy after 
experimental challenge 
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METHODOLOGICAL CONSIDERATIONS  
The work described in this thesis is based on two experimental studies in calves named MAP multi-stage 
vaccine (MSV)-1 and MAP MSV-2. In brief, MAP MSV-1 experiment was conducted to evaluate the effect 
of age on vaccine-induced immune response and the calves were vaccinated but not MAP challenged. In 
the MAP MSV-2 experiment, all the calves were challenged with MAP and then divided into different 
vaccine groups and a non-vaccine group.  
  
Animals 
Male jersey calves were used for the two experimental studies. All the calves were obtained at the mean 
age of 2 weeks from a farm, which by the Danish paratuberculosis surveillance program had a true 
prevalence equal or close to zero at all milk-antibody samplings from September 2006 to January 2011 
(101). For the MAP MSV-1 experiment, 27 calves were used that were divided into three groups- Vac2w, 
Vac8w and Vac16w. On the other hand, 28 calves were used for the MAP MSV-2 experiment and were 
randomly distributed into four groups- Early FET11, Late FET11, Silirum® (CZ Veterinaria, Spain) and 
Control. Silirum® is a heat-inactivated vaccine containing 2.5 mg of the culture of strain 316F of MAP 
combined with an adjuvant consisting of highly refined mineral oil.    
  
Inoculum preparation, challenge and vaccination 
All the calves in the MAP MSV-2 experiment were challenged with live MAP bacilli at the age of two 
weeks. The strain of MAP used for the challenge of the calves was a Danish clinical isolate, Ejlskov 2007 
isolated from the faeces of a 4 year old clinically MAP shedder cow in 2007. The MAP culture was 
growing on LJ medium slants. A single colony from the LJ slant was resuspended in MB7H9 medium 
supplemented with 10% oleic acid-albumin-dextrose complex plus 0.05% Tween 80 and 2% Mycobactin 
J. Culture was propagated in the medium as depicted through figure 7 and stocked with 15% glycerin at  
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Figure 7: Preparation of MAP Inocula (Figure Aneesh Thakur). 
1Middlebrook medium 
• MB7H9 broth (4.7 g/l) 
• Mycobactin J (2 mg/l) 
• Dubos Oleic Albumin Complex 
(100 ml/l) 
• Tween 80 (0.5 g/l)  
2at 37°C on shaker   
3Validation of purity 
• Blood agar plates (duplicate), 48 
hrs, 37°C (Contamination controls) 
• Ziehl-Neelsen staining 
• IS900 PCR 
4Contamination controls were performed   
  when sampled for optical density (OD)-   
  measurement 
5Quantification of live MAP bacilli 
  Serial dilutions of culture on MB7H10      
  agar plates for CFU count 
 
 
   
 
 
MAP Ejlskov  
(growing on LJ 
slants) 
A single colony in 20 
ml MB7H91 culture2 
until 0.3 OD600nm 
(21 days) 
Validation3 
Basis culture 
2 ml aliquots 
(+15% glycerin) 
Store at -80°C 
2 ml in 250 ml MB7H91 
until 0.3 OD600nm (20-30 
days4) 
500 ml MB7H91 until 0.3 
OD600nm (4-5 days4) 
Validation3 
Inoculum aliquotes 
1ml aliquotes, 1x109 cfu= 
0.3 OD600nm  (+15% 
glycerin) store at -80°C 
Inoculum-suspension  
48 hrs prior to inoculation 
1ml aliquot + 20 ml 
MB7H91 
Quantification5 
on the day of inoculation 
500 µl suspension used 
for serial dilutions for CFU 
on solid media MB7H10 
Inoculum  
rest suspension diluted in 
prewarmed 1 liter milk 
replacer and fed to calves 
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-80°C at the concentration of 1 x 109 CFU/ml. The number of CFU was determined using the pelleted wet 
weight method that estimates approximately 1 x 107 CFU/mg pelleted wet weight (52). Two days before 
inoculation, 1 ml inocula aliquot was thawed in water bath (37°C) and added to pre-warmed media 
(MB7H9 with supplements; 20 ml) to prepare MAP inoculum for individual animal. The whole 
suspension was then incubated on a shaker at 37°C for 48 h. For inoculation, calves were fed 20 ml MAP 
suspension in a liter of pre-warmed (38°C) commercial milk replacer three times within a week period.  
 
As the principal route of MAP infection in calves is through the contaminated milk at an early age, we 
believe that our method of experimentally infection of calves is relatively close to the natural infection. 
Infection dose of 1 x 109 CFU/ml was selected based on published MAP experimental studies and 
considering the recommendations of the International committee for standardization of MAP challenge 
models (52). Vaccination of the calves in both studies was performed by inoculating MAP recombinant 
proteins formulated in CAF01 adjuvant sub-cutaneously in the right mid-neck region about 7 cm ahead 
of the prescapular lymph node. We believe that this method of vaccination should result in a better 
antigen presentation and strong TH1 immune response based on prior knowledge using CAF01 adjuvant 
in mice models of human tuberculosis (90).  
 
Antigens incorporated in multi-stage vaccine in both MAP MSV-1 and MAP MSV-2 experimental studies 
were selected based on previous immunogenicity studies in MAP infected and free cattle and 
experimental knowledge from in vitro and in vivo expression studies with M. tuberculosis proteins in 
mice (99, 101). Figure 8 illustrates the approximate molecular weights of the five vaccine proteins used 
in the MAP MSV-2 experimental study.  
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Figure 8: SDS-PAGE analysis of purified recombinant MAP proteins. Lane M: marker of protein size (kDa); 
Lane E: empty; following lanes show 1 µg of each of ESAP-5, ESAP-2, MAP-3, ESAP-3, and LATP-5. Protein 
bands were visualized by silver staining (Photo Aneesh Thakur). 
 
Whole-blood IFN-γ test 
The antigen-specific IFN-γ secretion in 18-20 hrs whole-blood culture supernatants was determined by 
use of an in-house monoclonal sandwich ELISA as has been described previously (102). We also 
considered the incubation time of 48 and 96 hrs but found higher background values at both time 
points. Earlier we have reported enhanced IFN-γ responses in whole-blood cultures using recombinant 
IL-12 or anti-IL-10 antibodies (99). Therefore, we tested using recombinant bovine IL-12 and IL-18 
(porcine and human) in the blood cultures for measuring IFN-γ responses. After recombinant IL-12 or IL-
18 costimulation, a significant increase in the IFN-γ response was observed. The increase in the IFN-γ 
response using either porcine or human recombinant IL-18 was found to be identical. We did, however, 
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find that recombinant IL-12 or IL-18 as well as their combination apparently resulted in higher 
background values, at least in samples from few vaccinated animals as well as an adjuvant control 
animal in MAP MSV-1 (not reported) experiment. Incubation and costimulation kinetics were not 
pursued further in the whole-blood cultures for IFN-γ measurement.  
 
Antigen-specific serum IgG1 ELISA 
An in-house developed and optimized indirect ELISA was applied for the demonstration of serum IgG1 
antibody responses in MAP MSV-1 experiment. In this study, serum IgG2 levels were also measured but 
were found to be very weak for any useful interpretation and thus were excluded from serological 
response analysis. The important considerations for quantitative and qualitative solid phase 
immunoassays including ELISA are choice of solid phase surface, coating proteins and their coating 
concentrations, blocking buffer, secondary antibody or conjugate, positive control and the substrate. 
For antigen coating, we tested MAP recombinant proteins at coating concentrations of 0.2 µg/ml, 1 
µg/ml and 5 µg/ml and selected 0.2 and 1 µg/ml as optimum for our setup. Bovine serum albumin (BSA) 
as well as casein was tried as blocking buffer. However, an increased background response was 
observed in plates using casein as blocking buffer in two adjuvant control animals in MAP MSV-1 
experiment. So the BSA buffer was employed as blocking buffer in this assay. Anti-bovine IgG1: HRP 
conjugate was titrated and 1:500 dilution (final conc. 0.5 µg) was found to be optimum. As a positive 
control included on all plates, we used the serum samples of a vaccinated calf with consistently high 
antibody responses, while the sera sample on the day of vaccination from the same calf was used as 
negative control.  
 
Multicolor Intracellular cytokine staining and flow cytometry  
As we hypothesize earlier that polyfunctional T cells could be an immunological correlate of vaccine- 
induced protection, so we used multi-color flow cytometry to substantiate our statement. However, due 
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to non-availability of bovine specific IL-2 antibody at that point of time and some difficulties with bovine 
anti-TNF-α staining, we only managed to measure IFN-γ production by flow cytometry. With bovine TNF-
α antibody we observed surface as well as intracellular expression of TNF-α as has been reported earlier 
in one study (49). We were not able to differentiate bovine TNF-α expression between PBS stimulated 
and SEB stimulated cultures in few animals. With the recent availability of bovine specific IL-2 antibody, 
polyfunctional T cells producing IFN-γ, TNF-α and IL-2 have been demonstrated in cattle naturally 
infected with bovine tuberculosis (183) and we were able to replicate the polyfunctional T cell staining 
protocol in our lab (Figure 9). In addition, we also looked at the expression of surface markers including 
CD25, CD44, CD62L and CCR7. 
 
For the measurement of antigen-specific IFN-γ production, a protocol was developed in order to identify 
the specific cell populations producing IFN-γ in the stimulated PBMCs cultures including CD4+, CD8+, γδ 
T cells and NKp46+ cells. Two different 18-20 hrs culture protocols were tried for measuring IFN-γ 
release, one protocol included Brefeldin and Monensin A for the last 6 hrs and the other used Brefeldin 
and Monensin A for the last 12-14 hrs. The first protocol was used due to high production levels of IFN-γ 
in PBMCs cultures. For the surface phenotyping of IFN-γ producing cells, anti-CD2, anti-CD3, anti-CD4, 
anti-CD8, anti-WC1, and anti-NKp46 antibodies were used. In six of the MAP MSV-1 experimental 
animals, the anti-CD4 monoclonal antibody (Clone CC8) didn’t stain at all and anti-CD4 antibody (Clone 
IL-A11) was, therefore used for the rest of the study. Potentiation of the IFN-γ responses was also 
studied using recombinant IL-12, porcine or human recombinant IL-18, anti-CD28, anti-CD49d, or anti-
CD5 antibodies. We also looked into CD4+, CD8+ and γδ T lymphocytes proliferation and activation using 
carboxyfluorescein succinimidyl ester (CFSE) proliferation assay and expression of activation markers 
CD25, CD44, and CD62L in 5 days old cultured PBMCs. A high expression of activation markers was 
observed among proliferating lymphocytes.  
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Figure 9: Identification of lymphocytes producing IFN-γ, IL-2 and TNF-α. PBMCs from experimental 
calves were isolated, stimulated with PPDj antigen, stained by intracellular cytokine staining (ICS) and 
interrogated by flow cytometry. Plots were gated on live lymphocytes and analyzed for all combinations 
of concurrent IFN-γ, IL-2 and TNF-α production. Numbers indicate percentage of lymphocytes in the 
seven individual cell subsets (Illustration of FACS plots for polyfunctional ICS, Aneesh Thakur). 
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0.17 
0.03 
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In MAP-MSV-2 study, we also stimulated PBMCs at defined time points with vaccine antigen cocktail, 
superantigen and PBS for 4 hrs and froze the cells at -70°C in RLT buffer for future mRNA expression 
analysis.  
 
Comparative intradermal tuberculin skin testing 
Comparative intradermal tuberculin skin testing using bovine and avian PPD was performed on all the 
animals from both studies before slaughter. The skin thickness was recorded 72 hours after intradermal 
injection of PPDs, and results were interpreted according to guidelines of European Communities 
Commission regulation 141 number 1226/2002 (105). Additionally, protein and peptide cocktails 
containing ESAT-6, CFP10 and Rv3615c were used for skin testing to rule out cross-reaction with bovine 
TB. In MAP-MSV-2 study, we collected PBMCs from all animals prior to skin testing and froze down the 
PBMCs at -70°C in freezing mixture comprising of 10% dimethyl sulfoxide (DMSO) and 50% foetal calf 
serum (FCS) in RPMI medium.     
   
Necropsy 
In MAP MSV-2 experiment, the first eight born calves were euthanized and necropsied at 44 weeks and 
remainder 20 calves at 52 weeks of age. Fourteen tissue samples from each animal were collected 
separately in RLT buffer (for mRNA expression), sterile PBS (for IS900 qPCR), and 10% neutral buffered 
formalin (for histopathology) and included: ileocaecal valve, ileum (0 cm, -25 cm, -50 cm, -75 cm; 
distance indicated relative to the location of ileocaecal valve in proximal direction), jejunum (-100 cm, -
150 cm, -250 cm, -300 cm), and lymph nodes (ileocaecal lymph node; mesenteric lymph nodes 
corresponding to respective distances). Tissue samples in RLT buffer were frozen at -20°C for future 
analyses. For IS900 qPCR, tissue samples were rinsed with sterile PBS. Epithelium, submucosa, and 
lamina propria were scraped from the serosa with sterile object glass. The tissue scrapings were then 
frozen at -20°C in 10 ml sterile PBS. Later, scrapings were homogenized by blending in a homogenizer, 
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centrifuged, weighed and processed for DNA extraction. Samples collected in formalin were embedded 
in paraffin wax and sectioned. Hematoxylin and Eosin (HE) and Ziehl-Neelsen staining was performed on 
the sections using standard histological methods. The analyses of these sections were not performed 
prior to submission of this thesis. We also collected ileocaecal lymph node and spleen tissues in Hank’s 
balanced salt solution (HBSS) at necropsy from each animal and froze down the lymphocytes at -70°C in 
freezing mixture comprising of 10% DMSO and 50% FCS in RPMI medium.     
 
Quantitative Real Time PCR (qPCR) 
qPCR targeting MAP-specific IS900 sequence was employed for the detection and quantification of MAP 
in faecal samples and tissues collected at necropsy. We followed the protocol as has been published 
earlier for the quantification of MAP in ovine faecal samples (69). Primers used in this paper are MAP-
specific and targets the IS900 sequence. However, we were unable to get efficient amplification with 
this primer set and calculations of melting temperature (Tm) gave 75.2°C for the forward and 65.9°C for 
the reverse primer. Because of the large difference in Tm we designed two new primers targeting the 
IS900 sequence in MAP with Tm, 71.7°C and 72°C respectively for the forward (5’-
GGCAAGACCGACGCCAAAGA-3’) and reverse (5’-GGGTCCGATCAGCCACCAGA-3’) primers and found high 
efficiency. Primers were designed using Primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3www.cgi) (133).  
 
For DNA extraction, tissue samples were homogenized and subjected to bead beating (Zirconia/Silica 
beads) followed by genomic DNA extraction using DNAeasy Blood and Tissue kit (Qiagen). DNA 
extraction from faecal samples was done using QIAmp DNA stool kit after bead beating. We didn’t 
culture the faecal samples and tissues in our study due to long culturing time and poor sensitivity of 
MAP culturing. PCR is a highly sensitive technique compared to MAP culturing and has been 
demonstrated to quantify the absolute MAP numbers in clinical samples (68). In our study, we did a 
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relative quantification of MAP among faecal samples and tissues and compared the samples between 
the vaccinated and non-vaccinated groups to observe the protective effect of vaccine. For this we 
designed two standard curves, one for the tissue samples and another for faecal samples by spiking 
their extracted DNA with DNA from the reference MAP bacteria (MAP Ejlskov) in ten-fold dilutions. 
Tissue (jejunum at -250 cm) and faecal sample DNA from an animal found to be consistently negative 
through qPCR was used for spiking. By spiking the tissue and faecal DNA samples with known 
concentration (CFU) of bacterial DNA, we were able to make two standard curves and relatively quantify 
the bacterial number in all the samples. The analyses of faecal samples were not performed prior to 
submission of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
RESULTS 
Article 1 
Cell-mediated and humoral immune responses after immunization of calves with recombinant multi-
antigenic MAP subunit vaccine at different ages    
Neonates and juvenile ruminants are more susceptible to paratuberculosis infection. Thus if calf 
susceptibility to MAP infection is related to maturation of the immune system, the immune response to 
a MAP vaccine may also be influenced by the age of vaccination. The aim of the study was to evaluate 
the appropriate age of vaccination of the animals against a subunit vaccine comprised of five MAP 
recombinant proteins formulated with CAF01 adjuvant in order to generate a high frequency of antigen-
specific T cells with more rapid effector functions. A significant IFN-γ production against the vaccine 
recombinant proteins in all three groups of vaccinated calves as compared to the adjuvant controls was 
observed. Among the five proteins, the most significant responses were observed against MAP-3, LATP-
4 and ESAP-2. Vaccinated calves had IFN-γ levels below 50 pg/ml against both PPDj and PPDb antigens 
confirming the specificity of the vaccine-induced immune response. Among the three vaccine age 
groups, Vac16w had the most consistent IFN-γ responses post vaccination, although there were no 
significant differences in IFN-γ levels against vaccine proteins between the groups. Only exception was 
protein MAP-3, with significantly lower IFN-γ levels in group Vac8w. We couldn’t associate IFN-γ 
producing capacity of the blood cells with the age of the animals when stimulated with superantigens. In 
addition, we didn’t observe any significant increase in the IFN-γ levels after second booster vaccination 
in all three vaccine groups. The humoral IgG1 immune responses against vaccine recombinant proteins 
mostly mimicked IFN-γ responses. Most significant responses were observed against LATP-4, MAP-3, 
ESAP-2 proteins followed by Ag85B and SECP-1. Likewise, the second booster vaccination couldn’t 
elevate the IgG1 responses against any of the five MAP proteins in three vaccine groups. In addition to 
the CMI and humoral immune responses, the effect of subunit vaccine and cross-reaction with bovine 
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tuberculosis was also assessed. No visible swelling or palpable growth or other side effects were noticed 
post vaccination. Comparative intradermal tuberculin testing confirmed all calves used in the study to 
be negative for bovine tuberculosis, which was supplemented by low whole-blood IFN-γ levels against 
PPDb and PPDa. Interpretation as a single tuberculin test also showed negative values in all but one calf.      
       
Article 2 
Increasing the ex vivo antigen-specific IFN-γ production in subpopulations of T cells by anti-CD28, anti-
CD49d and recombinant IL-12 costimulation in cattle vaccinated with recombinant proteins from 
Mycobacterium avium subspecies paratuberculosis 
In MAP infection, the inflammatory environment in the small intestine provides necessary costimulatory 
signals that might be missing on evaluating the IFN-γ responses in ex vivo PBMC assays. The aim of the 
study was to identify the effect of costimulation using signal 2 costimulatory molecule, anti-CD28 
(aCD28) or anti-CD49d (aCD49d) and anti-CD5 (aCD5) mAbs, alone or in combination with a 
costimulatory signal 3 cytokine, recombinant IL-12 (rIL-12) on the frequency of T cells responding to 
MAP antigens in ex vivo PBMCs cultures in experimentally challenged and vaccinated calves. Both 
aCD28/aCD49d and aCD5/aCD28/aCD49d were found to significantly (p<0.01) elevate the MAP vaccine 
antigen-specific IFN-γ production in PBMCs cultures compared to control animals. A significant 
interaction (p<0.05) was observed between aCD28 and aCD49d mAb. Same cultures showed a further 
increase in the IFN-γ levels after addition of rIL-12 alone or rIL-12 with aCD28/aCD49d, though 
accompanied by background IFN-γ release in one of the control animals. Flow cytometry based 
integrated mean fluorescence intensity (iMFI) was measured to detect the enhanced IFN-γ production 
by signal 2 and signal 3 costimulatory molecules among CD4+, CD8+, γδ T cells and NK cells. aCD28 was 
found to enhance more IFN-γ iMFI as compared to aCD49d or aCD5 mAb alone in all cell subsets. 
However, the significant increase in the IFN-γ iMFI with low non-specific background signal was 
observed with aCD28/aCD49d combined with strong effect of interaction (p<0.05). rIL-12 with or 
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without aCD28/aCD49d potentiates IFN-γ production among all four subsets with strong increase in 
CD4+, CD8+ and γδ T cells. This increase was, however, accompanied with an increased background in 
the control animals that was absent in case of aCD28/aCD49d costimulation. While the profile of IFN-γ 
producing cells after aCD28/sCD49d costimulation still reflected the profile without costimulation, the 
marked increase in the IFN-γ production of CD3+CD4+ T cells after addition of rIL-12, with or without 
aCD28/aCD49d, skewed the profile of IFN-γ producing cells towards a CD3+CD4+ T cell dominance.  
 
Article 3 
Immune markers and correlates of protection for vaccine-induced immune responses 
Vaccine development is a cumbersome and lengthy process. The aim of the study was to review 
immune markers and new candidates for correlates of protective vaccine-induced immune responses 
against chronic infections and their possible role in defining the protective immunity in human and 
veterinary medicine. Well-defined and newly recognized immune markers and correlates of CMI and 
humoral immunity were extracted from literature and summarized in two tables. A third table 
summates the T cell immunoassays used to identify CMI based immune markers. While the different 
stages involved in the induction and regulation of CMI and humoral immune responses against 
pathogens has been represented through a figure. Almost all of the commercially available vaccines 
induce a robust antibody response that correlates with the level of protection. The neutralizing antibody 
titers for majority of the available vaccines along with their protective threshold values have been 
reported. Other recognized and potential immune markers and correlates of humoral immunity have 
been discussed as functions of ADCC, immunoglobulin class and subclass (IgG1, IgG2, IgA) and memory B 
cells citing references from many chronic infections. For intracellular infections with antibodies as poor 
correlate of protection, several characteristics of T cell such as phenotype, function, antigen specificity 
and MHC-restriction have been reviewed and discussed as potential correlates of protection. The role of 
TH1, TH2 and TH17 cells, CTL and associated cytokines, particularly IFN-γ has been described as potential 
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immune correlates against chronic infections. MHC tetramers and multimers have been described in the 
light of their potential as immune markers and correlates for viral infections requiring CD8+ T cell 
response. Furthermore, central and effector memory T cells, polyfunctional T cells and innate effector 
cells such as iNKT and γδ T cells have been detailed as proven and potential new candidates. Specific 
examples of existent and potential immune correlates and methods to analyze them for chronic 
infections in veterinary medicine have been explained. A perspective describing the potential of and 
challenge associated with identification of immune correlates especially in infections requiring CMI has 
been set forth. 
 
Article 4 
A novel multi-stage subunit vaccine against paratuberculosis induces significant immunity and 
reduces bacterial burden in tissues 
Paratuberculosis is a staged infection. Effective vaccines are lacking for paratuberculosis control in 
cattle. We hypothesize that a vaccine incorporating proteins from different stages of infection could 
decrease MAP shedding and prevent reactivation of disease. The aim of the study was to develop a 
novel multi-stage paratuberculosis vaccine, FET11 and characterize the protective efficacy in MAP 
infected calves. A fusion of four early expressed MAP proteins and a latency-associated MAP protein 
were formulated with CAF01 adjuvant and injected to MAP challenged calves at two different age 
groups. Efficacy of FET11 vaccine was measured as a function of CMI responses to component vaccine 
proteins and relative bacterial burden in gut tissues (ileum and jejunum) as quantified by IS900 qPCR 
assay. Relative quantification of MAP load in the tissues from six different sites of gut revealed a mean 
1.1 log10 reduction in animals from late FET11 vaccine group compared to control. This decrease was 
correlated with IFN-γ levels in response to vaccine proteins at week 32. IFN-γ response to PPDj was 
correlated with higher bacterial load in non-protected animals at week 48 and 52. A differential immune 
response profile was observed among vaccine groups. Significant IFN-γ production against vaccine 
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proteins ESAP-2, ESAP-5 and LATP-5 was observed in late FET11 vaccinated animals. Antigen-specific 
IFN-γ responses to latency protein, LATP-5 were characteristically absent from control and Silirum® 
vaccinated animals. Two MAP proteins ESAP-2 and MAP-3, that were also present in the MAP MSV-1 
experiment, show reduced immunogenicity in this study. None of the animals from the FET11 vaccine 
groups responded positively to comparative intradermal tuberculin test. While one animal each from 
control and Silirum® groups reacted to PPDb and one of the Silirum® vaccinated animals was positive 
with skin test. Older animals developed a more robust antigen-specific immune response after FET11 
vaccination.             
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DISCUSSION 
FET11 vaccine 
In article 4, we hypothesized that for a vaccine to be effective against paratuberculosis, it should 
incorporate proteins from different stages of infection and such a vaccine could decrease MAP shedding 
and prevent reactivation of disease. A similar approach in human tuberculosis has shown superiority of 
multi-stage vaccine, H56 over BCG vaccine in mice models (1). FET11 vaccine, developed from a fusion 
of four early expressed and a latency-associated protein formulated with CAF01 adjuvant induced 
significant antigen-specific IFN-γ responses in animals vaccinated at 16 weeks of age (Late FET11 
vaccination). Late FET11 vaccination confers protection characterized by a mean 1.1 log10 reduction in 
bacterial load in gut tissues in comparison with control group. This reduced bacterial burden however, 
did not correlate with corresponding whole-blood IFN-γ responses to all component vaccine proteins at 
all time points but at week 32 of the study. This discrepancy implies possible role of antibodies (74) or 
polyfunctional T cells in accordance with our hypothesis that needs to be validated. A differential 
immune response to early and late stage MAP proteins and consistent CMI responses in older animals 
complements our earlier findings from MAP MSV-1 study (Article 1). A correlation between IFN-γ 
responses to PPDj in advanced weeks of the experiment and relative bacterial burden in the tissues 
emphasize PPDj responses as a measure of infection status in experimental MAP infections. The delivery 
of selected candidates as a single fusion protein has the potential benefit of enhanced responses to low 
responder proteins such as MAP-3 and ESAP-3 in our study. Similar observation was found for low 
immunogenic ESAT-6 when used with antigen 85B in a strong adjuvant DDA-MPL (12, 178).     
 
Age of vaccination and immune response to MAP 
In article 1, we hypothesized that the age of calves when being vaccinated against MAP affects the 
vaccine- induced immune response. Results from this study showed reduced cell-mediated immune 
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responses when the animals were vaccinated at 8 weeks of age compared to those vaccinated at 2 or 16 
weeks of age. The 8 weeks time point correlates with dietary stress from the calves being weaned off 
milk.  The humoral response seems independent of this as we saw no difference in the three vaccination 
groups in terms of MAP vaccine-induced antibody responses. In contrast, findings from a recent study 
suggested that ingestion of colostral antibodies interfere with the immune capacity of the young calves 
to produce antigen-specific antibody responses, with little or no effect on cell-mediated immune 
response (115). Among the three vaccine age groups, animals vaccinated at 16 weeks of age had the 
most consistent IFN-γ responses against vaccine proteins (Article 1 and 2). Based on the findings 
presented in article 1, we did not consider vaccination of calves at 8 weeks of age in MAP MSV-2 
experiment (Article 4). It seems that dietary stress could jeopardize the immune response and 
vaccination of older calves appears to result in more sustained CMI responses (Article 1). Thus the 
animal age at vaccination should be considered when designing vaccination experiments in calves. No 
experimental MAP challenge was performed in this study (MAP MSV-1). Nevertheless, considering the 
pathogenesis of MAP infection in cattle, analyzing the establishment of infection in young calves 
combined with age of vaccination could shed light on the methods to improve development of a strong 
immunity against the disease. We used this information to design early and late FET11 vaccination 
groups in MAP MSV-2 experiment.   
 
Acute and latent stage MAP infection proteins  
Our results demonstrate that MAP proteins expressed in different stages of infection have different 
immune response profiles following vaccination (Article 1 and 4). We surmised that slow pathogenesis 
of paratuberculosis can be described as an initial acute stage followed by a latent stage and that protein 
expression profile changes between the stages with some genes being relatively higher expressed in one 
or the other stage.  This multi-stage vaccine strategy (H56 vaccine) has been shown to efficiently contain 
late stage human tuberculosis infection in mice models as compared to Ag85B-ESAT6 (H1) and BCG 
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vaccine (1). We observed significant higher IFN-γ as well as IgG1 levels against Esx-secretion system 
proteins, ESAP-2 and MAP-3 (Article 1), ESAP-2 and ESAP-5 (Article 4) and latency-associated proteins 
LATP-4 (Article 1) and LATP-5 (Article 4). However, proteins SECP-1 and Ag85B that are supposedly 
highly immunogenic owing to their extracellular environment were found to be poorly immunogenic 
(Article 1). Despite the established role of Ag85B in early proliferative and IFN-γ responses in natural and 
experimental tuberculosis infection in cattle and mice (131), its role in the protection against MAP 
infection when used as a recombinant subunit vaccine still remains to be elucidated. Significant and 
consistent immune response to Esx-secretion system and latency proteins in this study (Article 1 and 4) 
supports their role as potential candidates for a MAP subunit vaccine. The results also showed different 
immunogenicity for two MAP proteins, ESAP-2 and MAP-3 common in both MAP MSV-1 and MAP MSV-
2 studies, which emphasizes the possibility of dynamics of MAP infection in guiding the differential 
immune response.  
 
T cell signaling and costimulatory molecules  
We have demonstrated in article 2 that costimulation through aCD28/aCD49d antibodies potentiate an 
antigen-specific production of IFN-γ against recombinant MAP proteins in ex vivo recall responses in 
different T cell subsets. This increase was accompanied by an increase in the iMFI of activated T cells. 
The study also shows the degree of signaling in T cells is regulated by the costimulatory environment. 
The inflammatory environment at the site of infection provides the necessary costimulatory signals that 
are critical in shaping the extent and nature of the immune response (24, 149). These signals might be 
missing when evaluating the peripheral immune responses as in the whole-blood or PBMC leading to a 
deficit of immune response. This deficit can be compensated by adding costimulatory molecules (signal 
2 and 3) to the ex vivo T cell assays and has been routinely used in mice and human immunology (43, 
173). Development of bovine anti-CD28 antibody allowed us to verify the use of this molecule as signal 2 
costimulation in bovine T cell immunoassays. In combination with anti-CD49d, anti-CD28 costimulatory 
68 
 
molecule increased antigen-specific IFN-γ production with very low background. However, using rIL-12 
(a signal 3 costimulatory molecule) alone or with signal 2 molecules showed the maximum antigen-
specific IFN-γ production, though accompanied by a high non-specific response (Article 2). This 
observation highlights the bias towards a Th1 type immune response with rIL-12 as compared to a 
balanced or less biased response with signal 2 molecules, anti-CD28/CD49d.  
 
A large number of cell surface signaling molecules have been identified to play a critical role in the 
control of immune responses (200). Modulation of these signaling molecules is one of the strategies 
adopted by pathogens to establish their existence in the host (73). Observations from article 2 define an 
important role for signaling molecules in MAP vaccine-induced immune responses. These findings offer 
the possibility of using signal 3 costimulatory molecules for supporting antigen-specific responses in 
diagnostic assays and signal 2 molecules to study the antigen-specific responses during e.g. an ongoing 
infection or vaccination over time.       
 
Role of CD8+ T cells, γδ T cells and NK cells in MAP vaccine-induced immune responses 
IFN-γ is a key cytokine in protective immune responses against mycobacterial infections including MAP. 
The role of CD8+ T cells, γδ T cells and NK cells in MAP vaccine-induced immune response as producer of 
IFN-γ has been demonstrated in article 2. Though the CD4+ T cells were the major producers of IFN-γ, 
CD8+ T cells and innate immune cells also contribute to the antigen-specific IFN-γ levels. CD8+ T cells 
have been found to play a role in the control of M. tuberculosis infection through different mechanisms 
such as IFN-γ release, cytotoxicity via granule-dependent exocytosis pathway, cytotoxicity mediated 
through Fas/Fas ligand interaction, and direct microbicidal activity (88). For the CD8+ T cells to produce 
IFN-γ, antigens must be presented on the MHC class I molecules through cross-presentation with 
macrophages or DCs. Thus we can rightfully speculate here that sufficient cross-presentation did occur 
in our in vitro cultures. 
69 
 
 
It is known that neonatal calves have significantly higher levels of circulating innate immune cells, NK 
cells and γδ T cells, than adult cattle (83). Each of these cell populations can interact with mycobacteria 
infected antigen presenting cells and secrete high level of IFN-γ (117, 127). We also found IFN-γ 
production by these innate immune cells against MAP recombinant proteins induced recall responses 
following vaccination (Article 2). Neonatal vaccination with BCG vaccine confers significant protection in 
cattle and is used widely in human infants (146). Relative immaturity of the neonatal immune system is 
compensated by increased numbers of these innate immune effector cells that enables effective 
immune response to vaccination by secretion of high levels of IFN-γ (146). In addition to production of 
IFN-γ, NK cells and γδ T cells execute their effector functions against mycobacterial infections by 
production of cytokines such as IL-17, IL-22 (34) as well as killing through perforin and granulysin (35). 
Detailed role of both these innate immune cells in MAP infection still remains to be fully elucidated.     
 
Vaccine immune correlates  
Based on our hypothesis that polyfuctional T cells will be an immunological correlate of vaccine-induced 
protection and curiosity to identify other immunological correlates, we conducted a literature review to 
explore the current knowledge about immune markers and correlates of protection for vaccine-induced 
immune responses (Article 3). Vaccination and infection-induced immune markers and correlates of cell- 
and antibody-mediated immunity were studied, with special emphasis on chronic intracellular 
infections. Presently, all the well-defined immune correlates for the commercially available vaccines 
belong to antibody-mediated immunity (126). Majority of these antibody-mediated immune correlates 
have been outlined for antiviral vaccines due to strong humoral responses in viral infections. For CMI 
based immune correlates, various recognized and potential immune markers were discussed. Findings 
from the article 3 largely support our hypothesis. However, for chronic intracellular infections in which 
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cell-mediated immunity plays an important role, identifying the appropriate immune correlates still 
remains to be validated. 
 
Immune correlates of antibody-mediated immunity have been described for many chronic infections as 
a function of neutralization titer, ADCC, immunological class and subclass and memory B cells. Serum 
neutralizing antibody titers measured through ELISA and neutralization assays has been well-defined for 
many viral infections (125). FcγR mediated effector functions including ADCC have been found to be a 
better correlate of protection for viral infections including HIV. Likewise, serum and mucosal IgG and IgA 
levels and memory B cells have been associated with vaccine-mediated protection in many viral 
infections (126). Regarding the immune correlates of cell-mediated immunity for chronic intracellular 
infections, IFN-γ production by CD4+ T cells has been the most studied and recognized immune 
correlate. However, new findings challenge the role of IFN-γ in protection (42). Instead, other effector 
cells and cytokines of CMI have been invariably linked with protection following vaccination in various 
infectious disease setups. Simultaneous production of cytokines IFN-γ, TNF-α and IL-2 at single cell levels 
by CD4+ and CD8+ T cells referred to as polyfunctional or multifunctional T cells has been increasingly 
correlated with protection following vaccination and infection (30, 90, 142). In addition, TH17 cells, CTL, 
memory T cells (central and effector), MHC tetramers, cytokines and chemokines such as IL-1, IL-10, IL-
12, IL-17, IP-10, TGF-β, granulocyte macrophage colony-stimulating factor (GM-CSF) have been 
elaborated as potential immune correlates in the light of available evidence from many chronic 
infections. Innate immune cells such as NK cells, NKT cells and γδ T cells and their effector cytokines 
have been linked to various extents with vaccine-mediated protection. 
 
For large animal species, there is a major focus on measuring IFN-γ response as an immune correlate in 
vaccination studies. One of the challenges is the limited immunological toolbox in veterinary sciences. In 
cattle, the possibility of measuring polyfunctional T cells has only recently been demonstrated with the 
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development of bovine IL-2 antibody (183). Likewise, development of peptide-MHC tetramers in pigs 
has allowed monitoring CD8+ T cells responses post vaccination (122). In addition, gene expression 
studies have allowed evaluating many cytokines, chemokines and effector T cell responses (44). Thus 
with the expansion of available immunological reagents and techniques, specific immune markers and 
correlates of protection for diseases of veterinary importance should be expected in near future.      
Based on the knowledge gained from this review, we continued to explore the role of CMI based 
immune responses chiefly IFN-γ production by CD4+ T cells in our MAP challenge and vaccination 
studies keeping in mind the possible role of other immune cells especially γδ T cells, CD8+ T cells and 
polyfunctional T cells. In addition, humoral immune responses were also measured as a possible 
correlate. We also measured the CFSE proliferation, expression of activation markers, CD25, CD44, 
CD62L and chemokine receptor CCR7 in our study to identify possible vaccine immune correlates.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
CONCLUSIONS AND PERSPECTIVES 
In this thesis, information about the development of a multi-stage subunit vaccine against 
paratuberculosis infection was obtained through experimental infection studies in calves. The results 
also accentuates consideration of age for vaccination against MAP, costimulation signals for 
measurement of T cells responses, role of CD8+ T cells, γδ T cells and NK cells in MAP infection/vaccine 
immune responses and possible immunological markers and correlates of protection.    
 
The results show that vaccination with multi-stage vaccine, FET11 at 16 weeks of age induces significant 
immune response and confers protective immunity characterized by a mean 1.1 log10 reduction in 
bacterial load in gut tissues compared to control animals. These findings are important due to the fact 
that existing MAP vaccines do not significantly reduce bacterial burden in infected animals. The 
protective efficacy of the late FET11 vaccination correlated well with the IFN-γ responses to vaccine 
proteins about 12 weeks after vaccination. However, we saw a decrease in the IFN-γ responses to 
component vaccine proteins after one year. Therefore, a booster vaccination at this stage could be 
useful to amplify the immune response. It would be of interest to investigate the protective efficacy of 
FET11 vaccine in experimental animals over an extended period of time exceeding one year. In addition, 
an evaluation of the performance of FET11 vaccine over a number of years in a natural MAP infected 
cattle herd is needed, as this could be a much better method to access the level of protection or 
decreased faecal shedding in animals at different stages of the disease as well as to rule out reactivation 
of infection. In the one-year time frame, early FET11 vaccination performed poorly. Likewise, 
commercial Silirum® vaccine did not show significant protection. More studies are required to address 
their performance over a longer period of time. Our results also highlight the application of qPCR for the 
evaluation of microbial load in tissues and vaccine efficacy.      
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Experimental infection of young calves using mid-log-phase frozen stock MAP cultures and correlation of 
infection with PPDj responses in this study highlights the possibility of establishing a uniform and 
reproducible bovine MAP infection model despite non-availability of age matched calves in desired 
numbers at the same time for vaccine experiments. In addition, vaccine-induced immune responses 
were influenced by the age of vaccination of calves with poor responses when vaccination coincided 
with the age of weaning. Both MAP MSV-I and II studies, support that older animals (4 months) develop 
a more robust immune response, even when infection occurs at an earlier age. The results showed that 
proteins expressed at different levels during various stages of MAP infection induce different 
immunological profile when used with CAF01 adjuvant as a subunit vaccine, with significant immune 
responses against Esx-secretion system and latency proteins. Differential immune response against two 
MAP proteins common in both MSV experiments emphasizes the possibility of dynamics of MAP 
infection guiding the vaccine-induced immune response. Investigation of more candidate proteins with 
over expression in different stages of MAP infection and playing a key role at the host-pathogen 
interface, metabolism, and persistence could help decide optimal selection of components of a multi-
stage subunit vaccine inducing stronger immunity.     
 
CD8+ T cells and innate immune cells including γδ T cells and NK cells appear to be important antigen-
specific IFN-γ producers following vaccination in addition to already well-recognized CD4+ T cells. Future 
studies should examine the detailed role of γδ T cells and NK cells in MAP infection and vaccine-induced 
immune responses.  
 
Costimulation of T cell subsets by anti-CD28 and anti-CD49d antibodies was observed to enhance 
vaccine antigen-specific IFN-γ production. Recombinant IL-12 also increased IFN-γ levels but leads to a 
strong TH1 bias and thus appears more useful for diagnostic purposes than to characterize the 
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contribution of all T cells to the vaccine-induced immune response. It would be interesting to investigate 
the costimulation effect on combined cytokine profiles such as polyfunctional T cells.   
 
The significant IFN-γ responses to MAP vaccine proteins in our study may supplement the common 
notion of role of IFN-γ as an immunological marker of protection. However, we didn’t find a strong 
correlation between IFN-γ responses to all component proteins and reduction in bacterial load in tissues 
at all time points throughout the study. One speculation could be that IFN-γ is not an ideal measure of 
protection and rather antibodies have an important role as a possible correlate, which need to be 
examined. We were able to identify polyfuntional T cells in our study. These results rouse further 
investigations to determine the significance of these cells as possible correlates of protection or 
infection or memory generation, for instance by looking at the cryopreserved lymphocytes from animals 
with differential bacterial burden within late FET11 group as well as comparing them with animals from 
other groups. This analysis may spotlight the possible duration of and type of memory cells induced by 
FET11 vaccine.      
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ABSTRACT 26 
     Neonates and juvenile ruminants are very susceptible to paratuberculosis infection. This is likely 27 
due to a high degree of exposure from their dams and an immature immune system. To test the 28 
influence of age on vaccine induced responses a cocktail of recombinant MAP proteins (SECP-1, ESAP-29 
2, LATP-4, MAP-3 and Ag85B) was formulated in a cationic liposome adjuvant (CAF01) and used to 30 
vaccinate animals of different age. Male jersey calves were divided into 3 groups that were vaccinated 31 
at 2, 8 or 16 weeks of age and boosted twice at week 4 and 12 relative to the first vaccination. Vaccine 32 
induced immune responses, the IFN-γ cytokine secretion and antibody responses were followed for 20 33 
weeks. In general, the specific responses were significantly elevated in all three vaccination groups 34 
after the first booster vaccination with no or only minor effect of the second booster. However, 35 
significant differences were observed in the immunogenicity of the different proteins and it appears 36 
that the older age group produced a more consistent IFN-γ response. In contrast, the humoral 37 
immune response is seemingly independent of the vaccination age as we found no difference in the 38 
IgG1 responses when comparing the three vaccination groups. Combined, our results suggest that 39 
appropriate age of vaccination should be considered in vaccination protocols and there is a possible 40 
interference of vaccine induced immune responses with weaning (week 8). 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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INTRODUCTION 51 
     Paratuberculosis is a chronic non-treatable granulomatous enteritis affecting all domestic and non-52 
domestic ruminants and some non-ruminants worldwide. It is an economically significant and 53 
widespread disease of the ruminants caused by Mycobacterium avium subsp. paratuberculosis (MAP). 54 
Neonates and juvenile animals are most susceptible to infection which progresses  through subclinical, 55 
clinical and advanced clinical disease stages (14, 39).  56 
 57 
     Currently available vaccines against MAP consist of killed or attenuated MAP in an oil adjuvant, which 58 
has been reported to provide partial protection through delayed fecal shedding and reduction in 59 
clinically affected animals (27, 37). Whole-cell based vaccines, however, induce production of antibodies 60 
and a sensitization to delayed type hypersensitivity (DTH), making it impossible to differentially diagnose 61 
naturally infected from vaccinated animals. Vaccination against MAP also interferes with the diagnosis 62 
and surveillance of bovine tuberculosis due to false-positive skin test results  (38). Moreover, whole-cell-63 
based live vaccines suffer with lack of characterization, localized prolonged swelling and granuloma 64 
formation at the site of injection and potential side effects on accidental self-inoculation among 65 
veterinarians while vaccinating animals (12, 13, 26). 66 
 67 
     Subunit vaccination with identified protective protein antigens in combination with an adjuvant 68 
inducing strong Th1-type immune responses could be an ideal strategy to surmount the limitations 69 
associated with whole-cell-based vaccines (10, 10, 29). Recently, paratuberculosis experimental vaccines 70 
based on recombinant proteins expressing mycobacterial antigens (11, 21, 28, 30, 37), DNA vaccines 71 
(30) and expression library immunizations (9) have been found to induce partial protection against 72 
experimental infection with MAP. Immaturity of the neonatal immune system contributes to an 73 
increased susceptibility of the young animal to infectious disease and may limit its capacity to develop a 74 
protective response to vaccination (22). Cattle usually become infected with MAP as calves, either 75 
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through in-utero transmission or as neonates via ingestion of fecal material, milk or colostrum 76 
containing MAP organisms (5, 34, 36). Newborns have a tendency to exhibit a Th2 profile (19) and 77 
paratuberculosis infection is characterized by a distinct Th1 response (33). If calf susceptibility to MAP 78 
infection is related to maturation of the immune system, the immune response to a MAP vaccine may 79 
also be influenced by the age of vaccination. Evaluating the appropriate age of vaccination of the 80 
animals against MAP is therefore important in order to generate a high frequency of antigen-specific T 81 
cells with more rapid effector functions. We hypothesized that age of vaccination influences the quality 82 
of MAP vaccine induced T-cell responses.  In order to substantiate this hypothesis, we vaccinated calves 83 
with well-defined MAP recombinant proteins at 2, 8 or 16 weeks of age followed by two booster rounds 84 
4 and 12 weeks after the first vaccination. Vaccine induced IFN-γ release and antibody responses were 85 
analyzed in individual animals to assess the immunogenicity of the vaccine. The upregulation of these 86 
immune responses were prospectively correlated with the age of the calves.  87 
 88 
MATERIALS AND METHODS   89 
     Animals. A total of 27 male jersey calves were used in the present study. The animals were obtained 90 
at the age of 2 weeks from a farm which by the Danish paratuberculosis surveillance program had a true 91 
prevalence equal or close to zero at all milk-antibody samplings from September 2006 to January 2011 92 
(17). Animals were housed and raised under appropriate biological containment facilities (BSL-2) in a 93 
community pen with straw bedding. Calves were fed commercial milk replacer (DLG, Denmark) and 94 
green start (DLG, Denmark) for the first two months twice a day. At 8 weeks of age, calves were weaned 95 
and fed pellets and ad lib hay for the remainder of the study period. Calves had access to ad lib water 96 
and bedding was changed every day. Calves were checked daily for general health.    97 
 98 
     The use of animals described in this experiment was approved by the Danish National Experiments 99 
Inspectorate and carried out in compliance with their regulations and policies. 100 
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     Antigens.  Antigens in the vaccine are detailed in table 1. They were selected based on their 101 
immunogenicity as studied in naturally infected heifers and representing one protein from each of the 102 
Secreted proteins (SECP-1), Latency proteins (LATP-4), and ESAT-6 family member proteins (ESAP-2) 103 
along with a hypothetical protein (MAP-3) as reported earlier (17). Ag85B was included as a positive 104 
control  105 
 106 
TABLE 1. Details of antigens used in the study 107 
 
Antigen 
 
Homology in 
MAA (%) 
 
Homology in 
M. bovis (%) 
 
Protein size 
(amino acids) 
 
Product of MAP 
SECP-1 99 83 300 Secreted protein 
Ag85B 99 85 330 Secreted antigen 85B (Ag85B) 
ESAP-2 100 87 98 Hypothetical ESAT-6 like protein 
LATP-4 100 71 146 Heat shock protein (latency protein)      
MAP-3 100 84 97 Hypothetical antigen 
 108 
antigen based on earlier studies reporting significant IFN-γ responses in cattle and mice to Ag85B 109 
component of MAP  (21, 28). All antigens were produced in E. coli and purified by metal affinity and 110 
anion columns as previously described (17). The protein concentration of the final products was 111 
measured by NanoOrange® protein quantification kit (Invitrogen).        112 
 113 
     Experimental design. Calves were distributed into three groups Vac 2w, Vac 8w and Vac 16w with 9 114 
calves in each group. Each group comprised of 7 vaccine calves and two randomly assigned adjuvant 115 
controls. Calves were born over a period of 4 months and assigned into groups as they were born i.e. 116 
group Vac 16w includes the 9 oldest animals followed by Vac8w and Vac 2w.  All vaccine calves in the 117 
three groups received 100 µg of each recombinant vaccine antigen SECP-1, ESAP-2, LATP-4, MAP-3 and 118 
Ag85B formulated with the DDA/TDB (CAF01) adjuvant (2500 µg/500 µg) (3). After mixing, the vaccine 119 
antigens were allowed to adsorb to the adjuvant CAF01 for 1 hour at RT before injection. Controls 120 
received the adjuvant only along with sterile PBS. Vaccinations were performed through sub-cutaneous 121 
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route in the right mid-neck region 7 cm ahead of the prescapular lymph node. The age at the first 122 
vaccination in the groups Vac 2w, Vac 8w and Vac 16w was 2, 8 and 16 weeks, respectively. All vaccine 123 
calves were vaccinated three times with revaccinations at week 4 and 12 relative to the first vaccination 124 
(Fig. 1). Blood samples were collected every 2 weeks throughout the experiment. Heparinized samples 125 
were used for whole blood IFN-γ assay and serum samples were taken for serological analysis.     126 
 127 
FIG. 1. Experimental design. Within each age-group of 7 MAP vaccinated animals, 2 calves received the 128 
CAF01 adjuvant only.  129 
 130 
     IFN-γ assay. Heparinized whole-blood samples were collected by the vacutainer system. 0.5 ml whole 131 
blood was stimulated in 48-well culture plates (Greiner Bio-One, Heidelberg, Germany) with previously 132 
added purified protein derivative Johnin (PPDj), purified protein derivative bovine (PPDb) and avian 133 
(PPDa) (a kind gift from James McNair, AFBI, Belfast), each of the five MAP vaccine antigens, or PBS and 134 
two positive control stimulations with phytohaemagglutinin (PHA; Sigma) or the superantigen 135 
Staphylococcus enterotoxin B (SEB; Sigma), respectively (50 µl volume). All MAP antigens, PPDb, PPDa 136 
and SEB were added to a final concentration of 1 µg/ml, while PHA and PPDj were added to a final 137 
concentration of 5 µg/ml and 10 µg/ml, respectively. Whole blood cultures were incubated for 18-20 h 138 
at 37°C and 5% CO2 in air. Following overnight incubation, 55 μl heparin solution (10 IU/ml in blood) was 139 
added to avoid clots in the supernatant after freezing. Plates were then centrifuged and approximately 140 
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0.35 ml of supernatant was collected into 96-well 1-ml polypropylene storage plates (Greiner Bio-One, 141 
Heidelberg, Germany) and frozen at -20°C until analysis.  142 
 143 
     The antigen-specific IFN-γ secretion in supernatants was determined by use of an in-house 144 
monoclonal sandwich ELISA as described earlier (18). The levels of IFN-γ (pg/ml) were calculated using 145 
linear regression on log-log transformed readings from the two-fold dilution series of a reference plasma 146 
standard with predetermined IFN-γ concentration. The IFN-γ response to PBS was subtracted from IFN-γ 147 
response to each of five recombinant MAP antigens among all the calves and defined as the antigen-148 
specific IFN-γ response.   149 
 150 
     Antigen-specific serum IgG1 ELISA. An in-house developed and optimized indirect enzyme-linked 151 
immunosorbent assay (ELISA) was applied for the demonstration of serum IgG1 antibody responses 152 
against the five vaccine recombinant proteins throughout the study. Serum IgG2 levels were also 153 
measured but were found to be very weak for any useful interpretation and thus have not been 154 
discussed further. Briefly, microtiter plates (MaxisorpTM, Nunc A/S, Roskilde, Denmark) were coated 155 
overnight with 100 µl of 1 µg/ml of each of the five MAP antigens in Sodium carbonate buffer except for 156 
LATP-4 for which 0.2 µg of coating concentration was used. Next day plates were blocked using 200 µl 157 
PBS with 0.05% Tween-20 and 1% bovine serum albumin (PBS-T-BSA). The plates were then washed 158 
with PBS with 0.05% Tween-20 (PBS-T) and sera in a final dilution of 1:40 in PBS-T-BSA were added to 159 
test wells in duplicate and incubated at RT in a shaking incubator for 1 h. To allow for plate-to-plate 160 
calibration, Positive (PosC) and negative (NegC) control sera, added to test wells in triplicate, along with 161 
blank (PBS-T-BSA) were included on each plate. PosC sera were the sera from a vaccinated calf with 162 
consistent higher antibody responses against all vaccine antigens collected at 4 weeks after second 163 
vaccination (V2), and 2 and 4 weeks after third vaccination (V3) and following an exponential curve. 164 
NegC sera were the sera from the same calf on the day of vaccination (Day 0). The plates were washed 165 
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with PBS-T buffer and incubated with 100 µl 1:500 dilution of horseradish peroxidase-conjugated mouse 166 
anti-bovine IgG1 (Clone IL-A60; AbD Serotec) for 1 h at room temperature. After washing with PBS-T 167 
buffer, substrate (OPD, 1, 2-orthophenyl-diamine; H2O2) was added to each test well, and the 168 
absorbance was read at 493 nm with 649 nm reference substraction. The mean OD value for each test 169 
serum (ODSample) was calibrated according to the OD-values of the control sera on the respective plate 170 
and presented as calibrated OD (ODCal) 171 
ODCal = (ODSample – ODNegC) x (ODPnorm - ODNnorm) + ODNnorm 172 
              (ODPosC – ODNegC)  173 
where  174 
ODSample is the sample OD 175 
ODPosC is the mean of positive controls on the plate (mean OD of three sera all in triplicate) 176 
ODNegC is the mean of negative control on the plate (mean OD of Day 0 sera in triplicate)  177 
ODPnorm is the mean over all runs of positive controls 178 
ODNnorm is the mean over all runs of negative controls 179 
 180 
     Tuberculin skin test. To evaluate the development of the cell-mediated immune response and to 181 
negate the possibility of any cross-reactivity with surveillance testing for bovine tuberculosis, tuberculin 182 
skin testing was performed 6 weeks after the third immunization. The single comparative intradermal 183 
tuberculin test with avian and bovine purified protein derivative (PPD-A and PPD-B respectively; 2000 IU 184 
each) was performed by intra-dermal inoculation of 0.1 ml of PPD-A and PPD-B (a kind gift from James 185 
McNair, AFBI, Belfast) and reactions were read 72 hours later. Results were recorded as increase in skin 186 
thickness at 72 hours compared to thickness before injection and interpreted according to the standard 187 
protocol (European Communities Commission regulation 141 number 1226/2002) (20). Reactions to 188 
each of the tuberculin’s were interpreted as follows: a skin test reaction was considered positive when 189 
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skin thickness increased 4 mm or more, inconclusive when there was an increase of more than 2 mm 190 
and less than 4 mm, and negative when the increase was not more than 2 mm. 191 
 192 
     Following the guideline to the official interpretation of the intradermal comparative cervical 193 
tuberculin test an animal was scored positive if the increase in skin thickness at the bovine site of 194 
injection was more than 4 mm greater than at avian site, inconclusive if the increase in skin thickness at 195 
the bovine site was 1 to 4 mm greater than the avian reaction, and negative if the increase in skin 196 
thickness at the bovine site of injection was less than or equal to the increase in the skin reaction at the 197 
avian site of injection. 198 
 199 
     Statistical analysis and interpretation. For the statistical analyses of the antigen-specific immune 200 
responses the adjuvant control animals were pooled into one group. In order to obtain a single value of 201 
the immune response following each vaccination, the mean of the IFN-γ values obtained 2 and 4 weeks 202 
after each vaccination was used. For each antigen, data were analyzed with a zero-inflated model due to 203 
the excess amount of data registered with a 0 measurement. The probability that an IFN-γ measurement 204 
was positive was modeled (model A) with a logistic regression model where vaccine group (Vac 2w, Vac 205 
8w, Vac 16w or Control) and Vaccination number (1, 2 or 3) were entered as deterministic explanatory 206 
variables, while an animal effect was included as a random effect. In order to obtain normality 207 
distributions, the responses above 2 pg/ml were log-transformed and modeled (Model B) with a mixed 208 
linear model with the same set of explanatory variables, and the two models were combined into one 209 
zero-inflated model (Model C). A statistically significant immunological response to the individual 210 
antigen was defined as a statistically significant effect in Model C (p<0.05). Tests were performed with 211 
the likelihood method, using the Wald test (4). For MAP-3, the number of positive values were so 212 
different between vaccinated and non-vaccinated animals, that a logistic regression model (A) and thus 213 
a zero-inflated model (C) did not apply. Instead, a non-parametric Wilcoxon test (15) was used. This was 214 
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modified to the Kruskal-Wallis rank test (15) when comparing more than two groups. For each antigen, 215 
the corresponding antibody responses were modeled with a model similar to model B. Log-216 
transformation of ODcal values were performed for all antibody responses except for antigen SECP-1 217 
which were normally distributed. Identical analyses were also performed using only results after the first 218 
two vaccinations to assess the immune response following a two-dose regimen. All analyses were 219 
carried out in Splus©, version 6.1.  220 
 221 
RESULTS 222 
     Observations following vaccination. The animals were observed throughout the study for any visible 223 
effects post vaccination. However, no side effect, such as swelling or palpable growth was observed 224 
following mid-neck subcutaneous inoculation of the recombinant proteins formulated in CAF01 adjuvant 225 
or by adjuvant alone.  226 
 227 
     Cell-mediated immune responses to vaccine antigens. IFN-γ release towards each of the five 228 
antigens in the vaccine was followed in individual animals for 20 weeks (Fig. 2). In general, adjuvant 229 
control calves did not show antigen-specific response to the vaccine antigens. However, the heat-shock 230 
protein LATP-4 induced some IFN-γ responses in all adjuvant controls and one calf responded to several 231 
of the other antigens at the first sampling prior to vaccination and at two samplings after the third 232 
vaccination.   233 
 234 
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 235 
FIG. 2. Antigen-specific IFN-γ responses in whole-blood cultures. (a to d) Levels of IFN-γ released from 236 
whole-blood cultures stimulated with MAP recombinant antigens from calves in groups Vac 2w (a), Vac 237 
8w (b), Vac 16w (c) and adjuvant control (d) following vaccinations indicated as dotted lines. (i to v) 238 
Whole-blood IFN-γ responses to stimulation with MAP recombinant proteins. IFN-γ levels are expressed 239 
as mean values (± standard deviation [SD]) for plasma concentrations (pg/ml).  240 
 241 
Statistically significant immune responses to all the vaccine antigens were observed following 242 
vaccination compared to adjuvant controls (table 2). The most significant responses were observed 243 
against MAP-3, LATP-4 and ESAP-2, while responses against Ag85B and in particular SECP-1 were less 244 
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significant. Comparison of the response levels to different vaccine antigens confirmed that MAP-3 and 245 
LATP-4 induced significantly higher levels than other antigens. Vaccinated calves had IFN-γ levels below 246 
50 pg/ml towards PPDj and PPDb antigens (data not shown).  247 
 248 
TABLE 2. P-values and parameter estimates – Full zero-inflated model (IFN-γ) 249 
Antigen  
 
 
 
Vac 2w vs. 
control 
 
 
 
Vac 8w vs. 
control Vac 16w vs. 
control 
 
 
Vaccination 
response at 
three 
vaccinations 
equal? 
 
Vaccination 
at all time 
points  
vs. control 
 
Effect of 
Age 
SECP-1  p=0.13 p=0.18 p=0.006** YES p=0.28 p=0.04* p=0.64 
Ag85B   p=0.30 p=0.003** p=0.005** YES p=0.15 p=0.005** p=0.68 
ESAP-2 p=0.0009*** p=0.02* p<0.0001*** YES p=0.55 p<0.0001*** p=0.08 
LATP-4 p<0.0001***◊ p<0.0001***◊ p<0.0001***◊ YES p=0.70◊ p<0.0001*** NA 
MAP-3 p<0.0001***◊ p<0.0001***◊ p<0.0001***◊ NO p=0.02◊ NA p=0.13◊ 
◊: All non-controls were positive. For group Vac 2w and Vac 16w (MAP-3), the difference is significant w.r.t. level of response 250 
(p=0.03 and 0.01). For LATP-4, all controls except 3 were positive; one at vaccination number 2 and two at vaccination number 251 
3.  For LATP-4, the p-value on time for positive level is thus based on a very small sample; which makes it unreliable.   252 
  253 
     From fig. 2 it appears that immune responses in group Vac16w were more consistent than responses 254 
in younger age-groups. However, no statistically significant differences in the immune responses 255 
between the three vaccine age-groups were observed in the zero-inflated model, except for the 256 
response to MAP-3 where the Vac8w responded with significantly lower levels. There was no 257 
statistically significant effect of the second vaccine booster on IFN-γ responses against vaccine antigens, 258 
however, for Vac2w and Vac8w animals the response to SECP-1 was not statistically significant different 259 
from controls after only 2 vaccinations.   260 
 261 
     To investigate if the animal’s age had an effect on the IFN-γ producing capacity of blood cells, whole-262 
blood from all vaccinated calves were stimulated with SEB (a bacterial superantigen) at 2 weeks interval 263 
throughout the study (Fig. 3) or PHA (Phytohaemagglutinin) at the time of the three vaccinations (data 264 
not shown). There was no effect of animal age on the IFN-γ producing capacity. 265 
13 
 
2 10 18 26 34
1.0×100
1.0×101
1.0×102
1.0×103
1.0×104
1.0×105 Vac 2w
Vac 8w
Vac 16w
Age (weeks) at sampling
IF
N
- γ
 (p
g/
m
l)
 266 
FIG. 3. Secretion of IFN-γ in whole-blood cultures stimulated with SEB from the calves in the vaccinated 267 
groups Vac 2w, Vac 8w and Vac 16w. Individual IFN-γ levels are plotted against the age of the calves at 268 
the time of blood collection. Line represents mean for each age-group.  269 
 270 
     Antibody responses to vaccine proteins. Antigen-specific IgG1 levels in serum from immunized calves 271 
were measured at first vaccination and 4 weeks after second and third vaccination (Fig. 4). In general, 272 
the humoral responses emulate the IFN-γ responses. IgG1 responses were statistically significant to all 273 
the vaccine antigens in the vaccinated groups compared to the adjuvant controls. As seen with the IFN-γ 274 
responses, the most significant responses were observed against LATP-4, MAP-3, ESAP-2 followed by 275 
Ag85B and SECP-1. However no significant differences in the humoral immune responses were observed 276 
between the three vaccine groups.  277 
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FIG. 4. Seroreactivities to MAP recombinant proteins in calves in groups Vac 2w, Vac 8w and Vac 16w 279 
following vaccinations indicated as dotted lines.  Antigen-specific IgG1 antibody responses were 280 
measured by ELISA and expressed as ODcal. Age at first vaccination (V1) in group Vac 2w, Vac 8w and Vac 281 
16w was 2, 8 and 16 weeks, respectively followed by booster immunizations 4 (V2) and 12 weeks (V3) 282 
later. IgG1 antibody production in response to stimulation with MAP recombinant proteins MAP-3 (a), 283 
LATP-4 (b),    ESAP-2 (c), Ag85B (d), SECP-1 (e). IgG1 levels are expressed as mean values (± standard 284 
deviation [SD]) for serum ODcal values.  285 
 286 
     The second vaccination strongly boosted the IgG1 antibody response towards all five vaccine antigens 287 
which were statistically strongly significant (p<0.0001) whereas the third vaccination did not increase 288 
the IgG1 levels above the level found after the second vaccination. Among the various recombinant 289 
antigens used, IgG1 response levels were the highest for LATP-4 (irrespective the coating concentration 290 
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for this Ag was only 0.2 g/ml), followed by MAP-3, ESAP-2, Ag85B and SECP-1. None of the pre-291 
vaccination serum samples from any of the calves reacted with any of the MAP recombinant antigens 292 
used.  293 
 294 
     Skin test reactivity of the MAP-vaccinated and control calves. The cross-reactivity with surveillance 295 
testing for bovine tuberculosis is a major drawback of available live or killed whole-cell MAP vaccines. 296 
Vaccinated calves were therefore evaluated for cross-reactivity using the standard tuberculin skin test 297 
six weeks after third vaccination. All 27 calves were found to be negative with the comparative 298 
intradermal tuberculin test. The skin test results corroborate with the low IFN-γ levels against PPDb and 299 
PPDa in the samples collected at that time point (data not shown). Interpretation as single tuberculin 300 
test also showed negative reading in all calves except for one with a 5.9 mm reaction to bovine 301 
tuberculin and 2.6 mm to avian tuberculin.  302 
 303 
DISCUSSION 304 
     In this study, we investigated the effect of age on the vaccine induced immune response following 305 
subunit vaccination using defined MAP recombinant proteins. Vaccinations in the three groups Vac 2w, 306 
Vac 8w and Vac 16w unveiled three immune response profiles. After first vaccination, there was an 307 
immediate rise in the IFN-γ levels against vaccine proteins in vaccinated animals compared to the 308 
adjuvant control group. In mycobacterial infections including paratuberculosis, CD4 Th1-cell-mediated 309 
immunity is essential to keep the infection in check and IFN-γ has a central role (6, 8, 32, 35). Since IFN-γ 310 
is a quintessential cytokine in the Th1 response, it is supposedly an immune response variable and a 311 
correlate of vaccine induced immune protection (7, 33). In our study, the vaccine proteins did induce a 312 
significant IFN-γ response relative to controls indicating that CAF01 adjuvated vaccination induces a 313 
measurable antigen-specific cell-mediated immune response in cattle. There was no age-related 314 
correlation between vaccinations and the immune response to vaccine antigens which were significant 315 
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except for MAP-3 where Vac 8w had significantly lower response levels.  One of the possible 316 
explanations for the low IFN-γ responses of the calves in the group Vac 8w could be the change in the 317 
feeding schedule with milk being replaced with pellets and hay which coincides with the time of first 318 
vaccination. Thus a change in the feeding pattern with resulting  dietary stress (2, 22) could have 319 
modulated the IFN-γ responses following primary vaccination for the group Vac 8w calves and such 320 
dietary changes should be taken into account when designing vaccine experiments involving young 321 
animals. In addition, the responsiveness of the young cattle in the IFN-γ assay in mycobacterial 322 
infections has also been associated with NK cells  (24). In our study we didn’t look at the IFN-γ 323 
production by NK cells and could not associate their role for any non-specific IFN-γ production. 324 
Although, one possible scenario could be that NK cells didn’t respond to recombinant MAP proteins 325 
used in our study.        326 
 327 
     IFN-γ responses following whole-blood stimulation with SEB and PHA revealed that all the animals in 328 
the three vaccine groups produce comparable levels of IFN-γ. Thus, there was no difference in the IFN-γ 329 
producing capacity of the animals with age or in response to the vaccinations. 330 
 331 
     Analysis of the immune responses among the groups considering only two vaccinations revealed a 332 
strikingly similar portrait as of three vaccinations, which was statistically significant. Notably, the third 333 
vaccination was not able to augment the levels of IFN-γ against all the recombinant vaccine antigens. 334 
Thus, it seems here likely that second booster dose for MAP vaccination is trivial at this time point and 335 
hence could be omitted.  336 
 337 
     Among the vaccine antigens used in this study, secreted proteins SECP-1 and Ag85B are expected to 338 
be highly immunogenic due to their extracellular environment with high likeliness to encounter the 339 
immune cells (25, 31). However, we found that post vaccination immune responses of the animals with 340 
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these antigens were weak compared to the other recombinant proteins. Also the antibody responses 341 
corroborated this observation. This contrasts with previously published data which showed that 342 
recombinant M. bovis Ag85B induces strong proliferative and ex-vivo IFN-γ responses following natural 343 
and experimental infection in cattle and mice (28). Despite the fact that Ag85B induces an early immune 344 
response following infection, whether it plays a major role in the protection against MAP infection when 345 
used as a recombinant subunit vaccine is still to be confirmed.  346 
 347 
     The recombinant MAP antigens encoded by MAP-3, LATP-4 and ESAP-2 induced most significant 348 
immune responses with higher IFN-γ levels compared to the secreted proteins. MAP-3, a conserved 349 
hypothetical protein the function of which is yet unknown, produced sustained and average higher IFN-γ 350 
levels in the animals. LATP-4 is an immunogenic latent protein (heat shock protein) which is known to be 351 
expressed during the latent stage of M. tuberculosis and may contribute to the control of mycobacterial 352 
infection (16). The vaccinated animals in all three groups responded very well to LATP-4 antigen 353 
throughout the study period supporting its role as potential candidate in subunit vaccine strategy 354 
against MAP infection. Another protein ESAP-2 which is a hypothetical ESAT-6 like protein was found to 355 
be comparatively weaker than MAP-3 and LATP-4; however, the responses peaked after first booster in 356 
the youngest animal group.    357 
 358 
     Although vaccinated calves developed strong cell-mediated immune response their humoral 359 
responses characterized by IgG1 antibody levels were low but detectable. Post vaccination antibody 360 
levels were differentially elevated for LATP-4, MAP-3 and ESAP-2 compared to other recombinant 361 
proteins in all three groups.  However, no significant differences in the humoral immune response were 362 
observed between the vaccine groups. This is in line with recent work suggesting age of the calf and 363 
ingestion of colostral antibodies to interfere with the immune capacity of the young calves to produce 364 
antigen-specific antibody responses, with little or no effect on cell-mediated immune responses  (22, 365 
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23). A significant booster effect was noticed following second vaccination for all vaccine antigens.  366 
Despite the fact that humoral responses are not considered protective in MAP infection, yet the 367 
production of IgG1 antibody in response to recombinant MAP antigens is indicative of the role of 368 
vaccine induced IFN-γ in the isotype switching from IgM to IgG (1). 369 
 370 
     Evaluation of the comparative skin testing results revealed no cross-reaction with either M. bovis PPD 371 
or M. avium PPD tuberculins. Only one calf reacted to bovine PPD tuberculin. This is an important 372 
observation considering the fact that the current available whole-cell MAP vaccines show cross-reaction 373 
with M. bovis PPD and thus pose a problem in the differentiation of the vaccinated and the naturally 374 
infected animals. The cross-reactivity of one of the calves to bovine PPD tuberculin in the skin test could 375 
not be explained and the same calf reacted poorly to Ag85B in the whole-blood IFN-γ assay performed 376 
on sample collected before the skin test. Ag85B is a major component of bovine PPD and the gene 377 
encoding the Ag85B protein from MAP shares 85% sequence identity with M. bovis Ag85B at the protein 378 
level  (17). Therefore, at the blood level there was no cross-reactivity between M. bovis and MAP for 379 
Ag85B. 380 
 381 
     In summary, we have shown enhanced cell-mediated and humoral immune responses after 382 
immunization of calves with recombinant MAP proteins at different ages and that age of vaccination of 383 
the calves has some correlation with the vaccine induced immune response to selected MAP proteins. In 384 
particular, vaccination of the calves against MAP at the age of weaning could jeopardize the immune 385 
response and vaccination of older calves appears to result in more sustained CMI responses. Also, that 386 
vaccination followed by a single booster could be sufficient for the generation of ample immune 387 
response and thus might circumvent the need for additional boosting of the immune response. We have 388 
provided supplementary evidence that vaccination of the calves using selected recombinant MAP 389 
proteins and administered as in this study will not result in any side effects and interference with M. 390 
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bovis diagnosis. Furthermore, it is interesting here in the context of vaccination that MAP-3, LATP-4, and 391 
ESAP-2 can elicit immune responses in calves which were statistically significant when administered as 392 
recombinant proteins in CAF01 adjuvant. No live MAP experimental challenge was performed in this 393 
study as the main purpose was to characterize and compare antigen-specific adaptive immune 394 
responses in different age-groups of calves using a cocktail of recombinant MAP proteins.   395 
 396 
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ABSTRACT  18 
T cells which encounter specific antigen (Ag) require additional signals to mount a functional immune 19 
response. Here, we demonstrate activation of signal 2, by anti-CD28 mAb (aCD28) and other 20 
costimulatory molecules (aCD49d, aCD5), and signal 3, by recombinant IL-12, enhance Ag-specific IFN-γ 21 
secretion by CD4, CD8, γδ T cells and NK cells. Age matched male jersey calves, experimentally infected 22 
with Mycobacterium avium subsp. paratuberculosis (MAP), were vaccinated with a cocktail of 23 
recombinant MAP proteins or left unvaccinated. Vaccine induced ex vivo recall responses were 24 
measured through Ag-specific IFN-γ production by ELISA and flow cytometry. There was a significant 25 
increase in production of IFN-γ by T cell subsets cultured in the presence of Ag and aCD28/aCD49d. The 26 
increase was accompanied by an increase in the integrated median fluorescence intensity (iMFI) of 27 
activated T cells. Addition of rIL-12 induced a significant additive effect leading to a maximum increase 28 
in responder frequency of Ag-specific T cell subsets with a heavy bias towards IFN-γ production by CD4 T 29 
cells. We provide the first description of using aCD28/aCD49d costimulation to potentiate an Ag-specific 30 
increase in the production of IFN-γ in bovine immunology. The study also shows the degree of signaling 31 
in T cells is regulated by the costimulatory environment.  32 
 33 
KEYWORDS 34 
Costimulation; IFN-γ; T cells; Flow cytometry; Cattle  35 
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1. Introduction   36 
Johne’s disease or paratuberculosis in ruminants is caused by infection with Mycobacterium avium 37 
subsp. paratuberculosis (MAP), and similar to other mycobacterial infections, the relevant immune 38 
response is thought to be dominated by CD4+ T cells secreting  IFN-γ(Stabel, 2000). In laboratory studies 39 
of immune responses to MAP infection or MAP vaccines, it is thus highly relevant to provide optimal 40 
conditions for an ex vivo measurement of the recall response of in vivo primed T cells.      41 
Costimulatory signals play a crucial role in all phases of T cell responses including activation, expansion, 42 
effector, and memory phases of the response. APCs provide three key signals for the activation of Ag-43 
specific T cells, signal 1 being the TCR cognate recognition of Ag through MHC presentation, signal 2 44 
being  costimulation mediated by  physical interaction with adhesion and costimulatory molecules on 45 
APC with receptors on T cells, and signal 3 mediated by cytokines secreted by APCs, respectively(Kalinski 46 
et al., 1999). In ex vivo studies, addition of the target Ag provides the first signal. Addition of monoclonal 47 
antibodies specific for ligands/receptors on the T cell surface, mimic the second APC costimulation 48 
signals.  Addition of recombinantly produced cytokines to the cultures provides the third signals. The 49 
CD28/B7 interaction is the prominent and most studied costimulatory signal for T cells(Lenschow et al., 50 
1996). CD80 (B7.1) and CD86 (B7.2) are members of the immunoglobulin superfamily with CD28 as one 51 
of their specific ligands.  Other costimulatory molecules that belong to the immunoglobulin superfamily 52 
include the tumor necrosis factor receptor family, and the integrin family. Integrin molecules are a 53 
family of heterodimeric covalently linked α and β glycoproteins. They are involved in the bi-directional 54 
signaling in and out of T cells. The family includes VLA-4 (CD49d/CD29). Another costimulatory molecule, 55 
CD5 is a type-I transmembrane glycoprotein found essentially on all T cells. Signal 2 costimulatory 56 
molecules control T cell proliferation, effector functions and memory development by regulating the 57 
intracellular PI3K/PKB/NF-κB signal transduction pathway(Lenschow et al., 1996). Through this pathway, 58 
costimulation controls expansion and proliferation of T cells by sustaining expression of survivin(Song et 59 
al., 2005b) and aurora B(Song et al., 2007). Long-term T cell survival and memory generation is mediated 60 
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through bcl-2 expression(Song et al., 2005a). IL-12 is a heterodimeric  signal 3 cytokine naturally 61 
produced by dendritic cells and macrophages which stimulates IFN-γ and TNF production from T cells 62 
and NK cells, thereby playing an important role in responses to pathogens like  mycobacteria(Xing et al., 63 
2000). Distinct T cell subsets and innate effector cells play a role in immunopathology and protection 64 
against mycobacterial infections, including paratuberculosis, through effector cytokine production, 65 
chiefly IFN-γ(Ladel et al., 1995; Stabel, 2000). Costimulation of whole blood or PBMC ex vivo with 66 
cytokines such as IL-2(Pintaric et al., 2008), IL-12(Jungersen et al., 2012; Mikkelsen et al., 2012) and IL-67 
18(Pintaric et al., 2008; Riber et al., 2011) or monoclonal antibodies blocking inhibitory IL-10 68 
signaling(Mikkelsen et al., 2012) have been investigated extensively in veterinary immunology. 69 
However, studies with monoclonal antibodies (mAbs) to costimulatory molecules CD28 and CD49d 70 
remain limited with available information mainly from studies in humans and rodents. In this study, we 71 
describe the first use of signal 2 costimulation using anti-CD28 (aCD28), anti-CD49d (aCD49d), and anti-72 
CD5 (aCD5) mAbs in cattle, alone or in combination with a costimulatory signal 3 cytokine, recombinant 73 
IL-12 (rIL-12), to enhance Ag-specific production of IFN-γ by innate and adaptive T cell subsets. We 74 
report on the effect of costimulation on the frequency of T cells responding to MAP Ags in 75 
experimentally challenged and vaccinated calves.   76 
 77 
2. Materials and Methods   78 
2.1. Animals  79 
Animals used in the present study (N=8, 5 vaccinated and 3 control) were available from a larger post-80 
exposure MAP vaccine trial currently in progress. Male Jersey calves were obtained for the trial (mean 81 
age of 2 weeks) from a dairy farm proven to have a true prevalence equal or close to zero by the Danish 82 
paratuberculosis surveillance program(Mikkelsen et al., 2011). Animals were housed and raised under 83 
appropriate biological containment facilities (BSL-2) in a community pen with straw bedding. All calves 84 
were infected with a total of 1 x 109 CFU of a clinical isolate of MAP (Ejlskov 2007) grown in Middlebrook 85 
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7H9 medium supplemented with 10% oleic acid-albumin-dextrose complex (Difco, USA) plus 0.05% 86 
Tween 80 (Sigma Chemical Co., St. Louis, Mo.) and 2% Mycobactin J (Allied Monitor Inc., USA) and fed 87 
with milk replacer (DLG, Denmark) three times over a period of one week from 2 weeks of age.   88 
Vaccinated calves (n = 5) were immunized by the sub-cutaneous route in the right mid-neck region 89 
about 7 cm ahead of the prescapular lymph node at the age of 16 weeks followed by a second 90 
vaccination 4 weeks later. All vaccine calves received a recombinant vaccine with 100 µg each of a fusion 91 
protein of four MAP proteins from the ESAT 6 family and a MAP latency protein adsorbed to the 92 
adjuvant CAF01 (DDA/TDB; 2500 µg/500 µg) for 1 hour at RT before injection(Agger et al., 2008). 93 
Selection was based on previous immunogenicity studies in cattle and experimental knowledge from in 94 
vitro and in vivo expression studies with M. tuberculosis proteins in mice. All Ags were produced in E. 95 
coli and purified by metal affinity and anion columns as previously described(Mikkelsen et al., 2011). 96 
Control calves (n = 3) didn’t receive any vaccine. Blood samples were collected 8-10 weeks post second 97 
vaccination.  98 
 99 
All animal experiments were done following approval by and under control of the Danish National 100 
Experiments Inspectorate. 101 
 102 
2.2. Cell preparation and antigen stimulation 103 
Peripheral blood mononuclear cells (PBMC) were isolated from EDTA cattle blood by Ficoll-Paque PLUS 104 
(GE Healthcare Life Sciences) gradient density centrifugation. Cells were then washed twice in RPMI 105 
1640 media (Life Technologies, UK) supplemented with 2% heat-inactivated FCS (Sigma). After washing, 106 
cells were resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 100 U/ml 107 
penicillin (Gibco, UK), and 100 µg/ml streptomycin sulphate (Gibco, UK). All cell cultures were 108 
performed in 24-well CELLSTAR multi-well plates (Greiner Bio-One, Heidelberg, Germany) containing 5 x 109 
106 cells/well in a volume of 1 ml complete medium with 50 µl of MAP vaccine Ag cocktail (containing 1 110 
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µg of each MAP Ag/ml), 1 µg/ml of the superantigen staphylococcal enterotoxin B (SEB, Sigma-Aldrich) 111 
or sterile PBS. Costimulations were performed with combinations of rIL-12 (10 IU/ml (a kind gift from 112 
Jayne Hope, The Roslin Institute, University of Edinburgh), anti-bovine CD28 (1 µg/ml; Clone TE1A), anti-113 
bovine CD49d (1 µg/ml; Clone FW3-218), and anti-bovine CD5 (1 µg/ml; Clone CC17; AbD Serotec, UK). 114 
The cultures were incubated at 37°C in a humidified 5% CO2 atmosphere for 18-20 hours. Brefeldin A 115 
(10 μg/ml; Sigma-Aldrich) and monensin (2 µM/ml; Sigma) were added for the final 6 hr of culture to 116 
block protein secretion for intracellular IFN-γ detection. Following centrifugation of the culture plates, 117 
supernatants and cells were collected for IFN-γ analysis by ELISA and flow cytometry, respectively.  118 
 119 
2.3. IFN-γ assay 120 
Collected supernatants were stored at -20°C or less until analysis. IFN-γ secretion in supernatants was 121 
determined by use of an in-house monoclonal sandwich ELISA as described earlier(Mikkelsen et al., 122 
2009). The levels of IFN-γ (pg/ml) were calculated using linear regression on log-log transformed 123 
readings from the two-fold dilution series of a reference SEB stimulated plasma standard with 124 
predetermined IFN-γ concentration. The IFN-γ response in PBS cultures was subtracted from IFN-γ 125 
response to MAP vaccine Ag cocktail cultures for each sample and defined as the Ag-specific IFN-γ 126 
response.  127 
 128 
2.4. Flow cytometry for Intracellular cytokine staining (ICS)        129 
After collection of the supernatant, PBMC were harvested following addition of PBS-EDTA (20 mM) with 130 
10 minutes of shaking and pelleted in 96-well FACS plates (BD Biosciences). Surface staining was 131 
performed on pelleted cells using one of the four different staining panels (Table 1). All staining was 132 
performed at RT for 30 minutes. Cells were stained for surface markers using monoclonal antibodies 133 
anti-CD3, anti-CD4, anti-CD8, anti-WC1, and anti-NKp46. Cells were then washed in FACS buffer (PBS 134 
containing 0.1 % sodium azide and 1 % Foetal Calf Serum) and subsequently stained with secondary 135 
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antibodies as shown in the panel. Cells were then washed in FACS buffer, permeabilized using the 136 
Cytofix/Cytoperm kit (BD Pharmingen, USA) according to manufacturer’s instructions, and stained for 137 
intracellular IFN-γ for 30 minutes at RT. Cells were subsequently washed in perm wash buffer (BD 138 
Pharmingen, USA), resuspended in FACS flow, and analyzed using an eight-color BD FACSCanto II flow 139 
cytometer (BD Biosciences, USA) with a High Throughput Sampler (HTS) 96-well plates. Data analysis 140 
was performed using BD FACSDiva software vs. 6.1.2.  141 
 142 
Table 1: Flow cytometry staining panels 143 
 Primary staining Secondary staining 
Panel Monoclonal antibodies 
 
Isotype 
 
Clone Source Secondary antibodies Fluorochrome 
1 
 
 
anti-CD3  
anti-CD4 
anti-IFNγ 
IgG1 
IgG2a 
IgG1 
MM1A 
IL-A11 
CC302 
VMRD 
VMRD 
AbD Serotec 
anti mouse IgG1  
anti mouse IgG2a 
anti mouse IgG1  
FITC 
RPE 
AF647 
2 
 
 
anti-CD3  
anti-CD8 
anti-IFNγ 
IgG1 
IgG2a 
IgG1 
MM1A 
CC63 
CC302 
VMRD 
AbD Serotec  
AbD Serotec 
anti mouse IgG1  
anti mouse IgG2a 
anti mouse IgG1  
FITC 
RPE 
AF647 
3 
 
 
anti-CD3 
anti-WC1 
anti-IFNγ  
IgG1 
IgG2a 
IgG1 
MM1A 
CC15 
CC302 
VMRD 
AbD Serotec  
AbD Serotec 
anti mouse IgG1  
anti mouse IgG2a 
anti mouse IgG1  
FITC 
RPE 
AF647 
4 
 
 
anti-NKp46 
anti-CD8 
anti-IFNγ   
IgG1 
IgG2a 
IgG1 
AKS1 
CC63 
CC302 
Anne K. Storset, Norway 
AbD Serotec 
AbD Serotec 
anti mouse IgG1  
anti mouse IgG2a 
anti mouse IgG1  
FITC 
RPE 
AF647 
5 Isotype control 
 
 
IgG1 
IgG2a 
IgG1 
- 
- 
- 
Southern Biotech 
Southern Biotech 
AbD Serotec 
anti mouse IgG1  
anti mouse IgG2a 
anti mouse IgG1 
FITC 
RPE 
AF647 
 144 
Integrated median fluorescence intensity (iMFI) was calculated by multiplying the relative frequency of 145 
cells expressing IFN-γ with the MFI of IFN-γ signal. This provides a quantitative assessment of the 146 
magnitude as well as the quality of the cytokine response for different cell subsets(Seder et al., 2008). 147 
MAP vaccine Ag-specific iMFI was calculated by deducting iMFI responses to PBS cultures from those of 148 
MAP vaccine Ag cocktail(Cordes et al., 2012). 149 
 150 
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2.5. Statistical analysis 151 
Comparison of MAP vaccine Ag-specific IFN-γ release and IFN-γ iMFI responses between different 152 
costimulations in vaccinated calves was performed using non-parametric Friedman test and Dunn’s 153 
multiple comparison test. Differences between the magnitude of responses in signal 2 and signal 3 154 
costimulations and their interaction effect were determined using repeated measures ANOVA with 155 
Bonferroni post analysis test. Comparison of immune responses between vaccinated and control calves 156 
were done using a non-parametric two-tailed Mann-Whitney test. Statistical analysis was performed 157 
using GraphPad Prism software vs. 5 (GraphPad Software Inc., USA). 158 
 159 
3. Results and Discussion 160 
Production of IFN-γ by distinct T cell lineages(Coussens, 2001; Kaufmann, 2002) and innate effector 161 
cells(Ladel et al., 1995) plays an important role in the pathogenesis as well as resistance to 162 
mycobacterial infections. In MAP infection, the inflammatory environment in the small intestine 163 
especially the jejunum, distal ileum, and associated lymph nodes provides necessary costimulatory 164 
signals(Stabel, 2000; Coussens, 2001) that might be missing on evaluating the IFN-γ responses in ex vivo 165 
PBMC assays. This might lead to detection of only low activation threshold T cells while missing T cell 166 
populations with a higher threshold of activation. The addition of costimulatory molecules compensates 167 
for this deficit and enhances the sensitivity of PBMC, as well as whole-blood based assays(Waldrop et 168 
al., 1998), by bringing both qualitative and quantitative changes leading to lower activation threshold 169 
and an increase in T cell activity. Here, we demonstrate an increase in the amount of IFN-γ production 170 
by Ag-specific T cells cultured with IL-12 and mAbs to one or more costimulatory molecules. The data 171 
presented in this communication is based on a small subset of animals of a larger trial as described 172 
earlier. However, the results from this study enabled us to select the best combination of costimulatory 173 
molecules for the rest of the vaccine trial.   174 
 175 
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 3.1. Effects of addition of costimulatory molecules on IFN-γ release by PBMCs 176 
PBMCs from the vaccinated and control calves were stimulated with antigen alone or in combination 177 
with IL-12 and costimulatory mAbs.  IFN-γ levels were measured in the culture supernatant. Comparison 178 
of the different culture conditions revealed significant differences in the capacity of combinations of IL-179 
12 and costimulatory mAbs to enhance the production of IFN-γ (Fig. 1).  180 
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 181 
Figure 1. Antigen-specific IFN-γ responses in 18 hrs PBMC cultures with signal 2 and 3 costimulatory 182 
molecules added. (a) Levels of IFN-γ released from PBMC cultures stimulated with recombinant vaccine 183 
proteins (Ag) costimulated with aCD28, aCD49d, aCD5, aCD28/aCD49d, and aCD5/ aCD28/aCD49d. (b) 184 
Levels of IFN-γ released from PBMCs cultured with Ag and costimulated with rIL-12, aCD28/aCD49d, and 185 
rIL-12/aCD28/aCD49d. IFN-γ levels are expressed as mean values (± standard deviation [SD]) for plasma 186 
concentrations (pg/ml). Dotted line is the mean+2SD of IFN-γ production levels of vaccinated animals 187 
with nil costimulation (only Ag). Significant differences between nil costimulation (Ag stimulated) and 188 
signal 2 or 3 costimulation were determined by non-parametric Friedman test and Dunn’s multiple 189 
comparison test analysis (* p<0.05, ** p<0.01, *** p<0.001).   190 
 191 
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Among the combinations used in this study, both aCD28/aCD49d and aCD5/aCD28/aCD49d were found 192 
to significantly (p<0.01) elevate the MAP vaccine Ag-specific IFN-γ production compared to control 193 
animals (Fig. 1a). aCD5/aCD28/aCD49d increased the non-specific background in one control animal. In 194 
terms of interaction effect, there was a significant interaction (p<0.05) between aCD28 and aCD49d 195 
mAb. 196 
 197 
Relative to costimulation with mAbs alone, a further increase in the MAP vaccine Ag-specific IFN-γ 198 
production was obtained by addition of rIL-12 and the combination of rIL-12 with aCD28/aCD49d further 199 
increased IFN-γ release compared to rIL-12 alone (Fig. 1b). This combination, however, also led to an 200 
increase in the background IFN-γ release in control animals with very high levels in one of the controls.  201 
In contrast, aCD28/aCD49d didn’t increase the Ag-specific IFN-γ production in the control animals.     202 
 203 
3.2. Costimulation with Signal 2 molecules increase iMFI of Ag-specific IFN-γ producing T cell subsets 204 
To estimate which subset of T cell populations (CD4+, CD8+, γδ, or NK cells) might be responsible for the 205 
IFN-γ production with signal 2 costimulatory mAbs, we used flow cytometry for measuring Ag-specific 206 
IFN-γ iMFI in PBMC culture from vaccinated and control calves (Supplemental figure 1). The frequency of 207 
effector T cells and NK cells responding to MAP vaccine Ag cocktail with production of IFN-γ were found 208 
to increase in the presence of aCD28, aCD49d, or aCD5 mAb, as well as their combinations (Fig. 2). 209 
Costimulation with aCD28 was found to enhance more IFN-γ iMFI as compared to aCD49d or aCD5 mAb 210 
alone in all cell subsets. Maximum increase in the IFN-γ iMFI with low non-specific background signal 211 
was observed with aCD28/aCD49d combined. A significant effect of interaction (p<0.05) was observed 212 
with this combination in all T cell subsets except CD8+NKp46+ cells (Fig. 2d). However, addition of aCD5 213 
mAb was found to increase the background signal in the control animals either alone or in combination 214 
with aCD28/aCD49d in all IFN-γ producing subsets with no significant interaction effect. No significant 215 
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change in the distribution of IFN-γ producing cells among the T cell subsets was observed after addition 216 
of aCD28/aCD49d. 217 
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Figure 2. Antigen-specific IFN-γ iMFI of T cell subsets in PBMC cultures from vaccinated or control 219 
animals costimulated with mAbs aCD28, aCD49d and aCD5. Antigen-specific iMFI was calculated as iMFI 220 
from cultures with Ag – iMFI from cultures with PBS. (a) iMFI of CD3+CD4+ subsets, (b) iMFI of 221 
CD3+CD8+ subsets, (c) iMFI of CD3+WC1+ subsets, (d) iMFI of CD8+NKp46+ subsets. Dotted line is the 222 
mean+2SD of IFN-γ iMFI of vaccinated animals with nil costimulation (only Ag). Significant differences 223 
between nil costimulation (Ag stimulated) and signal 2 costimulation were determined by non-224 
parametric Friedman test and Dunn’s multiple comparison test analysis (* p<0.05, ** p<0.01, *** 225 
p<0.001). 226 
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Summarized, these data show there is an increase in the Ag-specific IFN-γ iMFI after addition of signal 2 227 
or other costimulatory molecules and their combinations with cross-linking of CD28 molecules as the 228 
most important costimulation as compared to aCD49d or aCD5 mAb alone and with an additive effect of 229 
aCD28/aCD49d. Possibilities of nonspecific or cross-reactive cytokine responses were not apparent as 230 
these mAbs had no stimulatory effect in the PBS stimulated samples (data not shown). This suggests 231 
that there exists a spectrum of T cell activation thresholds, with some requiring only one strong signal 232 
while others requiring a combination of signals. It has been reported that signaling induced by CD28 233 
cross-linking primarily affects IL-2 production which further plays a role in T cell priming and augments 234 
Th1 (IFN-γ) and Th2 type (IL-4, IL-5, and IL-10) cytokine production(Seder et al., 1994). Other studies 235 
reported that addition of aCD28 didn’t lead to significantly increased per cell IFN-γ production, but 236 
rather an increased frequency of cytokine producing T cells(Waldrop et al., 1998). However, 237 
aCD28/aCD49d  has been found to potentiate the low threshold T cells in many low infection disease 238 
models and vaccine experiments(Horton et al., 2007; Lindenstrom et al., 2009; Geluk et al., 2010).  239 
 240 
3.3. Signal 3 costimulation induce maximum iMFI of Ag-specific IFN-γ producing T cell subsets  241 
To further explore the potentiation of IFN-γ levels and contribution of distinct T cell subsets, we 242 
analyzed the iMFI of Ag-specific IFN-γ producing T cells after addition of signal 3 cytokine rIL-12 and its 243 
combination with aCD28/aCD49d. In all lymphocyte subsets, there was a significant effect of interaction 244 
(p<0.01) between rIL-12 and aCD28/aCD49d that was most prominent in case of CD3+CD8+ and 245 
CD8+NKp46+ populations (p<0.001). By screening IFN-γ iMFI of the CD3+CD4+ T cells with rIL-12 and its 246 
combinations, it was observed that signal 3 cytokine alone (~40 fold) and together with aCD28/aCD49d 247 
(~56 fold), significantly increase the Ag-specific IFN-γ iMFI in vaccinated compared to control animals 248 
(Fig. 3a). This increase was 14 and 26 fold in CD3+CD8+ T cells (Fig. 3b) and 2.5 and 21 fold in CD3+WC1+ 249 
T cells, respectively (Fig. 3c). In the CD8+NKp46+ subset an increase of about 4 fold was observed with 250 
both signal 3 as well as signal 2 and 3 costimulatory molecules (Fig. 3d).  251 
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Figure 3. Antigen-specific IFN-γ iMFI of T cell subsets in PBMC cultures from vaccinated or control 253 
animals costimulated with signal 3 (rIL-12) and signal 2 (aCD28/aCD49d) costimulatory molecules (a) 254 
iMFI of CD3+CD4+ subsets (b) iMFI of CD3+CD8+ subsets (c) iMFI of CD3+WC1+ subsets (d) iMFI of 255 
CD8+NKp46+ subsets. Dotted line is the mean+2SD of IFN-γ iMFI of vaccinated animals with nil 256 
costimulation (only Ag). Significant differences between nil costimulation (Ag stimulated) and signal 3 257 
costimulation were determined by non-parametric Friedman test and Dunn’s multiple comparison test 258 
analysis (* p<0.05, ** p<0.01, *** p<0.001). 259 
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The strong potentiation of IFN-γ with rIL-12, however, also increased the background in the control 260 
animals that was absent in case of aCD28/aCD49d costimulation. While the profile of IFN-γ producing 261 
cells after aCD28/sCD49d costimulation still reflected the profile without costimulation, the marked 262 
increase in the IFN-γ production of CD3+CD4+ T cells after addition of rIL-12, with or without 263 
aCD28/aCD49d, skewed the profile of IFN-γ producing cells towards a CD3+CD4+ T cell dominance.  264 
 265 
Signal 3 inflammatory cytokines such as IL-12, IFN-γ, and type I IFNs regulate multiple aspects of the T 266 
cell response including expansion, differentiation and effector functions(Kaech and Ahmed, 2001). 267 
However, the signal 3 inflammatory signature in vivo is pathogen-specific as different types of 268 
pathogens are likely to induce different inflammatory cytokine environments. IL-12 stimulates the 269 
production of IFN-γ by the activation of transcription factor STAT4(van, V et al., 2003) and has been used 270 
as a costimulatory molecule(Valenzuela et al., 2002; Geluk et al., 2010) as well as an immunostimulatory 271 
agent or adjuvant in vaccination protocols(Afonso et al., 1994). There has been evidence of IL-12 272 
mediated augmentation of IFN-γ secretion by γδ T cells and NK cells(Skeen and Ziegler, 1995). IL-12 has 273 
earlier been shown to significantly increase the IFN-γ production with a corresponding increase in the 274 
percentages of single IFN-γ+CD3+CD4+ T cells(Geluk et al., 2010). Supplemental exogenous rIL-12 has 275 
been demonstrated to show a dose-dependent capacity to synergistically promote IFN-γ production in 276 
both in vitro and in vivo conditions after BCG vaccination(O'Donnell et al., 1999).  277 
 278 
Taken together, our data show that maximum Ag-specific IFN-γ production can be measured with a 279 
combined signal 2 and 3 costimulation in the form of aCD28/aCD49d and rIL-12. The data also show that 280 
individual subsets and cells differ in their costimulatory requirements for activation as well as IFN-γ 281 
production. With the strong shift towards a Th1 type response following exogenous IL-12 282 
supplementation, this costimulation is likely to introduce a bias in the ex vivo read-out and should 283 
preferentially be used to support an Ag-specific IFN-γ production e.g. for diagnostic purposes. In other 284 
15 
 
ex vivo applications where costimulation is intended to enhance a more complete picture of the ongoing 285 
Ag-specific immune responses, e.g. to characterize CMI responses in response to infection or 286 
vaccination, the powerful signal 3 costimulation should not be used. In this place a signal 2 287 
costimulation with aCD28/aCD49d appears to promote a less biased read-out.  288 
 289 
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Vaccines  have  been  a major  innovation  in  the  history  of  mankind  and  still  have  the  potential  to address
the  challenges  posed  by  chronic  intracellular  infections  including  tuberculosis,  HIV and  malaria  which
are leading  causes  of  high  morbidity  and  mortality  across  the  world.  Markers  of  an  appropriate  humoral
response  currently  remain  the  best validated  correlates  of  protective  immunity  after  vaccination.  Despite
advancements  in  the ﬁeld  of immunology  over  the past few  decades  currently  there  are,  however,
no  sufﬁciently  validated  immune  correlates  of vaccine  induced  protection  against  chronic  infections
in neither  human  nor  veterinary  medicine.  Technological  and  conceptual  advancements  within  cell-
mediated  immunology  have  led  to a number  of  new  immunological  read-outs  with  the  potential  to
emerge  as  correlates  of  vaccine  induced  protection.  For  TH1 type  responses,  antigen-speciﬁc  production
of interferon-gamma  (IFN-)  has  been  promoted  as  a quantitative  marker  of protective  cell-mediated
immune  responses  over  the  past  couple  of  decades.  More  recently,  however,  evidence  from  several
infections  has  pointed  towards  the  quality  of the  immune  response,  measured  through  increased  levels
of antigen-speciﬁc  polyfunctional  T cells  capable  of  producing  a triad  of relevant  cytokines,  as  a  bet-
ter  correlate  of sustained  protective  immunity  against  this  type of  infections.  Also  the  possibilities  to
measure  antigen-speciﬁc  cytotoxic  T cells  (CTL)  during  infection  or in  response  to vaccination,  through
recombinant  major  histocompatibility  complex  (MHC)  class  I tetramers  loaded  with  relevant  peptides,
has  opened  a new  vista  to include  CTL responses  in  the  evaluation  of protective  immune  responses.  Here,
we  review  different  immune  markers  and  new  candidates  for correlates  of  a protective  vaccine  induced
immune  response  against  chronic  infections  and  how  successful  they have  been  in deﬁning  the  protective
immunity  in human  and  veterinary  medicine.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
The development of novel vaccines is a lengthy process and
requires scientiﬁcally proven basic research in animal models,
safety testing and prolonged clinical testing in humans before
reaching the licensure phase. In cases of seasonal diseases and
pandemics, newly emerging diseases and chronic infections with
long stages of latency, clinical trials are not always feasible. In
such cases, where measuring the immune response from the clini-
cal endpoint is impossible, the rational development of vaccines,
and in some cases even their approval, will rely on demonstra-
tion of immunological correlates of protection after vaccination.
In addition, validated correlates of protection may  be used to
ensure vaccine potency and efﬁcacy in batch-to-batch control and
serial validation. According to the Food and Drug Administration
(FDA), a correlate of protection is a laboratory parameter which
∗ Corresponding author. Tel.: +45 35 88 62 34; fax: +45 35 88 66 01.
E-mail address: GRJU@vet.dtu.dk (G. Jungersen).
is associated with protection from the occurrence of clinical dis-
ease as shown after sufﬁcient and controlled trials [1].  A correlate
of protection can thus only be identiﬁed following statistical anal-
ysis within a large group of vaccinated or infected individuals in
which some of the individuals are protected and others are not.
Recently, it has been proposed to subdivide correlates of protection
into (i) mechanistic correlates of protection, when the measured
immune parameter is causally responsible for the observed pro-
tection, and (ii) non-mechanistic correlates of protection, when
the measured parameter is signiﬁcantly correlated with protection,
but not a mechanistic causal agent of the protection [2].  In many
cases descriptions of immune responses that reﬂect likely biolog-
ical functionality are provided even though they have not been
shown to statistically correlate with protection. Such measures
should be labeled as relevant immune markers and not confused
with correlates [3].  Similarly, it will not always be feasible to use
development of (or protection against) the actual clinical disease to
evaluate the efﬁcacy of a vaccine, in which case the use of surrogate
clinical endpoints become necessary. Surrogates are thus labora-
tory or physical signs (correlates) that are used in clinical trials as a
0264-410X/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
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substitute for a clinically meaningful endpoint. Surrogates may  be
used to predict protection or meaningful clinical beneﬁt when an
absolute immune correlate of protection is unknown [3,4].
A number of immunological parameters have been investigated
as potential immune correlates of protection (Table 1). These can
be broadly categorized into cell-mediated and humoral immune
correlates and must reﬂect induction of the type of immunological
response that is required for protective efﬁcacy against the relevant
pathogen (Fig. 1). The majority of vaccines have been developed
empirically, with little or no understanding of a known mechanism
of immune protection, and the success behind these vaccines is
mostly related to induction of strong humoral immune responses
by eliciting long lived plasma cells (Table 2). However, for chronic
intracellular infections caused by e.g. Mycobacteria, Chlamydia,
Apicomplexa parasites and others, the vaccinology research and
development has been challenged by agents that are not easily con-
trolled by antibodies [5].  In such diseases, it is the cell-mediated
immune (CMI) response of the adaptive immune system that is
central to the mediation of protection. Since empirical vaccine
development so far has proven unsuccessful for these infections,
it can be argued that a more rational approach of vaccine develop-
ment is needed to activate an effective CMI  response [6].  Such an
approach should be based on an understanding of the molecular
basis of microbial pathogenicity, host–pathogen interactions and
the nature of the protective T cell responses for the individual infec-
tion. Irrespective of whether vaccine development against chronic
intracellular infections will be most successful through an empir-
ical vaccinology approach or applied immunological research, it is
imperative to establish methods that assess the magnitude and
quality of particular immune responses after vaccination. Such
methods can be used to guide the vaccine development and could
also be developed into potency tests.
2. Immune correlates of antibody-mediated immunity
In late years of the 20th century it was largely believed
that immunity to intracellular pathogens is conferred by a CMI
response (TH1) while immunity to extracellular pathogens rely
on antibody-mediated mechanisms (TH2). However, this notion
of immunological duality has been challenged by the fact that
antibody-mediated immunity confers protection in most viral
vaccines despite their obligate intracellular life. There is convinc-
ing evidence that intracellular pathogens elicit a mixed immune
response characterized by both TH1 and TH2 type response. These
mixed protective responses have been very well demonstrated for
Chlamydia,  Plasmodium, Schistosoma and Cryptococcus neoformans
infections [7–9].
Almost all available licensed vaccines elicit a robust antibody
response that correlates with the level of protection extended by
the vaccine (Table 2) [10,11].  This is due to the fact that most
pathogens at some point in the pathogenesis are susceptible to anti-
body neutralization such as during replication on mucosal surfaces,
in an extracellular state after passage through the bloodstream or in
a transient extracellular phase. However, recent ﬁndings have also
revealed a signiﬁcant immunoregulatory effect of antibodies on
T-cell immunity against Mycobacteria, Chlamydia and others [12].
Speciﬁc antibody isotypes modulate TH1 activation via Fc receptors
(FcR) by facilitating a rapid uptake, processing and presentation of
pathogen-derived antigen (Ag) for a strong T-cell response [13].
Thus a protective T-cell memory response appears to require an
effective primary humoral immune response [7,12].  Many charac-
teristics of antibodies such as titer, phenotype, function, speciﬁcity
and location have been investigated in a number of immunologi-
cal assays as potential correlates of immune protection in various
vaccine trials (Table 1). Most of these assays have been used for
quantifying and deﬁning the protective concentrations and thresh-
olds of the antibodies against infections.
2.1. Neutralizing antibody titer
Persisting antibody following vaccination has been recognized
as a ﬁrst line of host defense against infection and in the past
regarded as a hallmark of an effective vaccine [14,15].  Moreover,
most of the successful commercially available vaccines have the
ability to induce strong antibody responses which are protec-
tive. Several commercial vaccines induce deﬁned serum antibody
titers as measured by binding using an enzyme-linked immunosor-
bent assay (ELISA) as well as haemagglutination and neutralization
assays which serve as correlates or markers of protection [15].
Smallpox and yellow fever vaccines which are both live attenuated
vaccine are classical examples. Both have been developed at a time
when no immunological techniques were available to deﬁne the
immunological correlates. However, vaccine experiments around
1970s conﬁrm the neutralizing antibody titers as the key play-
ers of protective immunity with 1:20–1:32 for smallpox [16,17]
and 0.7 LNI (log neutralizing index) for yellow fever [18]. Like-
wise, serum neutralizing antibody titers for a variety of intracellular
pathogens particularly the viruses have been deﬁned (Table 2).
However, deﬁned threshold levels of protective antibody titers
for intracellular bacterial infections remains elusive. The antibody
response is crucial for preventing many intracellular bacterial and
Table 1
Immunological parameters investigated as potential correlates of protection.
Parameter Response/mechanism Correlate of protection References
Humoral
Neutralizing antibodies Humoral Correlate [17,220–223]
Serum  IgG Humoral Correlate [220,224–228]
Mucosal IgG, IgA Humoral Correlate [38,229,230]
Cell-mediated
IFN-  TH1 Inconsistent data [84–86,98,231,232]
TNF-  TH1 ND [74,110,112]
IL-2  TH1 ND [75,112,114]
IL-17  TH17 ND [116,119,233]
IL-1,  4, 10 TH2 ND
IFN-,  TNF-, IL-2 Polyfunctional T cells Inconsistent data [79,112,168,169]
MHC  class I and II tetramer-speciﬁc T cells MHC restriction ND [127,128,134,141,143]
CCR7hi, CD45RA+, CD62hi, CD44+, CD127hi, CD27+, CD28+ TCM: IL-2, IFN-low, IL-4low, IL-17Alow Inconsistent data [65,155,156,158]
CCR7low, CD45RA− , CD62low, CD44+, CD127low, CD27+/− , CD28+ TEM: IFN-, IL-2, IL-4, IL-17A Inconsistent data [74,161,163,164]
CD27+, FCRL4+ Memory B cells, humoral Surrogate [56,59]
  TCR+, CD3+  T cells: IFN-, IL-17A, IL-17F, IL-22 ND [186–189]
CD3lowCD56+NKT cells IFN-, IL-17A, IL-4 ND [175,176]
ND, not determined.
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Table 2
Thresholds of vaccine induced correlates and surrogates of protection (FDA licensed vaccines).
Vaccine Trade name (s) Vaccine type Test Threshold of protection Serum IgG Mucosal IgG Mucosal IgA T cells References
Hepatitis A Havrix, VAQTA Inactivated ELISA 10 mIU/ml  ++ [224,234]
Hepatitis  B Recombivax HB,
Engerix-B
Recombinant ELISA 10 mIU/ml ++ [225]
Hib  polysaccharide
(Hib PS)
Hib vaccine Polysaccharide (PS) ELISA 1 g/ml ++ + [235]
Hib  conjugate PedvaxHIB,
Pentacel
PS-protein
Conjugate
ELISA 0.15 g/ml ++ ++ [236]
Human
papillomavirus
Gardasil, Cervarix Virus-like particles ELISA ND ++ ++ [230]
Inﬂuenza  No trade name Inactivated/live
attenu-
ated/(intranasal)
HI 1:40 titer ++ + + (CD8+) (intranasal) [226]
Japanese
encephalitis
JE-vax,  Ixiaro Inactivated/live
attenuated
Neutralization 1:10 titer ++ [220]
Measles  MMRII, Attenuvax Live attenuated Microneutralization 120–200 mIU/ml ++ + (CD8+) [221,222]
Meningococcal Menactra Polysaccharide Bactericidal 1/4 ++ + [228]
Mumps  MMRII, Mumpsvax Live attenuated Neutralization ND ++ [223]
Polio  Poliovax, IPOL Live attenu-
ated/inactivated
Neutralization 1:4–1:8 titer ++ ++ ++ [38]
Rabies  Imovax, RabAvert Inactivated Neutralization 0.5 IU/ml ++ [237]
Rotavirus  ROTARIX, Rotateq Live attenuated Serum IgA ND ++ [229]
Rubella  MMRII, Meruvax II Live attenuated Immunoprecipitation 10–15 mIU/ml ++ [227,238]
Smallpox  ACAM2000 Live attenuated Neutralization 1:20–1:32 titer ++ [16,17]
Tuberculosis BCG Live attenuated IFN-,
Polyfunctional T
cells
ND ++ (CD4+) [231]
Varicella  Varivax Live attenuated FAMA, gp ELISA 1:64 titer, 5 IU/ml ++ + (CD4+) [239,240]
Varicella  zoster Zostavax Live attenuated CD4+ T cell
proliferation
ND ++ [241]
Yellow  fever YF-Vax Live attenuated Neutralization 0.7 LNI ++ [18]
Adapted from Plotkin (2008, 2010) with modiﬁcations.
ND, not deﬁned.
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Fig. 1. Schematic representation of the different stages involved in the induction and regulation of cell-mediated and humoral immune response against pathogens. Stage 1:
Innate  activation – Pathogens or antigens can be taken up by antigen presenting cells (APC), namely macrophages, dendritic cells (DCs) or B-cells once they breach the epithelial
barrier.  Antigens are presented to the naive T-cells by the activated DCs through MHC–TCR interaction (signal 1). Interaction of adhesion and costimulatory molecules on
APC  such as CD80 (B7.1) and CD86 (B7.2), with CD28 on the surface of T cells and CD40 on B cells with CD40L on TH2 cells (signal 2) leads to activation and expansion of
antigen-speciﬁc T-cells. Cytokine production by APCs (signal 3) and innate activation involving interaction of pathogen-associated molecular patterns (PAMPs) with Toll-like
receptors (TLRs), cytokines milieu (IL-1, -2, -4, -6, -12, -18, -21, -23, TGF-), transcription factors (T-bet, STAT-1, -3, - 4, -5, -6, GATA-3, ROR-T, FoxP-3, SMAD) leads to
activation and differentiation of naive T cells into either, TH1, TH2, TH17 or Treg cell lineage. Stage 2: Adaptive regulation and effector functions – This stage is characterized by
the  cell-mediated immunity through TH1 cells and humoral immunity through TH2 cells. TH1 cells activate macrophages and cytotoxic lymphocytes (CTL) through secretion
of  cytokines (IFN-, IL-2, -12, -18, TNF-, GM-CSF) enabling them to destroy pathogens or induce apoptosis in infected cells. TH2 cells activate B-cells through production
of  cytokines IL-4, -5, -6, -10, -13, TGF- and induce B-cell differentiation, antibody class-switching and afﬁnity maturation. TH17 and Treg cells participate in neutrophil
activation and immune regulation by producing cytokines IL-17A, -F, -21, -22 and IL-10, TGF-, respectively. TH1 effector functions are characterized by killing of the ingested
microbes through maximized killing efﬁcacy of macrophages by producing inducible nitric oxide synthase (iNOS) and reactive oxygen intermediates (ROI) and lysis of infected
cells  by CTL through perforins and granzymes. TH2 effector functions represent increased neutralizing antibody production, opsonization and phagocytosis. Activated T cells
differentiate into memory phenotypes-effector memory (TEM) homing to peripheral tissues and central memory (TCM) homing to secondary lymphoid organs. While activated
B  cells differentiate into short-lived (secrete IgM) and long-lived plasma cells (secrete IgG, IgA, IgE, IgD).  T cells and NK/NKT cells serves as a bridge connecting the stages
1  and 2.  T cells and NK/NKT cells modulate the immune response by producing both pro and anti-inﬂammatory cytokines (IFN-, IL-17A, -17F, -21, -22).
viral infections and may  also contribute to resolution of infection.
Antibodies can neutralize viral infectivity in a number of ways,
they may  interfere with virion binding to receptors, block virus
uptake into cells, prevent uncoating of the viral genome in endo-
somes, or cause aggregation of virus particles. Also many enveloped
viruses are lyzed when antiviral antibodies and serum comple-
ment disrupt membranes. Many studies have investigated the
role of neutralizing antibodies for protection against non-bacterial
non-viral intracellular pathogens. Neutralizing species-speciﬁc or
serovar-speciﬁc antibodies are produced in response to Chlamydia
infection in humans and in some animal species [19]. High levels
of Chlamydia-speciﬁc neutralizing antibody titers (IgG, IgA) were
reported in various vaccine experiments with no [20], partial [21]
and optimal protective immunity [22]. In malaria, antibodies with
neutralizing properties have been reported to be induced during
infection and provide support for their potential importance in the
development of vaccines and immunotherapy [23,24]. Neutraliz-
ing antibody responses of the subclasses IgG1 and IgG3 have been
associated with protection from clinical malaria following mero-
zoite vaccination [25]. Although Mycobacteria are prototypical for
a CMI  response, neutralizing antibodies of the subclass IgG and
IgA have been found to prolong survival against tuberculosis in
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various vaccine experiments through Ag clearance and preventing
dissemination of the bacilli [26,27].
2.2. Antibody dependent cell-mediated cytotoxicity (ADCC)
ADCC is one of the mechanisms through which the anti-
bodies can act to limit and contain infection. Classical ADCC
is mediated by natural killer cells with membrane bound Fc
receptors (FcRIII or CD16) which bind to antibody-coated (IgG1
or IgG3) microbes and execute killing through various modal-
ities, perforin, granzymes, reactive oxygen intermediates and
cytokines. Neutrophils, eosinophils and macrophages can also
mediate ADCC through FcRII or FcRIII, FcRI, and FcRII,
respectively. ADCC eliciting properties of antibodies or effector
cells can be measured though various labeling assays such as
chromium-51 [Cr51] release assay, europium [Eu] release assay
and sulfur-35 [S35] release assay. A coupled bioluminescence based
non-radiometric GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) enzyme release assay is now widely used for ADCC
as well as in other cytotoxicity assessments [28]. Recently, a
high-throughput bioluminescent cytotoxicity assay based on intra-
cellular protease biomarker release has been developed [29].
ADCC-mediating antibodies were proposed to be a better corre-
late of protection and prognosis than virus-speciﬁc neutralizing
antibodies and cytotoxic T cells following anti-HIV immunization
and immunotherapy [30]. ADCC activity has been found as an
immune correlate that protects against HIV infection and disease
progression [31,32]. While weaker protection was observed follow-
ing inﬂuenza A vaccination [33] and in defense against malaria [34].
FcR mediated effector functions including ADCC have also been
found to facilitate the clearance of intracellular pathogens including
parasitic infections [13,35–37].
2.3. Immunoglobulin class and subclass
Most of the commercial available vaccines mediate humoral
protection through induction of serum IgG and mucosal IgG and
IgA immunoglobulins (Table 2). Irrespective of the type of vaccine
formulation serum IgG levels have been found to correlate with
protection against a variety of pathogens. In addition, mucosal IgG
levels have also been reported to confer protection [38–41].  IgA is
the dominant immunoglobulin in secretions, especially in intesti-
nal and respiratory tracts and mediates protection chieﬂy through
neutralization and less potent opsonization and complement acti-
vation than IgG [42–45].  Furthermore, high afﬁnity IgG and IgA
antibodies can neutralize bacterial toxins and prevent adherence
of pathogenic bacteria to host cells. Mucosal IgG and IgA have been
demonstrated as a cocorrelate of protection following intranasal
inﬂuenza vaccination [46]. It was found during the vaccine trial
that both immunoglobulins act synergistically as children nega-
tive for both antibodies shed virus 63% of the time compared to
just 3% in doubly antibody-positive vaccinated children. Neutraliz-
ing antibodies are not always protective but may  in some cases be
mere indicators of vaccination [47], i.e. non-mechanistic correlates
of protection.
2.4. Memory B cells
Memory B cells provide defense in those infections in which
the pre-existing antibody levels are very low or if the invading
pathogen is able to overcome the existing antibody titers. Mem-
ory B cells serve as a second line of immune defense owing to
rapid isotype switching, afﬁnity maturation and effector functions.
Humoral memory may  provide life-long protection against previ-
ously encountered pathogens and has been detected more than
50 years after smallpox vaccination [48]. B cell central memory
is prolonged with high level of protective efﬁcacy [49,50].  Func-
tional memory B cells and long lived plasma cells can be measured
by ELISpot and more recently by multicolor ﬂow cytometry using
markers CD19, CD27, CD45, CD38 and CD138 [51,52]. Memory B
cells have been reported to protect against progression to chronic
hepatitis following vaccination [53,54].  On the other hand, a very
weak correlation was  found between circulating intestinal memory
B cells in children and protection after vaccination with attenuated
human rotavirus vaccine [55]. Similarly, low but signiﬁcant cor-
relation between numbers of Ag-speciﬁc memory B-cells and the
corresponding circulating antibody titers were found for measles
virus [56] while others have reported no correlation at all [57].
However, therapeutic potential of virus-speciﬁc memory B cells
have been proven by the demonstration of adoptive transfer of
memory B cells [58]. In hepatitis B virus infection, B cell memory
acts as a marker of protection and is mediated by the Ag stimulation
of memory cells [59].
3. Immune correlates of cell-mediated immunity
It is now well known that for many intracellular infections the
development of antibodies is a poor correlate of protection and in
recent years a lot of effort has been put into characterization of the
more appropriate CMI  responses. Several characteristics of T cells
such as phenotype, function, Ag-speciﬁcity and MHC  restriction
have been investigated as potential correlates of immune protec-
tion in infections and after vaccination (Table 1). Delayed type
hypersensitivity (DTH) has commonly been used for the assess-
ment of CMI  responses in relation to the infection status and
vaccination. However, as the speciﬁc antigens are often unknown
and DTH via the vaccine preparation will evaluate the entire anti-
genic repertoire, DTH is a poor immune correlate [60]. Therefore,
the immunogenicity against pathogens is better determined by
measuring Ag-speciﬁc CD4+ and CD8+ T cell responses and their
associated cytokines. Recently developed ex vivo assays measure
the frequency and phenotype of responding T cells as well as their
proliferative potential and killing capacity (Table 3).
3.1. Helper CD4+ T cells and associated cytokines
CD4+ T cells play a central role in coordinating and culminat-
ing the adaptive immune response. After recognition of Ag through
MHC  class II presentation, activated CD4+ T cells differentiate into
functional subsets termed T helper 1 (TH1), TH2, TH17, or regula-
tory T (Treg) cells (Fig. 1). Effector activity of the TH1 cells is brought
about by the release of the cytokines such as interferon-gamma
(IFN-), tumor necrosis factor-alpha (TNF-) and interleukin-2 (IL-
2) (commonly referred to as TH1 cytokines). In addition, CD4+ T
cells provide growth factors and signals for the generation and
maintenance of CD8+ T cells [61,62]. Most vaccine studies mea-
sure the cytokine secretion by T cells in response to Ag speciﬁc for
the vaccine as the chief immune marker of CMI  induction.
Cytokines can be readily detected at the RNA-level by reverse-
transcriptase polymerase chain reaction (RT-PCR) or as proteins in
ELISA or ELISpot assays after in vitro stimulation of whole blood
or puriﬁed cell suspensions with speciﬁc Ag [63]. While the ELISA
assay provides a quantitative measure of the total cytokine pro-
duction, the ELISpot assay enumerates the Ag-speciﬁc cytokine
secreting cells in response to Ag stimulation. Although the amount
of secreted cytokines cannot be quantiﬁed the ELISpot assay is
very sensitive with detection of less than 0.01% Ag-speciﬁc T
cells. Each of these techniques have been utilized for the devel-
opment of functional and molecular correlates of vaccine-induced
protection [64–69].  At the next level of detail, ﬂow cytometry
is a powerful technology that is capable of deﬁning lineage and
4912 A. Thakur et al. / Vaccine 30 (2012) 4907– 4920
Table 3
T cell immunoassays.
Assay Sample/substrate Read out Comments
IFN- assay Whole blood/PBMC IFN- Cytokine production by all cells in
the culture (quantitative)
ELISpot PBMC Total T cell response Number of cells secreting cytokine
of  interest (qualitative and
quantitative), possible to spot two
cytokines
Multiplex cytokine assay Plasma or serum Cytokines Multiparameter readout
Cytotoxic assay PBMC Cr51, Eu or S35 release, GAPDH
enzyme release, Protease
biomarker release
T cell-mediated cytotoxicity, ADCC
Fluorescent Ag-Transfected Target Cell (FATT)-CTL assay PBMC Lytic activity of virus speciﬁc CTL Ag-speciﬁc cell-mediated
cytotoxicity
3H-thymidine proliferation PBMC Total T cell response Single parameter readout
CFSE  proliferation PBMC CD4 and CD8T cell proliferation Multiparameter readout,
functional proﬁle and
differentiation
Intracellular cytokine staining (ICS) Whole blood or PBMC Surface (CD4 and CD8) and
intracellular markers
Multiparameter readout,
Ag-speciﬁc T cells
Polyfunctional T cells Whole blood or PBMC Polyfunctional T cells Multiparameter readout
Phosphoﬂow Whole blood or PBMC Intracellular signaling molecules
(phosphorylation)
Multiparameter readout
Tetramer Whole blood or PBMC Epitope speciﬁc CD8 and CD4 T cell speciﬁcity but no
functionality, MHC  allele typing is
required
activation state along with a quantiﬁcation of cytokine production
on a single-cell basis. This is achieved by parallel immune stain-
ing of delineation and activation markers expressed on the cell
surface as well as secreted cytokines in the intracellular compart-
ment. Labeling of the lymphocyte cell membrane with CFSE prior
to cell culture makes it further possible to measure the individual
proliferation of cells. CFSE labeling has largely replaced the 3H-
thymidine proliferation assay and tracks the cell proliferation by
progressive two-fold reduction in ﬂuorescence intensity for each
cell division [70]. Technological advancements in multi-parametric
ﬂow cytometry now permit the staining and detection of up to 18
different markers, and identiﬁed patterns of cytokine secretion can
thus be used to differentiate between effector/memory T cell with
different immune functions [71]. Intracellular cytokine staining and
multi-parametric ﬂow cytometry has been used to suggest immune
correlates of protection after vaccination against many human and
animal pathogens [72–80].
IFN-  has been identiﬁed as a canonical cytokine of the TH1
response and plays a crucial role in the vaccine induced protec-
tion against several infections [81–83].  One of the best cases for
the importance of IFN- is the Bacille Calmette Guerin (BCG) vac-
cine against tuberculosis [84] which generates CD4+ protective T
cells producing IFN- after stimulation with speciﬁc Ag. The detec-
tion of Ag-induced de novo production of IFN- in cultures of whole
blood or peripheral blood mononuclear cells (PBMC) has become a
standardized approach for accessing the T cell immune responses
following vaccination in chronic infections [83–86].  These IFN-
release assays (IGRAs) have not only overcome the limitations of
DTH but also have improved the ability to distinguish acute and
latent infections and in predicting vaccine efﬁcacy [87]. In 2001,
QuantiFERON-TB test (QFT) was the ﬁrst IGRA to be approved by
FDA [88]. Cytokine production and T cell proliferation has also been
correlated with protection following inﬂuenza vaccination in older
adults compared to young adults [89,90].  Similarly, T cell medi-
ated protection is needed to control latent infection and disease
in cytomegalovirus infection despite the fact that antibodies have
been shown to be protective [91,92].
Detection of IFN- production does not always reliably pre-
dict vaccine success, whether total or individual T cell IFN-
responses are measured [93]. In some reports protection against M.
tuberculosis infection did not correlate with production of IFN-
by speciﬁc CD4+ effector cells [94–97] suggesting the possibility
of IFN- independent protective mechanisms or the importance
of other cellular sources of cytokines. Most recently compelling
evidence was provided that CD4+ T cells can induce M.  tubercu-
losis growth arrest, even without secreting IFN-, TNF- or both
cytokines [98]. While another report showed that Ag-speciﬁc CD4+
effector T cell activation is suboptimal in the lungs of tuberculosis
infected animals that leads to persistence of infection in the host
[99]. These results emphasize that despite the critical role of IFN-
in TH1 mediated immunity, this cytokine is not a sufﬁcient immune
correlate of protection of its own  [100,101].
Another cytokine of effector T cell functional range is TNF-
which mediates killing functions of intracellular bacteria, viruses
and parasites [102,103].  With its role in the expansion of T cells, IL-2
has also frequently been associated with the quality of T cell func-
tion [104], and these cytokines have been shown to play a role in the
host defense against a variety of intracellular pathogens [105–109].
Thus it has been demonstrated that T cells capable of producing
multiple cytokines with subsets of IFN-, TNF- and IL-2 correlated
well with vaccine induced protection against chronic bacterial and
viral infections compared to T cells producing only one cytokine at
a time [74,110–114]. These polyfunctional T cells will be described
in detail later.
3.1.1. Other cytokines and chemokines
The TH17/IL-23 pathway can play a crucial role in protec-
tive immunity against pathogens [115,116].  It has been shown
that ablation of an IL-17 response following both vaccination
(Ag-speciﬁc production) [115] and infection may  lead to reduced
protection [116–118]. The TH17/IL-23 pathway, through  T cells
and  CD4−CD8− T cells, is also involved in the induction of neu-
trophil attracting chemokines and associated protection against
pathogens [119,120].  Based on the inputs from mycobacterial infec-
tion studies in human and cattle it was proposed that IL-17 may
be essential in vaccine-induced control of tuberculosis, keeping in
balance other immune responses to avoid immunopathology [121].
A range of cytokines and chemokines have been investigated
as potential biomarkers of risk, infection and protection in dif-
ferent infections using techniques such as multiplex bead array,
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intracellular cytokine staining and mRNA expression analysis. IL-
1, IL-4, IL-10, IL-12, MIP, MIG, IP-10, MCP, TGF-, GM-CSF have
been explored as differentiating biomarkers for infection, vaccines
and chemotherapy in serum, plasma, and cell cultures. Addition-
ally, IP-10/CXCL10 produced by monocytes has been recognized
as a potential biomarker of latent tuberculosis and following BCG
vaccination [122]. MIG  and the regulatory cytokines IL-10 and
TGF-1 correlate with malaria vaccine immunogenicity and efﬁ-
cacy in human volunteers [69]. Beta-chemokines such as MIP-1,
MIP-1,  MIP-3 and RANTES have been found to contribute to
protection against infection and in conjunction with vaccination
[123–125].
3.2. Cytotoxic CD8+ T cells
In recent years the scientiﬁc ﬁelds of immunology and bio-
chemistry have seen great advances in the ability to detect and
isolate Ag-speciﬁc cytotoxic CD8+ T cells (CTL) [126–128]. Succes-
sive modiﬁcations of methods like the recombinant MHC  tetramer
approach for staining of speciﬁc CTLs [126,129],  ELISA [130] and
ELISpot [63,131], usage of chimeric molecules and transgenic ani-
mals [132,133],  and cell proliferation assays to monitor speciﬁc CTL
killing [134] have all contributed to the increasing amount of data
available in regard to cytotoxic immune responses during infec-
tion and in vaccination studies. For decades it has been common
practice to measure CTL cytotoxicity using the chromium-release
assay (51Cr-release). However, a limitation of this assay is the abil-
ity to provide only semi quantitative data (unless limiting dilution
assays are performed) and furthermore the 51Cr-release assay has
a relatively low level of sensitivity [131]. As an alternative, one of
the major mechanisms displayed by immune-activated CTLs is the
exocytosis of cytotoxic proteins such as pore forming proteins (per-
forin), serine proteases (granzymes), and cytokines such as IFN-,
TNF- and IL-2, IL-4, and IL-10 [135]. Such components, reveal-
ing the state of activation for individual CTLs, provide a relatively
simple set of cytokines that can be used to monitor and deﬁne
both CTL frequency and function in responses against infections
that require T cells for protection [136]. The IFN- ELISpot assay is
widely used to monitor speciﬁc CTL reactivity against MHC  class I
binding peptides, to determine speciﬁc T cell subsets responsible
for a response using receptor-blocking antibodies (Ab), to con-
ﬁrm MHC  restriction of speciﬁc CD8+ T cell responses, to measure
the secretion of IFN- triggered by a virus infection and to verify
the availability of cross-reactive research tools to expand cytokine
studies between species such as cattle and goats [137–139]. A draw-
back of the ELISpot assay, however, is that the secretion of many
cytokines such as IFN- is not necessarily a means of CTL activa-
tion, but can also be released by non-cytotoxic cells of both the
innate and adaptive immune response (Fig. 1). An assay measur-
ing the secretion of molecules associated with lytic activity or the
frequency of killing of speciﬁc target cells by CTLs would provide
another angle to approach the assessment of T cell functional activ-
ity. Present and future approaches combining one such assay with
highly speciﬁc MHC  tetramer staining of CTLs and additional ﬂow
cytometry-based cytokine release or intracellular staining assays
are state-of-the-art in its ﬁeld and applicable to not only the well
known mouse models but almost any species model of interest
that being livestock, companion animals or primates. Today such
assays are capable of (i) providing a tool for the enumeration
and determination of the relative frequencies of epitope-speciﬁc,
cytokine-secreting CTLs in a sample, (ii) evaluating the effector
function of such CTLs, i.e. the identiﬁcation of speciﬁc cytokines
and chemokines and their ability to speciﬁcally kill infected tar-
gets, and (iii) identifying viral as well as tumor derived peptide T
cell epitopes [127,134,140].
3.3. MHC tetramers and multimers as immune markers or
correlates of protection
MHC  tetramers are four recombinant MHC  molecules loaded
with pathogen-derived synthetic peptides and brought together
(usually through the Biotin–Streptavidin interaction) along with a
ﬂuorescent tag. They have been well known for more than a decade
[126] and are becoming more and more important in the search
for new vaccine candidates and as a tool in monitoring immune
responses as well as in the enumeration and characterization of T
cells [141–143]. With the correct tetramers, Ag-speciﬁc CTLs can
be directly enumerated ex vivo from peripheral blood samples
[129,134] although in vitro manipulations such as cell enrichment,
cell expansion, and/or prolonged stimulation may  enhance the
individual signals for more detailed analyses [144–146].  However,
such in vitro manipulations may  hinder the accuracy of monitor-
ing the exact responses (frequency and function) of CTLs elicited to
disease or vaccination [147]. Despite the established importance of
virus-speciﬁc CTL-mediated killing of virus infected cells and the
possibility to quantify CTLs by tetramer staining of CD8+ T cells,
the MHC  heterogeneity of any outbred population, and the exclu-
sive speciﬁcity of the MHC  tetramer with the corresponding T cell
receptor, has so far not allowed validation of CD8+ tetramer stain-
ing as an immunological correlate of protection. Tetramer stained
CTLs are, however, important immune markers of the effects of vac-
cination as different vaccines or vaccine strategies can be directly
evaluated for their induction of peptide-speciﬁc CD8+ CTL subsets.
Furthermore, tetramers allow the investigation of different T cell
engagement patterns with peptide/MHC/2m (pMHC) complexes
following vaccination.
3.4. Central memory/effector memory T cells
The goal of an efﬁcient vaccine is to generate long-lived memory
CD4+ or CD8+ T cells capable of recognizing and rapidly expand-
ing to combat an infection [148]. Brieﬂy, there are three distinct
phases in the generation of memory T cell response: expansion,
contraction and differentiation into memory. The expansion phase
yields a large population of effector T cells, most of which die in
the contraction phase. However, the expansion phase also yields
cells that will eventually form the memory cell pool. Immunolog-
ical memory has been termed as the incomplete unhappening of
the primary immune response [149] due to the fact that once the
pathogen has been eliminated, most of the activated T cells die.
Still a small population survives this contraction phase and become
memory cells. Hence, the antigen-activated T cell expansion in a
secondary immune response will be more rapid and contraction
less severe. Such primed memory cells are maintained for long
term after immunization, and cross-sectional studies in humans
suggest that the memory response can persist for more than 50
years [150,151].  The memory cell pool is not monolithic. Instead it
contains diverse and ﬂexible populations. Two  broad categories of
memory cells are effector-memory (TEM) (CD62LlowCCR7low) and
central-memory (TCM) (CD62LhiCCR7hi) cells [152]. TEM cells traf-
ﬁc through nonlymphoid tissues and have high ex vivo cytotoxic
potential (perforin) but relatively poor proliferative capacity. TCM
screen the lymphoid tissues for the presence of speciﬁc Ag and have
a longer life span and high proliferative capacity to produce effector
cells. Very recently an additional memory T cell subset, T mem-
ory stem (TSCM) cells, have been reported which exhibits stem cell
properties and vigorous proliferative potential [153]. It has been
demonstrated in several vaccine systems that long-term protection
is often maintained by subsets of memory T cells including TEM cells
that rapidly produce cytokine upon re-exposure to Ag along with
TCM cells that have the additional property of being able to undergo
homeostatic proliferation in order to maintain the memory pool.
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TCM and TEM cells may  work together to provide optimal immu-
nity against infection [75,114,154]. CD4+ and CD8+ TCM cells have
been correlated with protection and reduced levels of infection in
various vaccine experiments primarily dominated by a TNF-+IL-
2+ or IL-2+ cytokine proﬁle [65,72,77,155,156]. TCM cells have a
selective advantage over TEM cells for protective responses against
disease owing to higher Ag recall response, high IL-2 production,
high killing function in vivo and their location in the peripheral
lymphoid organs where Ag presentation and priming occurs. The
belief that persistence of the Ag, as after high Ag dose or vacci-
nation, impairs TCM cells and generates memory cells with a TEM
proﬁle has been supported by published data [157–159]. These
ﬁndings suggest a role for TEM cells as correlate of protection follow-
ing persistence of Ag after vaccination or in cases of high infection.
Recently it was found that the detection of multifunctional CD4TEM
rather than TCM following parenteral BCG vaccination is due to per-
sisting BCG bacilli post vaccination [160]. CD4 and CD8TEM cells
that proliferate and produce IFN- and TNF- or IFN- alone have
been implicated in protection following vaccination against various
chronic infections [74,161–164]. Thus the efﬁcacy of T cell-based
vaccines could dramatically be improved by manipulating the gen-
eration and maintenance of distinct memory T cell subsets. Further
the modulation of the composition of existing memory subsets
could become a major approach in developing a new generation
of therapeutic vaccination.
3.5. Polyfunctional T cells
Recently it has been shown that in several infections the qual-
ity of the CD4+ (or CD8+)T cell cytokine response, as measured
through polyfunctional T cells with combined simultaneous pro-
duction of IFN-, TNF- and IL-2 detected at the single cell level,
correlates best with vaccine induced protection [74,79]. Analysis
of polyfunctional T cells in response to vaccination should provide
a more complete assessment of effector and memory T cells. Fur-
thermore, polyfunctionality of the responses consistently correlate
with less pathogenicity and positive disease outcome in multiple
disease settings such as Leishmania major,  HIV-1, HIV-2, hepatitis C
virus (HCV), simian immunodeﬁciency virus (SIV), cytomegalovirus
(CMV), M.  tuberculosis and malaria [72–74,79,165,166].  Many stud-
ies have correlated CD4+ and CD8+ T cell polyfunctionality with
vaccine induced long term protective immunity in response to live
attenuated [167,168],  subunit [72,73,169], plasmid DNA [79,168],
recombinant proteins [74,170], peptides [79,165], viral vectored
[168] and protein-in-adjuvant vaccines [166,171] as well as prime-
boost immunizations [112,172,173].  These studies show a distinct
correlation between the frequencies of polyfunctional T cells
and the expression of protective immunity and have drastically
shifted the focus in T cell vaccine development, evaluation and
design towards the capacity of Ag-speciﬁc cells to secrete multi-
ple cytokines correlating with protection. Although many reports
position polyfunctional T cells in the center of vaccine induced
immunity, others have reported that CD4+ T cell expression of IFN-
, co-expression of IFN-, TNF- and IL-2 or CD8+ T cell responses
did not correlate with risk of disease or protection in cases of tuber-
culosis and measles infection [97,98,174].
3.6. Innate effectors
Innate effector T cells respond to infection without prior Ag
exposure. They are characterized by their location in thymus and
a limited T cell receptor (TCR) diversity but rapid effector func-
tions. Invariant natural killer (NK) T cells (iNKT cells) are deﬁned
by their expression of a semi-invariant TCR and dependence on
either MHC-Ib or CD1d presentation for the Ag recognition. Once
activated iNKT cells produce a variety of cytokines (IFN-, TNF-,
IL-4, IL-5, IL-13, and IL-17), chemokines and myeloid growth factors
and may  as such interfere with the interpretation of cytokine pro-
duction from T cells of the adaptive immune response. The role of
iNKT cells has been evaluated in the host response to intracellular
infections [175,176].  iNKT cells have limited capacity to expand fol-
lowing antigenic challenge. However, these cells have been found
to promote the development of effector and memory T cells when
used in conjunction with vaccination [177–179].
The  T cells are another subset of innate T cells deﬁned by
the surface expression of the  TCR. They function in immune
regulation and epithelial cell repair and play a role in the early
response to infections and are primarily located in the mucosal tis-
sues [180,181].  Interestingly, these innate T cells occur in much
higher numbers in blood of both cattle and pigs with as many
as 10–25% of total circulating T lymphocytes in adult cattle and
12–30% of the total peripheral blood leukocytes in 12 months old
pigs. Even higher numbers are observed in young animals with
approximately 40% in young calves and 23–57% in 3–4 weeks old
pigs [182–184]. It is likely that there are as yet unknown immune
functions connected with this abundant T cell phenotype in these
species and that they may  play an important role in the activa-
tion of immune responses and vaccine responsiveness [185,186].
The upregulation of  T cells has also been linked with vaccine
induced protection in primates [187] and chickens [188]. Vacci-
nation against chronic pathogens generated potent TH1 response
while the involvement of  T cells induced innate immunity which
was associated with blocking the infection [189,190].  Generation of
robust  and effector memory T cells was found to be protective
against smallpox.
4. Measurements of immune markers and correlates for
cell-mediated immunity in large animal species
Similar to medical vaccinology there is an increasing focus on
the characterization of CMI  responses and the development of pro-
tective vaccines against chronic infections in veterinary medicine,
although it is a common feature that the inventory of monoclonal
antibodies for veterinary species does not match that of mice and
men. One of the common assays for a direct CMI read-out is the
whole-blood IFN- assay followed by quantiﬁcation through ELISA.
Various co-stimulatory cytokines such as IL-2 [191], IL-7 [192],
IL-12 [193,194],  and IL-18 [191,195] have increasingly found appli-
cation in such assays for the potentiation of the CMI  response.
Flow cytometry based evaluation of the TH1, TH2 cells and vari-
ous cytokines following stimulation with Ag in cultured cells have
been successfully demonstrated in various infections in cattle and
pigs [78,196–198]. However, the measurement of polyfunctional T
cells through multicolor ﬂow cytometry has been severely ham-
pered due to lack of reagents. Recently anti-bovine IL-2 antibodies
have been reported along with their use to demonstrate develop-
ment of polyfunctional CD4+ T cells in cattle infected with bovine
tuberculosis [199]. In pigs, currently available anti-IL-2 monoclonal
antibodies stain a much higher proportion of cells compared to
other species, which makes it difﬁcult to perform reliable identiﬁca-
tion of the rare polyfunctional T cells. In characterization of vaccine
induced CMI  responses, veterinary vaccinologists have therefore,
used IFN- mean ﬂuorescence intensity (MFI) as an approximation
of polyfunctional T cells as these cells in mice and humans have
been shown to make up to 10-fold more IFN- on a per-cell basis
compared to monofunctional CD4+ T cells [200,201]. MFI is a direct
correlate of the physical amount of cytokines produced per cell and
is a ﬁrst approximation of the quality of the T cell response [136].
Multiplying MFI  with the relative number of cells that make them,
i.e. percent positive cells or frequency of Ag-speciﬁc T cells, pro-
vides a quantitative assessment of the magnitude as well as the
A. Thakur et al. / Vaccine 30 (2012) 4907– 4920 4915
quality of the cytokine response for different cells referred to as
the integrated MFI  (iMFI) [136]. Most recently, a new index called
Generalized iMFI (GiMFI) has been proposed by assigning differ-
ent weights to magnitude (percentage of positive cells) and quality
(MFI) of the responses [202].
New tools for the studies of MHC  restricted CD8+ responses
are still under constant development. Recently, the fully devel-
oped large-scale technology to produce, analyze, and validate
peptide–MHC (pMHC) interactions which was pioneered over three
decades for mice and humans [203–207], has been applied to
generation of porcine and bovine MHC  molecules. Together with
already existing knowledge on T cell epitopes in these species, this
has allowed in silico prediction servers that identify speciﬁc pep-
tides for MHC  binding, such as the artiﬁcial neural network based
NetMHCpan, also to include cattle and pigs [132,208–212].  Com-
bined with the tetramer technology described above for speciﬁc T
cell analysis this has enabled fast, accurate “one-pot, mix-and-read”
analyses of speciﬁc MHC  restricted CD8+ T cell reactivity following
vaccination and/or infection. In pigs, in silico prediction of virus
derived peptides bound by swine leukocyte antigen (SLA) class I
molecules has been veriﬁed by in vitro analysis of speciﬁc pep-
tide binding leading to the identiﬁcation of strongly bound viral
peptides, and the effects of T cell speciﬁc vaccinations have been
investigated by monitoring CD8+ T cell responses post vaccination
[132,134,212]. For cattle the evidence of a bovine MHC  class I (BoLA)
restriction of speciﬁc CD8+ T cells in response to FMDV infection and
vaccination has been unveiled by the detection of antigen-speciﬁc
IFN- release from CD8+ CTLs in infected and vaccinated cattle of
known MHC  class I genotypes [137]. Most recently it has been pro-
posed to use immunoinformatics such as the NetMHCpan to predict
CTL peptide epitopes in large animals. With expansion of the BoLA
repertoire to cover the most commonly expressed alleles, such pre-
dictions, followed by experimental veriﬁcation of T cell speciﬁcity
to candidate epitopes using pMHC tetramers, will make the predic-
tion and measurement of bovine T cell responses to any pathogen of
interest possible [213]. Such reverse immunology proposals were
based on recent porcine experiments providing a persuasive proof-
of-concept in regard of applying the human MHC  project [214]
to support the study of livestock immune responses. This was
done by producing frequent porcine MHC  class I (SLA) molecules,
map  their peptide-binding motifs followed by the prediction and
identiﬁcation of FMDV derived peptide binders using NetMHC-
pan leading to the testing of peptide-SLA tetramers on peripheral
blood mononuclear cells (PBMCs) from FMDV vaccinated swine
[132,134,208,212].
5. Conclusions
In December 2010, global health leaders (WHO, UNICEF, NIH,
Bill and Melinda Gates Foundation) called for the next 10 years
to be the “decade of vaccines” to research, develop and deliver
lifesaving vaccines globally, and especially to the poorest coun-
tries [215]. To accomplish this goal it is important to realize
that vaccine-mediated immunity is multifarious and cell-mediated
and humoral branches do not act in isolation. Rather the best
vaccine-mediated protection is achieved when both arms of
the adaptive immune system act in concert. Pre-existing anti-
body titers serves as the ﬁrst line of adaptive immune defense.
However, only when this defense is breached by the infections
then recall responses through memory B and T cells come into
play. An ideal vaccine should induce residual protective anti-
body titer, quick effector functions through anamnestic memory
B and T responses and active immunomonitoring through rapidly
proliferating and differentiating T cells. The immune correlates
of protection induced by most current vaccines seem to be
mediated by long-lived humoral immune responses. In contrast,
there are no currently available vaccines that are uniformly
effective against intracellular infections in which cell-mediated
immunity plays a crucial role. The challenge presented in devel-
oping potent vaccines against chronic infections, and especially
intracellular infections, is unique owing to their complex patho-
genesis, limited knowledge about their precise host–pathogen
interactions and partially-deﬁned immunological correlates of pro-
tection. Considering the dynamic nature of the host–pathogen
interaction and display, the establishment of the immune corre-
lates of protection is thus likely to include a combination of both
innate and adaptive immune platforms. Thus a signiﬁcant effort
is required to conduct validation and qualiﬁcation of a proposed
correlate before it can become a differentiating immunological cor-
relate of protection through comprehensive evaluation of efﬁcacy
and protection. Systems biology offers one integrative approach
to analyze the complex immunological networks after vaccination
and to predict and comprehensively characterize vaccine response
proﬁling [216,217].  As an example, this approach was used to deﬁne
the early gene signature (B-cell growth factor TNFRSF17), which
predicted the response of B cells, CD8+ T cells and neutralizing anti-
bodies following live replicating yellow fever vaccine YF-17D with
up to 100% accuracy [218]. Very recently using the same approach
to deﬁne the early gene signatures, the immunogenicity of human
trivalent inactivated inﬂuenza vaccine was predicted with up to
90% accuracy [219]. Nevertheless, remarkable progress is being
made in our ability to deﬁne immunological correlates of protection
with the application of novel technologies such as multi-color ﬂow
cytometry, high throughput quantitative gene expression analysis,
whole genome sequencing, vaccinomics, and reverse immunology
and genetics with desired optimism for realization of vaccines for
chronic infections.
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ABSTRACT 26 
Effective control of paratuberculosis is hindered by lack of a vaccine preventing infection, transmission 27 
and without diagnostic interference with tuberculosis. We have developed a multi-stage subunit vaccine 28 
in which a fusion protein of early expressed antigens is combined with a protein expressed in latent 29 
infection (FET11 vaccine). FET11 vaccine proteins were formulated with CAF01 adjuvant and injected to 30 
MAP challenged calves at two different ages. The FET11 vaccine induced a significant T cell response 31 
against constituent vaccine proteins. Of the two different age groups, late FET11 vaccination conferred 32 
protective immunity characterized by a significant containment of bacterial burden in gut tissues 33 
compared to non-vaccinated animals. There was no cross-reaction with bovine tuberculosis in FET11 34 
vaccinated animals.    35 
 36 
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Introduction 51 
Mycobacteria are capable of causing deadly infection in cattle populations worldwide with major 52 
infections caused by Mycobacterium bovis and Mycobacterium avium subsp. paratuberculosis (MAP). 53 
MAP is the causative agent of Johne’s disease or paratuberculosis, a chronic progressive granulomatous 54 
enteritic disease infecting young calves either via the oral route or in utero infection (41) and 55 
characterized by a long asymptomatic period during which the infection is spread. It may eventually 56 
cause wasting, weight loss and death months or years after infection due to severe immune pathology 57 
and chronic inflammation in the ileum, ileocaecal valve and associated lymph nodes (4, 40). 58 
Consequently, substantial economic losses occur at the farm level due to reduced milk yield, premature 59 
culling and reduced slaughter value (26). There is additional growing concern about MAP presence in 60 
the environment and dairy food products (8) as well as association of MAP with Crohn’s disease in 61 
humans (25).  62 
 63 
Currently available vaccines against paratuberculosis, such as live attenuated or heat-killed MAP, reduce 64 
bacterial shedding but fail to prevent transmission or induce sterilizing immunity (14, 29). Moreover, 65 
these vaccines results in false-positive reactors on TB skin testing as well as antibody responses in 66 
paratuberculosis diagnostic tests. New MAP vaccines including subunit (15, 17), DNA (34), expression 67 
library immunization (12), and mutant MAP strains (6) have been tried with partial protection. A number 68 
of putative recombinant MAP proteins have been tested in cattle as potential vaccine candidates 69 
including heat-shock protein 70 (Hsp70), members of MAP antigen 85 (Ag85) complex, and superoxide 70 
dismutase (SOD). Vaccination with MAP Ag85 complex proteins and SOD in MPL adjuvant induced some 71 
protection in calves but no significant differences were observed between vaccinated and non-72 
vaccinated groups (15). Also, Hsp70/DDA vaccination has been shown to reduce MAP faecal shedding 73 
without differences in tissue colonization compared to non-vaccinated animals (32, 33).  74 
 75 
4 
 
Effective vaccines are lacking for mycobacterial infections including MAP where protection is believed to 76 
be dependent on T cell-mediated immunity with CD4+ T cells playing a pivotal role through production 77 
of IFN-γ (35). In paratuberculosis, although the infection sets up at an early age, the classical clinical case 78 
of disease is an adult animal showing no apparent clinical signs, often recognized as the subclinical 79 
shedder (37). Thus, we hypothesize that slow pathogenesis of paratuberculosis can be described as an 80 
initial acute, active phase succeeded by a latent, dormant phase in which MAP is hiding inside the 81 
macrophages and persists for long periods of time. Further, the protein expression profile changes 82 
between the stages with some genes being relatively higher expressed in one or the other stage. We 83 
hypothesize that for a vaccine to decrease MAP shedding and prevent reactivation of disease, the 84 
vaccine should incorporate different proteins expressed in different phases of MAP infection. Such an 85 
approach is called a multi-stage vaccine and has been successfully demonstrated to confer efficient 86 
protection in mice models of human tuberculosis compared to BCG vaccine (1). Given the slow 87 
pathogenesis of MAP infection, we further hypothesized that the timing of vaccination is more 88 
important relative to age where a competent immune response develops, than to precede the time of 89 
infection. Here we show that proteins expressed in different stages of MAP infection generate distinct 90 
immunological profile and a significant CMI response after vaccination. The purpose of our study was to 91 
evaluate the efficacy of a subunit vaccine based on a fusion protein of four MAP proteins from Esx 92 
family and a latency-associated MAP protein formulated with CAF01 adjuvant. In this study, we show 93 
that this approach is quite promising and promotes an efficient immune response that is protective 94 
against MAP in experimentally infected calves.  95 
 96 
Materials and Methods   97 
Animals 98 
Male jersey calves were obtained over a period of four months from a dairy farm proven to have a true 99 
prevalence equal or close to zero by the Danish paratuberculosis surveillance program as reported 100 
5 
 
earlier (21). A total of 28 calves were acquired with a mean age of 14 days. Animals were housed and 101 
raised under appropriate biological containment facilities (BSL-2) located at the institute premises with 102 
community pen and straw bedding. This study and all experimental procedures were approved by the 103 
Danish National Experiments Inspectorate and all manipulations were performed under their control.   104 
 105 
MAP culture and experimental infection 106 
The strain of MAP used for the challenge of the calves was a Danish clinical isolate, Ejlskov 2007, isolated 107 
from the faeces of a clinically affected cow in 2007. The strain was growing on LJ medium slants and was 108 
propagated on Middlebrook 7H9 medium supplemented with 10% oleic acid-albumin-dextrose complex 109 
(Difco, USA) plus 0.05% Tween 80 (Sigma Chemical Co., St. Louis, Mo.) and 2% Mycobactin J (Allied 110 
Monitor Inc., USA) at 37°C. Mid-log-phase culture (OD600nm) was centrifuged and counted using pelleted 111 
wet weight method that estimates approximately 1 x 107 CFU/mg pelleted wet weight (11). Culture was 112 
frozen with 15% glycerin as 1 ml inocula aliquots containing 1x109 CFU after validation of purity by 113 
performing contamination controls in blood agar plates (37°C, 72 h), Ziehl-Neelsen staining, and IS900 114 
PCR. Two days before inoculation, 1 ml inocula aliquot was thawed in water bath (37°C) and added to 115 
pre-warmed media (MB7H9 with supplements; 20 ml) to prepare MAP inoculum for individual animal. 116 
The whole suspension was then incubated on a shaker at 37°C for 48 h. MAP inoculation was performed 117 
by individually feeding calves with the 20 ml culture suspension in a liter of prewarmed (38°C) 118 
commercial milk replacer (DLG, Denmark) thrice within the first week after acquisition (i.e. starting at 2 119 
weeks of age).  MAP bacilli in the culture suspension (of the 48 h, 20 ml culture) were enumerated by 120 
serial dilution plate counting on Middlebrook 7H10 agar (Becton Dickinson, USA) and cultured for about 121 
4 weeks. Retrospective quantification of CFU’s indicated that in total calves received a dose of 1 x 109 122 
live MAP bacilli after three inoculations. 123 
 124 
 125 
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Vaccine groups, antigen, adjuvant and immunizations  126 
All calves were inoculated with MAP. The first four calves were randomly assigned to early FET11, 127 
Silirum®, late FET11 and vaccine control groups, respectively. Calves were born over a period of 4 128 
months and followed the same grouping sequence according to date of birth. Calves in early and late 129 
FET11 groups received the vaccine proteins twice at the age of 3 and 7 weeks and 16 and 20 weeks, 130 
respectively. Silirum® group animals received 1 ml of Silirum® vaccine (CZ Veterinaria, Spain) at the age 131 
of 16 weeks as per the manufacturer instructions. Silirum® is a heat-inactivated vaccine containing 2.5 132 
mg of the culture of strain 316F of MAP combined with an adjuvant consisting of highly refined mineral 133 
oil. Control calves did not receive any vaccine. The FET11 vaccine antigens, a fusion protein of four MAP 134 
proteins ESAP-5, ESAP-2, MAP-3, and ESAP-3 and a MAP latency protein LATP-5 were produced as 135 
recombinant antigens. All antigens were produced in E. coli and purified by metal affinity and anion 136 
columns as previously described (21). Vaccine antigens were allowed to adsorb to the adjuvant CAF01 137 
(DDA/TDB; 2500 µg/500 µg) for 1 h at RT before injection (2). Calves were immunized by the sub-138 
cutaneous route in the right mid-neck region about 7 cm ahead of the prescapular lymph node. Calves 139 
were immunized with 100 µg of each of the fusion protein and LATP-5 in a total volume of 1.2 ml. Blood 140 
samples were evaluated for cell-mediated and humoral immune responses and animals were followed 141 
for up to 52 weeks (Figure 1).  142 
 143 
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 144 
Figure 1. Experimental design.  145 
 146 
Whole-blood IFN-γ assay  147 
Whole-blood IFN-γ production was accessed at various time points throughout the study (Figure 1). 0.5 148 
ml heparinized whole-blood was stimulated in 48-well culture plates (Greiner Bio-One, Heidelberg, 149 
Germany) with previously added purified protein derivative Johnin (PPDj), purified protein derivative 150 
bovine (PPDb) and avian (PPDa) (AHVLA, UK), each of the five MAP vaccine antigens produced 151 
individually in E. coli, or PBS and two positive control stimulations with phytohaemagglutinin (PHA; 152 
Sigma) or the superantigen Staphylococcus enterotoxin B (SEB; Sigma), respectively (50 µl volume). All 153 
MAP antigens, PPDb, PPDa and SEB were added to a final concentration of 1 µg/ml, while PHA and PPDj 154 
were added to a final concentration of 5 µg/ml and 10 µg/ml, respectively. In addition, a non-MAP but 155 
TB-specific protein, CFP10 was used at a final concentration of 1 µg/ml in the assay. Whole-blood 156 
cultures were incubated for 18-20 h at 37°C and 5% CO2 in air. Following overnight incubation, 55μl 157 
heparin solution (10 IU/ml in blood) was added to avoid clots in the supernatant after freezing. Plates 158 
were then centrifuged and approximately 0.35 ml of supernatant was collected into 96-well 1-ml 159 
polypropylene storage plates (Greiner Bio-One, Heidelberg, Germany) and frozen at -20°C until analysis.  160 
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IFN-γ secretion in supernatants was determined by use of an in-house monoclonal sandwich ELISA as 161 
described earlier (22). The levels of IFN-γ (pg/ml) were calculated using linear regression on log-log 162 
transformed readings from the two-fold dilution series of a reference SEB stimulated plasma standard 163 
with predetermined IFN-γ concentration. The IFN-γ responses in PBS cultures were subtracted from 164 
MAP vaccine antigen cultures to generate antigen-specific responses.  165 
 166 
Necropsy 167 
The eight first-born calves were euthanized and necropsied at 44 weeks and remainder 20 calves at 52 168 
weeks of age. Six tissue samples from each animal were collected and processed for IS900 qPCR: 169 
ileocaecal valve, ileum (0 cm, -25 cm, -50 cm; distance indicated relative to the location of ileocaecal 170 
valve in proximal direction), and jejunum (-150 cm, -250 cm). Tissue samples (8 cm in length) were 171 
rinsed with sterile PBS. Epithelium, submucosa, and lamina propria were scraped from the serosa with 172 
sterile object glass. The tissue scrapings were homogenized by blending in a rotor/stator type tissue 173 
homogenizer (Tissue-Tearor, BioSpec Products Inc.) and processed for DNA extraction.  174 
 175 
IS900 quantitative Real Time PCR 176 
DNA extraction from tissue samples 177 
DNA was extracted for qPCR analysis from tissue scrapings after bead beating using protocol of the 178 
Qiagen DNeasy Blood and Tissue kit (QIAGEN). Briefly, aliquots of 25 mg of tissue scraping homogenates 179 
were weighed and incubated on a shaker incubator overnight at 37°C in 400 µl buffer ATL. Particular 180 
attention was given while measuring weight of the tissue homogenates in order to use the precise 181 
amount of homogenized material each time. Next day, tubes were subjected to bead beating at full 182 
speed for 1 min with 200 µl of 0.1 mm Zirconia/Silica beads (BioSpec Products Inc.). Bead beaded 183 
material were centrifuged for 30 sec at 5000xg, before the 200 µl supernatants were transferred into 184 
new tubes and 20 µl proteinase-K was added. Tubes were then incubated for 10 min at 56°C. The 185 
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mixtures were centrifuged through a Qiagen Spin Column and washed according to the kit protocol. In 186 
the final step, DNA was eluted with 200 µl elution buffer and stored at -20°C prior to use. 187 
 188 
qPCR assay and standard curves for quantification 189 
Primers for qPCR were acquired (Sigma) referring to MAP IS900-like sequences as has been reported 190 
earlier (16). However, we were not able to use these primers because of very low primer efficiency 191 
(0.70). Therefore, a new set of primers (F: 5’-GGCAAGACCGACGCCAAAGA-3’; R: 5’-192 
GGGTCCGATCAGCCACCAGA-3’) binding to MAP-specific sites of the IS900 were designed using Primer3 193 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3www.cgi) (31). qPCR reactions were carried out in 25 194 
µl volumes, containing 2.5 µl DNA template, 12.5 µl of 2x QuantiTect SYBR Green PCR Master Mix 195 
(Qiagen), and 0.125 µl of 10 µM of each of the forward and reverse primers in nuclease free water. qPCR 196 
was performed on a Rotor Gene Q PCR system (QIAGEN). PCR cycling started with an initial denaturation 197 
at 95°C for 15 min, followed by 45 cycles of amplification at 95°C for 30 s and 68°C for 60s. After PCR 198 
amplification, melting curve data were collected and analyzed.  199 
 200 
For quantification of MAP in tissue samples, a standard curve was made by spiking of tissue DNA with 201 
DNA from MAP culture (MAP Ejlskov with 1x109 CFU/ml) in ten-fold dilutions. DNA from a tissue 202 
(jejunum at 250 cm) sample of an animal found to be consistently negative through qPCR was used for 203 
spiking. 2 µl of bacterial culture DNA in serial ten-fold dilutions of 1x109 organisms was used to spike 204 
tissue DNA samples.  205 
 206 
Comparative tuberculin skin test 207 
A single intradermal comparative cervical tuberculin test was conducted 3 days before killing the 208 
animals according to European regulations (European Communities Commission regulation 141 number 209 
1226/2002) (23). Briefly, 0.1 ml bovine tuberculin (2000 IU) and 0.1 ml avian tuberculin (2000 IU) were 210 
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inoculated intradermally in the left side of the neck of each animal. At 72 h post-inoculation, the skin-211 
fold thickness was measured and the increase in the skin-fold thickness compared to day 0 was noted. 212 
Reaction to each of the tuberculin was interpreted as follows: a skin test reaction was considered 213 
positive when skin thickness increased 4 mm or more, inconclusive when there was an increase of more 214 
than 2 mm and less than 4 mm, and negative when the increase was not more than 2 mm. 215 
 216 
According to the guideline, the official interpretation of the intradermal comparative cervical tuberculin 217 
test is: positive when the positive reaction to bovine PPD is more than 4 mm greater than the reaction at 218 
avian site, inconclusive when the positive reaction to bovine PPD is between 1 to 4 mm greater than the 219 
avian reaction, and negative when there is negative reaction to bovine PPD or when a positive or 220 
inconclusive reaction to bovine PPD is less than or equal to a positive or inconclusive reaction at avian 221 
site.  222 
 223 
Statistical analysis 224 
MAP vaccine antigen-specific IFN-γ production between different vaccine groups was compared by one-225 
way ANOVA followed by Dunn’s multiple comparison test. Data obtained from qPCR (Rotor Gene) was 226 
first analyzed through GenEx (MultiD, Göteborg, Sweden) in order to obtain the relative quantities. 227 
Based on the dynamic range, a Cq cut-off value of 34 was decided. A Cq value of 34 was assigned to 228 
samples with higher Cq or for negative samples. Measured Cq values were then corrected for PCR 229 
efficiency to account for suboptimal amplification. Cq values were then converted to linear scale. As the 230 
relative quantity values generated from qPCR analysis were not normally distributed, data were 231 
converted to base 10 for statistical analysis with parametric methods. Log-transformed data was 232 
compared between the four groups for each of the six selected tissue sites from 4 sites in ileum and 2 233 
sites in jejunum. A comparison was also made between the groups on combined ileal and jejunum 234 
tissues. At the same time, relative CFU’s of MAP were calculated in the tissues from all the animals 235 
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based on the standard curve analysis through Rotor Gene software. Protective efficacies of the vaccines 236 
were compared by one-way ANOVA followed by Dunn’s multiple comparison test using data obtained 237 
from both GenEx (log10RQ) or Rotor Gene (CFU). Log-transformed IFN-γ responses to vaccine proteins or 238 
PPDj and relative MAP concentration (log10RQ) were correlated by a non-parametric Spearman 239 
correlation. Statistical analysis was performed using GraphPad Prism software vs. 5.02 (GraphPad 240 
Software Inc., La Jolla, CA). P ˂ 0.05 was considered statistically significant.  241 
 242 
Results   243 
Clinical evaluation 244 
No clinical signs indicative of paratuberculosis were observed among the infected calves. No side effects 245 
were observed following subcutaneous FET11 vaccination in calves. However, subcutaneous Silirum® 246 
vaccination resulted in a transient nodule of approximately 2-2.5 cm, which subsided in about 3 weeks 247 
time.  248 
Immunization with FET11 vaccine induces increasing levels of antigen-specific IFN-γ responses 249 
To examine the immunogenicity and longevity of the FET11 vaccine proteins adjuvanted with CAF01, 250 
immune responses were assessed at multiple time points up to 44 (n=8) or 52 (n=20) weeks of age by 251 
measuring the vaccine antigen-specific whole-blood IFN-γ responses (Figure 2). In general, control calves 252 
did not show antigen-specific response to the vaccine proteins except two animals responding weakly to 253 
LATP-5 and ESAP-3, five weeks after MAP infection. In early FET11 vaccinated calves, IFN-γ levels in 254 
response to protein ESAP-5 peaked at one week after second vaccination and thereafter remained at 255 
low levels throughout the study period. In comparison, late FET11 calves showed immediate increase in 256 
levels of IFN-γ after first vaccination that remained consistently higher for a long period but dropped 257 
around week 48. Calves vaccinated with Silirum® had consistent ESAP-5-specific IFN-γ production after 258 
vaccination with levels in between early and late FET11 groups. In response to ESAP-2, IFN-γ levels for 259 
early FET11 vaccinated calves declined 3 weeks after second vaccination and remained at low levels 260 
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afterwards. On the other hand, in both late FET11 and Silirum® vaccine groups IFN-γ levels peaked after 261 
vaccination. However, IFN-γ levels that were higher for late FET11 vaccination than Silirum® dropped 262 
between weeks 38 up to 48 before coming up again. For the vaccine protein MAP-3, early FET11 263 
vaccinated calves had high IFN-γ levels that waned after week 16 while IFN-γ responses for Silirum® 264 
calves weakened after week 26.  265 
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 267 
Figure 2. Antigen-specific IFN-γ responses in whole-blood cultures. Levels of IFN-γ released from whole-268 
blood cultures for antigen ESAP-5 (a), ESAP-2 (b), MAP-3 (c), ESAP-3 (d), LATP-5 (e), and CFP10 (f) 269 
following vaccinations indicated as dotted lines. IFN-γ levels are expressed as mean values (± standard 270 
deviation [SD]) for plasma concentrations (pg/ml).   271 
 272 
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Late FET11 vaccinated calves responded poorly to MAP-3 through all the time points. Production of IFN-273 
γ against ESAP-3 was highest among all groups for early FET vaccinated calves 7 weeks after second 274 
vaccination but dropped afterwards. Late FET11 and Silirum® vaccinated calves showed low response to 275 
this protein. However, Silirum® vaccinated calves immediately responded to this protein before Silirum® 276 
vaccination. Only calves in early and late FET11 vaccination groups responded to LATP-5, with similar 277 
response in both groups, starting relative to time of vaccination and dropping around week 46. For the 278 
non-MAP TB-specific protein CFP10, responses were found to come up after 20 weeks of MAP infection 279 
in all vaccine and control group though the responses were very low. In terms of levels of significance 280 
for FET11 vaccine, late FET11 vaccine group responded significantly to ESAP-5 (p ˂ 0.001), ESAP-2 (p ˂ 281 
0.05) and LATP-5 (p ˂ 0.05) as compared to control group. However, early FET11 group had significant 282 
responses only to LATP-5 (p ˂ 0.001) in comparison with control group. Both early (p ˂ 0.001) and late 283 
FET11 (p ˂ 0.05) vaccine groups had significant differences from Silirum® group for LATP-5 induced IFN-γ 284 
levels. Silirum® vaccine did not have significant differences to control group against any of the vaccine 285 
proteins.         286 
 287 
qPCR assay performance: dynamic range and specificity 288 
Key performance characteristics of qPCR assay are summarized in table 1. The R2 value for the spiked 289 
tissue standard curve was above 0.99 and the PCR efficiency was 0.97. The detection limit for the spiked 290 
tissue was 1.2 x 102 MAP/g tissues. Detection limit was defined as the concentration giving a positive 291 
quantification cycle (Cq) value in one or more of the triplicate samples of the standard curves. The lower 292 
limits of the dynamic range were based on the mean of the triplicate values and define the 293 
quantification limits of qPCR assay. The dynamic range was four log units i.e. 1.2 x 109 – 1.2 x 105 CFU/g 294 
tissue (Figure 3a).  295 
 296 
 297 
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Table 1. Key characteristics of IS900 qPCR assay in spiked tissue samples  298 
Factor Spiked tissue 
PCR efficiency  0.97 
Coefficient of Determination (R2) 0.997 
Dynamic range (MAP CFU/g tissue) 1.2 x 109 – 1.2 x 105 
Detection limit (MAP CFU/g tissue) 1.2 x 102 
 299 
 300 
FET11 vaccination lowers tissue colonization of MAP  301 
At the end of the 44 weeks (n=8) or 52 weeks (n=20) of age, animals were subjected to necropsy. Six 302 
tissue samples from the gut of each animal were processed, DNA was extracted and relative 303 
quantification of MAP was performed using qPCR. These six tissue sites were selected, as they are more 304 
likely to harbor infection based on the prior published knowledge obtained from experimental MAP 305 
inoculation studies. Apparently, no significant variation was observed between relative quantities (RQ) 306 
of MAP among animals killed at week 44 and week 52. Therefore, data from both the time points were 307 
clubbed for analysis when required. In each of the six selected tissues, a lower mean relative 308 
concentration of MAP was observed in the late FET11 vaccinated animals as compared to control group 309 
(Table 2).  310 
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 311 
Table 2. Animal-wise relative quantities of MAP in individual gut tissues as quantified by IS900 qPCR and 312 
analyzed through GenEx. Relative quantities of MAP IS900 qPCR product for ileocaecal valve, ileum 0 313 
cm, ileum -25 cm, ileum -50 cm, jejunum -150 cm, and jejunum -250 cm. Distance in cm indicated 314 
relative to the location of ileocaecal valve in proximal direction. Relative quantities were generated from 315 
raw Cq values after correction for PCR efficiency using GenEx software. 316 
 317 
Silirum® and early FET11 vaccinated animals seemed to have comparable relative MAP tissue load 318 
(log10RQ) in all six tissues with two animals from both groups having very high relative bacterial 319 
numbers. Analysis after combining the four ileal tissues and two jejunum tissues revealed exactly similar 320 
picture with a mean 1.1 log10 reduction  in bacterial load in late FET11 vaccinated animals as compared 321 
Group Animal IC Valve Ileum 0cm Ileum -25cm Ileum -50cm Jejunum -150cm Jejunum -250cm
02204 1 1 1 1 1 1
02214 141 39 36 24 1 1
02221 28 18 13 26 10 1
02234 4 1 18 6 1 1
02250 7203 12390 7203 12390 48 9
02264 13260 21313 19916 7708 2126 2434
02291 4 4 16 32 1 1
02201 4 4 26 28 1 1
02212 260 548 1079 390 39 1
02219 7 5 9 11 1 1
02229 1 1 1 1 1 1
02236 28 26 26 30 13 1
02269 21 11 7 4 1 1
02299 880 586 365 243 63 51
02197 1 5 1 1 1 1
02205 16251 34259 29915 17391 3417 4795
02216 39 13 1 4 1 1
02225 36 67 30 16 28 12
02237 36 101 17 20 1 1
02251 115 198 48 48 9 1
02279 4481 9447 6731 10819 671 18
02198 1079 1008 769 1514 548 1
02207 151 243 298 243 162 17
02217 55 101 11 17 10 6
02227 151 243 298 243 162 17
02238 1008 718 298 123 108 123
02257 55 30 94 67 9 4
02281 1514 1155 1008 823 173 55
M
S
V
-2
 E
ar
ly
 F
E
T1
1
M
S
V
-2
 L
at
e 
FE
T1
1
M
S
V
-2
 S
ili
ru
m
M
S
V
-2
 C
on
tro
l
16 
 
to the control group(p ˂ 0.01) (Figure 3b and 3c). Analysis of CFU generated through standard curve 322 
analysis by Rotor Gene also revealed a mean 1.1 log10 reduction in MAP CFU in late FET11 group 323 
compared to control group (p ˂ 0.05).      324 
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 326 
Figure 3. Relative quantities of MAP in combined gut tissues as quantified by IS900 qPCR. Standard curve 327 
of IS900 qPCR in spiked tissue showing relative quantities (log10RQ) and log10MAP CFU (a), relative 328 
quantities of MAP (log10RQ) or IS900 qPCR product for combined ileal tissues (b), and combined jejunum 329 
tissues (c). Relative quantities (log10RQ) are expressed as mean values (± standard deviation [SD]) for 330 
relative number of MAP (b and c).  331 
 332 
PPDj-specific IFN-γ production correlates with MAP load in tissues 333 
All animals exhibited progressive PPDj-specific IFN-γ production following MAP infection (Figure 4a). 334 
Characteristically, in early FET11 vaccine group these responses declined after second vaccination but 335 
came up again after 8 weeks. Towards the advanced stages, early FET11 vaccinated animals had lower 336 
PPDj-specific responses than Silirum® or control group. Late FET11 vaccinated animals had consistently 337 
lower PPDj-specific responses after vaccination. In comparison, Silirum® and control group animals 338 
showed an increasing trend of IFN-γ responses against PPDj towards the advanced stages of the study 339 
(Figure 4b). A positive linear correlation between the log-transformed PPDj mean IFN-γ responses and 340 
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relative quantities of MAP (log10RQ) was found at weeks 48 (p ˂ 0.05) and 52 (p ˂ 0.01) post infection. 341 
These results were supplemented by the observation that an inverse statistical correlation was found 342 
between the relative quantities of MAP (log10RQ) and log-transformed mean IFN-γ responses against 343 
vaccine proteins at weeks 24, 32 and 40 of the study (p ˂ 0.05). IFN-γ responses to PPDj also correlated 344 
with MAP CFU calculated through standard curve at weeks 32 (p ˂ 0.001), 40 (p ˂ 0.05) and 52 (p ˂ 0.05) 345 
of the study.  In terms of vaccine group, we could see a significant correlation between IFN-γ responses 346 
to pooled vaccine proteins and MAP load in tissues for late FET11 vaccine group only at week 32 (p ˂ 347 
0.05). There was a correlation between IFN-γ response to vaccine proteins, ESAP-2, ESAP-5 and reduced 348 
bacterial load at week 22, 24 and 32 (p ˂ 0.05).  349 
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 351 
Figure 4. PPDj-specific IFN-γ responses in whole-blood cultures. Levels of IFN-γ released from whole-352 
blood cultures stimulated with PPDj relative to MAP inoculation (a) and between 32-52 weeks of age (b). 353 
IFN-γ levels are expressed as mean values (± standard deviation [SD]) for plasma concentrations (pg/ml).    354 
 355 
Tuberculin skin testing 356 
All the animals in the experiment were subjected to comparative intradermal tuberculin testing 72hrs 357 
before killing at the end of the week 44 (n=8) or 52 (n=20) (Figure 5). In Silirum® group, four animals had 358 
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positive skin reactions to PPDb while majority of animals from other groups had either negative or 359 
inconclusive reactions to PPDb. Most animals from the four groups had positive reactions to PPDa with 360 
strongest responses among the Silirum® vaccinated group. One animal from the Silirum® group had a 361 
positive comparative tuberculin test. However, majority of the animals from the four groups had 362 
reactors to PPDa. Only one animal each from control and Silirum® groups had a positive reaction to 363 
PPDb.  364 
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 365 
Figure 5. Increase in skin thickness after the comparative cervical intradermal tuberculin test three days 366 
before killing. Results are expressed as mm skin thickness increase for PPDb (a), PPDa (b), and mm size 367 
difference PPDb-PPDa (c) over a 72 hr period. A threshold of 4 mm over which an animal has a positive 368 
reaction, is shown by a horizontal dotted line. Skin thickness (mm) is depicted for all individual animals 369 
grouped by treatment. 370 
 371 
Discussion   372 
We have described a post exposure vaccine approach conceived to incorporate a single fusion protein of 373 
four early MAP proteins and a latency-associated protein as a novel subunit multi-stage vaccine, FET11. 374 
We hypothesize that such a vaccine could decrease MAP shedding and prevent reactivation of disease. 375 
Similar approach has demonstrated an efficient protection in mice models of human tuberculosis as 376 
compared to BCG vaccine (1). Five MAP proteins were selected based on previous immunogenicity 377 
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studies in cattle and experimental knowledge from in vitro and in vivo expression studies with M. 378 
tuberculosis proteins in mice.  (20, 21). Results show that vaccination with the FET11 vaccine after 379 
experimental infection of MAP results in significant CMI responses and a mean 1.1 log10 reduction in 380 
bacterial colonization of the gut in comparison with non-vaccinated animals at 8-12 months post MAP 381 
inoculation. Using the similar vaccine strategy, older animals developed a more robust immune 382 
response and were better able to check MAP load in the tissues even when the infection occurs at an 383 
earlier age. A discrete immunological profile for the five constituent FET11 vaccine proteins among early 384 
and late vaccinated animals was observed. Proteins of Esx family, ESAP-2 and ESAP-5 and a latency 385 
protein, LATP-5 were found to be highly immunogenic. Notably, animals vaccinated with FET11 vaccine 386 
at an older were better able to contain MAP infection in gut tissues as compared to a commercial 387 
whole-cell heat inactivated vaccine Silirum® or early FET11 vaccinated animals. Nevertheless, immune 388 
response to FET11 vaccine proteins was evident in Silirum® vaccinated animals but was characteristically 389 
absent against proteins ESAP-3 and LATP-5. FET11 vaccination did not lead to a significant induction of 390 
false positive reactors in the intradermal tuberculin test for bovine tuberculosis vis-à-vis Silirum® 391 
vaccine. In addition, an experimental challenge model in calves using mid-log-phase frozen stock MAP 392 
cultures and the correlation of infection with PPDj responses has been described. This emphasizes the 393 
possibility of establishing a uniform and reproducible bovine MAP infection model despite non-394 
availability of age matched calves in desired numbers at the same time for vaccine experiments.   395 
 396 
Significant differences in the vaccine-induced CMI responses to component proteins were observed 397 
between late FET11 vaccine group and control group over a long period after experimental challenge. 398 
These vaccine-induced IFN-γ responses were antigen-specific as indicated by the fact that control 399 
animals did not show any antigen-specific immune response following challenge. However, majority of 400 
the animals responded to a non-MAP TB-specific CFP10 protein between 4-7 months of age. Although 401 
levels were very low, we could not explain this considering the design of our experimental setup where 402 
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the animals attained this age over a four month period. There has been compelling evidence that TH1 403 
type immune responses, chiefly IFN-γ, is essential for immunity against mycobacterial infections 404 
including MAP (9, 36). In late FET11 group, immunogenicity and longevity of vaccine-induced immune 405 
responses were most stable for ESAP-2, ESAP-5, and LATP-5. But we did not find a strong correlation 406 
between IFN-γ productions to every component vaccine protein and reduced bacterial burden in the gut 407 
tissues after vaccination. However, we found that the vaccine protein pool was significantly correlated 408 
with reduced bacterial number at week 32 for late FET11 group. Interestingly, LATP-5 induced IFN-γ 409 
production was characteristically absent from Silirum® and control group. Since we did not have a non-410 
infected vaccine group, we do not know how the infection influences the observed IFN-γ responses to 411 
the vaccine. ESAP-2 and MAP-3 recombinant proteins were found to be low immunogenic in this study. 412 
This contrasts our earlier report in which significant IFN-γ responses were observed against both of 413 
these proteins after vaccination (Article 1). We do not understand this discrepancy but it emphasizes the 414 
possibility of dynamics of MAP infection in guiding the differential immune response to component 415 
vaccine proteins.  416 
 417 
We have previously shown that immunological maturity of the animals does seem to play an important 418 
role in vaccine-induced immune response (Article 1). This study also highlights the fact that despite 419 
getting exposed to the bacteria at the same time, age of vaccination and regimen do play a role in 420 
vaccine-induced immune responses and subsequent containment of infection as evidenced by 421 
significantly reduced bacterial load in FET11 animals vaccinated at an older age. Young calves in first 6-8 422 
months of life have relatively higher number of γδ T cells and NK Cells compared to adult cattle (18). The 423 
role of γδ T cells (28), NK cells (24) and polyfunctional T cells (19, 39) have been appreciated in 424 
mycobacterial infections but their precise contribution  in MAP infection is yet to be fully elucidated.  425 
 426 
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Quantitative real time PCR (qPCR) is a rapid and sensitive method for quantification of target DNA. Due 427 
to slow growth, long generation time and tendency of MAP to form aggregates, qPCR has been 428 
increasingly used for paratuberculosis diagnosis as compared to culturing (16, 27). The IS900 element is 429 
an insertion sequence considered to be a MAP-specific gene (10). IS900 qPCR is a highly sensitive and 430 
specific method for the detection of MAP due to multiplicity of IS900 within MAP genome, with one 431 
genome of MAP containing 15-20 copies of IS900 gene (10). In addition to diagnostics, qPCR has been 432 
used as a tool for monitoring of microbial load in tissues, disease pathogenesis, and efficacy of vaccines 433 
and drugs (7, 30). In our study, we exploited the potential benefits of qPCR based on IS900 gene to 434 
monitor the MAP load in the tissues samples and did a relative quantification of bacterial numbers in 435 
vaccinated versus control animals. The qPCR assay was validated based on a previously published report 436 
(16). However, we designed a new set of primers specific for MAP IS900 avoiding IS900-like sequences 437 
and having a relatively close Tm compared to ones in the published report. With these new primers we 438 
found a higher PCR efficiency. Determination of parameters such as PCR efficiency, dynamic range, and 439 
detection limit are important for qPCR assay (5). Our qPCR assay displayed optimal reaction conditions 440 
as evidenced by high efficiency of standard curve for spiked tissue sample (Table 1). Cq values obtained 441 
with qPCR assay were analyzed with GenEx® software. GenEx is intuitive software involving sequential 442 
analysis of data such as efficiency correction, calibration, normalization, relative quantification etc. and 443 
offers distinct advantages over ∆∆Cq method. The relative CFU calculation by standard curve method 444 
supplemented the results from GenEx analysis and emphasizes the usefulness of both the approaches.     445 
 446 
Vaccination against paratuberculosis interferes with diagnosis of tuberculosis on skin testing. In this 447 
study, the response of FET11 vaccinated animals to PPDb was lower than PPDa after comparative 448 
tuberculin skin testing. There were one reactor each from control and Silirum® vaccine groups and a 449 
positive animal among Silirum® vaccinated animals. Thus, an inference can be drawn that FET11 450 
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vaccination may not interfere with the official diagnostic test for tuberculosis when comparative skin 451 
test is used. 452 
 453 
We found a positive correlation between whole-blood IFN-γ responses against PPDj and relative number 454 
of MAP in gut, which was especially significant in advanced weeks of the experiment. PPDj is a crude 455 
antigenic mixture of a number of proteins. The use of PPDj for CMI based diagnosis of MAP has been 456 
challenged because of low specificity due to cross-reactive antigens (13). However, PPDj responses 457 
could be a good measure of tracking infection status in experimental MAP infections and thus can serve 458 
as an immunological correlate of infection for vaccine experiments. At the same time, the lack of a 459 
strong correlation between reduced bacterial burden and whole-blood IFN-γ responses to component 460 
FET11 vaccine proteins in our study could challenge the key role of IFN-γ as an immunological correlate 461 
of protection in MAP. Else, antibodies or polyfunctional T cells may play an important role in vaccine-462 
induced protection (17) that needs further verification. 463 
 464 
A number of recombinant MAP proteins have been tried and tested as subunit vaccines in calves. Study 465 
using proteins of antigen 85 complex and superoxide dismutase (SOD) with MPL or recombinant IL-12 466 
DNA as adjuvant reported some protection but did not find significant differences between any 467 
vaccinated groups (15). Recombinant MAP Hsp70/DDA vaccination was found to reduce bacterial 468 
shedding during almost two years after challenge in calves possibly through induction of antibodies (17). 469 
However, recent report suggest that this vaccine was unable to lower tissue colonization and initial 470 
faecal shedding of MAP (33). Moreover, Hsp70 vaccination did not induce strong antigen-specific IFN-γ 471 
responses compared to control animals. Contrary, we found significant antigen-specific IFN-γ responses 472 
in our study. Though, there was a differential immune response to constituent proteins, the delivery of 473 
selected candidates as a single fusion protein has the potential benefit of enhanced responses to low 474 
responder proteins such as MAP-3 and ESAP-3 in our study. Similar observation was found for low 475 
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immunogenic ESAT-6 when used with antigen 85B in a strong adjuvant DDA-MPL (3, 38). At present, 476 
levels of MAP shedding in faeces and the development of an antibody response to MAP and vaccine 477 
antigens in our study remains to be analyzed.  478 
 479 
Summarized, our study demonstrates that a multi-stage subunit vaccine based on a fusion protein of 480 
early secreted MAP proteins and a latency-associated MAP protein formulated in CAF01 adjuvant is able 481 
to reduce bacterial colonization of gut in challenged calves. Considering the slow pathogenesis and 482 
prolonged subclinical phase of MAP infection in cattle, further studies are required to evaluate 483 
protective efficacy and immunological memory of FET11 vaccine over a longer period of time. The 484 
possible role of various T cells and innate immune cells as an immune correlate responsible for the 485 
observed protection need to be further investigated. Our results lay the groundwork for the evaluation 486 
of possible long-term preventive and therapeutic effect of FET11 vaccine in chronic naturally infected 487 
cattle.   488 
 489 
Acknowledgement 490 
We thank Jeanne T. Jakobsen, Panchale Olsen and Lien T. M. Nguyen for their excellent technical help. 491 
The staff of DTU-Vet animal facilities is gratefully acknowledged for their technical assistance and care of 492 
the animals. Thanks to Marie Ståhl for her contribution on qPCR work and Peter Lind for statistical 493 
analysis. This work was supported by grant 368 274-08-0166 from the Danish Research Council for 494 
Technology and Production Sciences. 495 
 496 
  References 497 
 1.  Aagaard, C., T. Hoang, J. Dietrich, P. J. Cardona, A. Izzo, G. Dolganov, G. K. Schoolnik, J. P. 498 
Cassidy, R. Billeskov, and P. Andersen. 2011. A multistage tuberculosis vaccine that confers 499 
efficient protection before and after exposure. Nat. Med. 17:189-194. 500 
 2.  Agger, E. M., I. Rosenkrands, J. Hansen, K. Brahimi, B. S. Vandahl, C. Aagaard, K. Werninghaus, C. 501 
Kirschning, R. Lang, D. Christensen, M. Theisen, F. Follmann, and P. Andersen. 2008. Cationic 502 
24 
 
liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for 503 
vaccines with different immunological requirements. PLoS One 3:e3116. 504 
 3.  Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen. 2000. ESAT-6 subunit 505 
vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:791-795. 506 
 4.  Buergelt, C. D., C. Hall, K. McEntee, and J. R. Duncan. 1978. Pathological evaluation of 507 
paratuberculosis in naturally infected cattle. Vet. Pathol. 15:196-207. 508 
 5.  Bustin, S. A., V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M. 509 
W. Pfaffl, G. L. Shipley, J. Vandesompele, and C. T. Wittwer. 2009. The MIQE guidelines: 510 
minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 511 
55:611-622. 512 
 6.  Chen, J. W., S. M. Faisal, S. Chandra, S. P. McDonough, M. A. Moreira, J. Scaria, C. F. Chang, J. P. 513 
Bannantine, B. Akey, and Y. F. Chang. 2012. Immunogenicity and protective efficacy of the 514 
Mycobacterium avium subsp. paratuberculosis attenuated mutants against challenge in a mouse 515 
model. Vaccine 30:3015-3025. 516 
 7.  Decaro, N., F. Amorisco, C. Desario, E. Lorusso, M. Camero, A. L. Bellacicco, R. Sciarretta, M. S. 517 
Lucente, V. Martella, and C. Buonavoglia. 2010. Development and validation of a real-time PCR 518 
assay for specific and sensitive detection of canid herpesvirus 1. J. Virol. Methods 169:176-180. 519 
 8.  Eltholth, M. M., V. R. Marsh, W. S. Van, and F. J. Guitian. 2009. Contamination of food products 520 
with Mycobacterium avium paratuberculosis: a systematic review. J. Appl. Microbiol. 107:1061-521 
1071. 522 
 9.  Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential 523 
role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 524 
178:2249-2254. 525 
 10.  Green, E. P., M. L. Tizard, M. T. Moss, J. Thompson, D. J. Winterbourne, J. J. McFadden, and J. 526 
Hermon-Taylor. 1989. Sequence and characteristics of IS900, an insertion element identified in a 527 
human Crohn's disease isolate of Mycobacterium paratuberculosis. Nucleic Acids Res. 17:9063-528 
9073. 529 
 11.  Hines, M. E., J. R. Stabel, R. W. Sweeney, F. Griffin, A. M. Talaat, D. Bakker, G. Benedictus, W. C. 530 
Davis, G. W. de Lisle, I. A. Gardner, R. A. Juste, V. Kapur, A. Koets, J. McNair, G. Pruitt, and R. H. 531 
Whitlock. 2007. Experimental challenge models for Johne's disease: a review and proposed 532 
international guidelines. Vet. Microbiol. 122:197-222. 533 
 12.  Huntley, J. F., J. R. Stabel, M. L. Paustian, T. A. Reinhardt, and J. P. Bannantine. 2005. Expression 534 
library immunization confers protection against Mycobacterium avium subsp. paratuberculosis 535 
infection. Infect. Immun. 73:6877-6884. 536 
 13.  Jungersen, G., A. Huda, J. J. Hansen, and P. Lind. 2002. Interpretation of the gamma interferon 537 
test for diagnosis of subclinical paratuberculosis in cattle. Clin. Diagn. Lab Immunol. 9:453-460. 538 
 14.  Kalis, C. H., J. W. Hesselink, H. W. Barkema, and M. T. Collins. 2001. Use of long-term vaccination 539 
with a killed vaccine to prevent fecal shedding of Mycobacterium avium subsp paratuberculosis in 540 
dairy herds. Am. J. Vet. Res. 62:270-274. 541 
25 
 
 15.  Kathaperumal, K., S. U. Park, S. McDonough, S. Stehman, B. Akey, J. Huntley, S. Wong, C. F. 542 
Chang, and Y. F. Chang. 2008. Vaccination with recombinant Mycobacterium avium subsp. 543 
paratuberculosis proteins induces differential immune responses and protects calves against 544 
infection by oral challenge. Vaccine 26:1652-1663. 545 
 16.  Kawaji, S., D. L. Taylor, Y. Mori, and R. J. Whittington. 2007. Detection of Mycobacterium avium 546 
subsp. paratuberculosis in ovine faeces by direct quantitative PCR has similar or greater sensitivity 547 
compared to radiometric culture. Vet. Microbiol. 125:36-48. 548 
 17.  Koets, A., A. Hoek, M. Langelaar, M. Overdijk, W. Santema, P. Franken, W. Eden, and V. Rutten. 549 
2006. Mycobacterial 70 kD heat-shock protein is an effective subunit vaccine against bovine 550 
paratuberculosis. Vaccine 24:2550-2559. 551 
 18.  Kulberg, S., P. Boysen, and A. K. Storset. 2004. Reference values for relative numbers of natural 552 
killer cells in cattle blood. Dev. Comp Immunol. 28:941-948. 553 
 19.  Lindenstrom, T., E. M. Agger, K. S. Korsholm, P. A. Darrah, C. Aagaard, R. A. Seder, I. 554 
Rosenkrands, and P. Andersen. 2009. Tuberculosis subunit vaccination provides long-term 555 
protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182:8047-556 
8055. 557 
 20.  Mikkelsen, H., C. Aagaard, S. S. Nielsen, and G. Jungersen. 2012. Correlation of antigen-specific 558 
IFN-gamma responses of fresh blood samples from Mycobacterium avium subsp. paratuberculosis 559 
infected heifers with responses of day-old samples co-cultured with IL-12 or anti-IL-10 antibodies. 560 
Vet. Immunol. Immunopathol. 147:69-76. 561 
 21.  Mikkelsen, H., C. Aagaard, S. S. Nielsen, and G. Jungersen. 2011. Novel antigens for detection of 562 
cell mediated immune responses to Mycobacterium avium subsp. paratuberculosis infection in 563 
cattle. Vet. Immunol. Immunopathol. 143:46-54. 564 
 22.  Mikkelsen, H., G. Jungersen, and S. S. Nielsen. 2009. Association between milk antibody and 565 
interferon-gamma responses in cattle from Mycobacterium avium subsp. paratuberculosis 566 
infected herds. Vet. Immunol. Immunopathol. 127:235-241. 567 
 23.  Morrison, W. I., F. J. Bourne, D. R. Cox, C. A. Donnelly, G. Gettinby, J. P. McInerney, and R. 568 
Woodroffe. 2000. Pathogenesis and diagnosis of infections with Mycobacterium bovis in cattle. 569 
Independent Scientific Group on Cattle TB. Vet. Rec. 146:236-242. 570 
 24.  Olsen, I., P. Boysen, S. Kulberg, J. C. Hope, G. Jungersen, and A. K. Storset. 2005. Bovine NK cells 571 
can produce gamma interferon in response to the secreted mycobacterial proteins ESAT-6 and 572 
MPP14 but not in response to MPB70. Infect. Immun. 73:5628-5635. 573 
 25.  Olsen, I., S. Tollefsen, C. Aagaard, L. J. Reitan, J. P. Bannantine, P. Andersen, L. M. Sollid, and K. 574 
E. Lundin. 2009. Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T 575 
cells from intestinal biopsies of Crohn's disease patients. PLoS. One. 4:e5641. 576 
 26.  Ott, S. L., S. J. Wells, and B. A. Wagner. 1999. Herd-level economic losses associated with Johne's 577 
disease on US dairy operations. Prev. Vet. Med. 40:179-192. 578 
26 
 
 27.  Pathak, S., J. A. Awuh, N. A. Leversen, T. H. Flo, and B. Asjo. 2012. Counting mycobacteria in 579 
infected human cells and mouse tissue: a comparison between qPCR and CFU. PLoS. One. 580 
7:e34931. 581 
 28.  Price, S. J. and J. C. Hope. 2009. Enhanced secretion of interferon-gamma by bovine gammadelta 582 
T cells induced by coculture with Mycobacterium bovis-infected dendritic cells: evidence for 583 
reciprocal activating signals. Immunology 126:201-208. 584 
 29.  Rosseels, V. and K. Huygen. 2008. Vaccination against paratuberculosis. Expert. Rev. Vaccines. 585 
7:817-832. 586 
 30.  Roussel, Y., A. Harris, M. H. Lee, and M. Wilks. 2007. Novel methods of quantitative real-time PCR 587 
data analysis in a murine Helicobacter pylori vaccine model. Vaccine 25:2919-2929. 588 
 31.  Rozen, S. and H. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist 589 
programmers. Methods Mol. Biol. 132:365-386. 590 
 32.  Santema, W., S. Hensen, V. Rutten, and A. Koets. 2009. Heat shock protein 70 subunit vaccination 591 
against bovine paratuberculosis does not interfere with current immunodiagnostic assays for 592 
bovine tuberculosis. Vaccine 27:2312-2319. 593 
 33.  Santema, W. J., J. Poot, R. P. Segers, D. J. Van den Hoff, V. P. Rutten, and A. P. Koets. 2012. Early 594 
infection dynamics after experimental challenge with Mycobacterium avium subspecies 595 
paratuberculosis in calves reveal limited calf-to-calf transmission and no impact of Hsp70 596 
vaccination. Vaccine . 597 
 34.  Sechi, L. A., L. Mara, P. Cappai, R. Frothingam, S. Ortu, A. Leoni, N. Ahmed, and S. Zanetti. 2006. 598 
Immunization with DNA vaccines encoding different mycobacterial antigens elicits a Th1 type 599 
immune response in lambs and protects against Mycobacterium avium subspecies 600 
paratuberculosis infection. Vaccine 24:229-235. 601 
 35.  Stabel, J. R. 2000. Transitions in immune responses to Mycobacterium paratuberculosis. Vet. 602 
Microbiol. 77:465-473. 603 
 36.  Stabel, J. R. and S. Robbe-Austerman. 2011. Early immune markers associated with 604 
Mycobacterium avium subsp. paratuberculosis infection in a neonatal calf model. Clin. Vaccine 605 
Immunol. 18:393-405. 606 
 37.  Sweeney, R. W. 2011. Pathogenesis of paratuberculosis. Vet. Clin. North Am. Food Anim Pract. 607 
27:537-46, v. 608 
 38.  Weinrich, O. A., L. A. van Pinxteren, O. L. Meng, R. P. Birk, and P. Andersen. 2001. Protection of 609 
mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. 610 
Infect. Immun. 69:2773-2778. 611 
 39.  Whelan, A. O., B. Villarreal-Ramos, H. M. Vordermeier, and P. J. Hogarth. 2011. Development of 612 
an Antibody to Bovine IL-2 Reveals Multifunctional CD4 T(EM) Cells in Cattle Naturally Infected 613 
with Bovine Tuberculosis. PLoS. One. 6:e29194. 614 
 40.  Whitlock, R. H. and C. Buergelt. 1996. Preclinical and clinical manifestations of paratuberculosis 615 
(including pathology). Vet. Clin. North Am. Food Anim. Pract. 12:345-356. 616 
27 
 
 41.  Windsor, P. A. and R. J. Whittington. 2010. Evidence for age susceptibility of cattle to Johne's 617 
disease. Vet. J. 184:37-44. 618 
 619 
 620 
     PhD Thesis 
     Aneesh Thakur 
      
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
 
 
 
   
                                                                                         
                                                                                                                       
     National Veterinary Institute 
     Technical University of Denmark  
     Bϋlowsvej 27  
     1870 Frederiksberg C 
 
     Tel +45 35 88 60 00 
     Fax +45 35 88 60 01 
     www.vet.dtu.dk 
 
     ISBN:  
